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Abstract 
Coronary heart disease (CHD) is a global healthcare problem. Sometimes fatal for 
the individual, but always life-changing, and for the wider healthcare system, CHD 
causes an unprecedented financial burden. CHD commonly presents as an acute 
coronary syndrome (ACS), which is a prevalent cause of mortality. However, better 
symptom awareness, a shorter time between symptom onset and acute treatment, 
and a higher quality of routinely accessible treatments has significantly improved 
mortality and morbidity in the period soon after ACS. 
The disease pathway continues after the point of acute treatment and there are 
multiple behaviours that patients can adopt to prevent further coronary events. This 
includes lifestyle modification and the use of guideline-recommended medications. 
There are currently four main classes of medication recommended by consensus-
based guidelines following ACS. This includes antiplatelet therapies (aspirin and a 
P2Y12 antagonist), statins, angiotensin-pathway inhibitors, and beta-blockers. The 
combination of these four medications has been shown to be more effective at 
reducing the risk of future ACS by comparison to those who stop one or more 
medications. Many patients struggle with the task of taking these medications as 
accurately as prescribed (non-adherence) and others stop taking some or all 
medications (non-persistence). Despite well-established advances in the acute 
treatment phases of ACS, successful strategies to improve medication adherence and 
persistence have been lacking.  
The aim of the current study was to determine if an existing, pharmacist-led home-
visit service could be tailored toward the needs of patients following ACS and 
improve medication adherence and persistence at six months post-discharge. The 
currently funded Home Medicines Review (HMR) service was utilised. Patients with 
ACS are eligible for HMR referral, however, to what extent this service is utilised by, 
or beneficial for patients following ACS is unknown.  
vi 
 
To tailor the service toward the needs of patients with a recent ACS, accredited 
pharmacists (APs) who undertake HMRs were invited to participate in an online 
education package. This included five lectures covering: disease introduction and 
trial overview; in-hospital management of ACS; lifestyle modifications, cardiac 
rehabilitation (CR), and chest pain action plans; medication management following 
ACS; and strategies to improve adherence to therapy. Once viewing all lectures, APs 
sat a multiple-choice quiz and were required to achieve a 75% pass mark. The 
education package was peer-reviewed and also underwent a participant evaluation. 
Successful completion of the education package was a requirement of the trial 
protocol. The tailored service was termed a directed Home Medicines Review 
(dHMR). Twenty-seven Tasmanian APs completed the education package, 22 APs 
(81%) passed the quiz on their first attempt. Twenty-one APs (78%) who successfully 
completed the education package participated in the trial as described below. 
A conceptual framework was utilised to design and evaluate a randomised 
controlled trial of a dHMR delivered at two months post-discharge compared with 
usual care. The primary outcome was the proportion of patients who were adherent 
and persistent to a guideline-concordant regimen at six months. This outcome was 
assessed by a modified medication possession ratio (MMPR). The MMPR was 
calculated by applying a specialised algorithm to compare the available supply of 
medication, as obtained through dispensing records, against that required to be fully 
adherent. Modifications to the algorithm utilised in the current study allowed for 
determination of adherence and persistence as unique behaviours. Secondary 
outcomes included mortality, hospital readmissions, length of stays, cardiac 
rehabilitation completion, smoking cessation, quality of life, survey outcomes, and 
process outcomes. Data collection was undertaken at hospital discharge, six weeks 
for baseline surveys, two months for dHMR reports, and follow-up at six months 
post discharge. Statistical analysis was conducted using SPSS, following standard 
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procedures. The primary outcome was assessed by both univariate chi-square 
analysis and binary logistic regression to control for potential confounding.  
Three-hundred and fifty-nine patients with suspected ACS from two Tasmanian 
public hospitals were screened for enrolment. After exclusion criteria and informed 
consent, 184 patients were randomised to receive either usual care or a dHMR at two 
months following hospital discharge. Due to withdrawals and incomplete records a 
total of 76 control patients and 75 intervention patients were followed to the study 
endpoint at six months post-discharge. An intention-to-treat analysis was used, 
however, an on-treatment secondary analysis was also conducted, excluding those 
who had not followed the trial protocol with regards to timing of the intervention 
and completion of the education package. There were no significant differences 
between the study groups for baseline demographics or rates of guideline-
concordant prescribing on discharge, which was relatively low at 60.0%.  
There were only 90 patients who were discharged as guideline-concordant, meaning 
they could be assessed against the primary outcome. There were no significant 
differences in the primary outcome with 26 (59.1%) control patients and 22 (47.8%) 
intervention patients adhering and persisting with guideline-concordant therapy to 
six months (p=0.284). There was, however, a trend toward a lower proportion of 
persistence among patients in the intervention group versus the control group at six 
months (56.5% vs 75.0%, p=0.065). Multivariate analysis supported this finding with 
an odds ratio for persistence of 3.7 (1.1-12.3, p=0.035) in favour of allocation to the 
control group. There were no significant changes detected in the secondary 
outcomes. 
Similarly, there were few significant changes in the questionnaire results, however, 
the specific concerns scale of the beliefs about medications questionnaire decreased 
among intervention patients from six weeks to six months (p=0.034). It was unclear, 
however, if this decrease occurred as a result of information conveyed that relieved 
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concerns or if medications for which the patient was concerned were stopped, and if 
so, what degree of impact the intervention had on this action.  
Analysis of DRPs and review of individual dHMR reports did not clearly support or 
oppose the finding of lower persistence among intervention patients. Although this 
analysis did highlight that issues with medication adherence were being identified 
among some patients, it was interesting to find that other ACS-related problems, not 
related to adherence, were identified four times as often. This suggested that 
adherence may not have been given an adequate amount of attention during the 
dHMR, but also that there may have been improvements in medication management 
that were not adequately assessed by the primary outcome.  
Based on assessment of process outcomes, the implementation of the intervention 
was poor with a large proportion of dHMRs occurring much later than two months 
post-discharge and over 50% not obtaining GP follow-up. Interestingly this 
appeared to be somewhat provider specific, suggesting a potential benefit from the 
use of peer-support and mentorship in future models of research as well as a need to 
better evaluate the perceptions of the stakeholders involved, such that barriers and 
enablers to on time completion could be identified. Somewhat similarly, 
comparisons to other studies suggested that future models of research involving the 
HMR service may benefit from better integration within the healthcare system and 
better engagement with the patient. This could be achieved by starting the 
intervention in hospital and having follow-up sooner after discharge and future 
research should investigate these options. 
There were several study limitations. The small sample size limited the confidence in 
assessing the primary outcome, particularly the assessment of both adherence and 
persistence. The confidence in assessment of the persistence component, however, 
was improved by controlling for confounding from a wide variety of baseline 
variables and this was a positive aspect of the study design. There were also 
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limitations in the collection of complete dispensing records, an inability to assess for 
improvements in guideline-concordant prescribing, and a lack of quality control 
over the dHMRs conducted. Each of these factors potentially limits the 
generalisation of these results to routine practice. 
This study concluded by finding that the methods used did not adequately tailor the 
current model of the HMR service to improve adherence or persistence to guideline-
recommended medications following ACS. Future research should explore ways of 
targeting the patients most in need of intervention, utilising highly flexible 
interventions to suit a wide variety of needs, monitoring for a variety of outcomes 
that are not solely related to adherence, and providing support for the practitioners 
involved to deliver the highest quality service possible. Guidance from conceptual 
frameworks has proved valuable in the design and evaluation of the current study 
and such an approach could be bolstered with input from all stakeholders involved 
when designing and evaluating future research of similar interventions. 
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Chapter One: Introduction 
1.1 Introduction 
Acute coronary syndrome (ACS) is a term used to cover a spectrum of disease that 
results from an insufficient supply of oxygen to the muscular tissue of the heart.1 On 
the less severe end, unstable angina (UA) occurs when the oxygen supply is partially 
decreased, but not enough to cause permanent heart-muscle damage or “myocardial 
ischaemia”.2 In contrast, a complete lapse in oxygen supply causes death of muscular 
tissue and a potentially life-threatening episode, commonly referred to as a heart 
attack or an acute myocardial infarction (AMI).2,3 
In clinical practice, ACS is used as a preliminary diagnosis that should be updated 
once further investigations confirm disease severity.1 Such classification is important 
in guiding acute management; however, all patients with confirmed ACS should be 
considered for ongoing medication therapy aimed at reducing the risk of recurrent 
disease.1,2,4 This includes the prescription of dual antiplatelet therapy (DAPT), a 
statin, an angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker 
(ACEI/ARB), and a beta-blocker.1,5 To ensure the full benefit, the patient has to 
adhere to this regimen for at least a year, with certain medications often prescribed 
lifelong.6 This is not an easy habit to develop and many struggle to adhere to this 
routine of regular medication-taking.7  
It is important to recognise that the act of taking prescribed medication is often 
executed with some degree of imperfection and this should be further described. The 
term ‘adherence’ aims to assess how well a patient is following the instructions of 
their health professional and could relate to any prescribed therapy that requires the 
patient to undertake a prescribed task.8 When referring to medication, adherence 
assesses how accurately the patient takes their medication in accordance with the 
prescribed instructions.9 Common errors in adherence may include skipping doses, 
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either as ‘unintentional non-adherence’, for example, due to forgetfulness, or 
‘intentional non-adherence’, for example, when there is poor understanding of the 
importance of the medicine or if there is a fear of side effects.10 ‘Persistence’ refers to 
the time for which a specific medication has been taken continually, but without 
regard to how accurately the dosing has been during this period.9 When someone 
discontinues a medication without a recommendation to do so, they have become 
‘non-persistent’. Accurately identifying this type of behaviour as unique from other 
types of non-adherence has an important clinical implication as there is no further 
benefit gained from the medication once it has been stopped, whereas a patient who 
is persistent, but poorly adherent may still gain some degree of benefit. When 
referring to the treatment of patients with ACS, the term ‘guideline non-adherence’ 
is often used to described deviation away from guideline-recommended therapy and 
it is important to recognise that both patient and prescriber actions may contribute to 
this outcome.  
Despite best intentions, patients with ACS are at a high risk of suffering future 
ischaemic events and disease recurrence contributes a large proportion of the overall 
burden of ACS.11 The incidence of recurrence is higher among those who are non-
adherent,12 and while acute treatments have progressed substantially;13 
understanding adherence barriers, and the development of interventions to 
overcome them, has been somewhat elusive.10 
1.2 The burden of disease from ACS and the impact of recent therapeutic 
advances 
“I am pleased to see that at present the devastating effects of AMI have been 
ameliorated by the combined efforts of the clinician, the interventional cardiologist 
and the cardiovascular surgeon.”13 
29 
 
Upon reflection of thirty years’ developments in surgical techniques, open heart 
surgery pioneer, Rene G. Favaloro (1923 – 2000), described the significant advances 
in patient survival following AMI.13 Despite the clear survival benefit resulting from 
acute interventions, the devastating effects of AMI were perhaps underestimated 
based on a paucity of information to quantify morbidity following ACS at the time. 
Further research was required to better understand the severity and duration of 
morbidity among those receiving successful surgical intervention.  
1.2.1 Insights into morbidity and guideline non-adherence from “GRACE” 
and “DMACS” 
The establishment of the “Global Registry of Acute Coronary Syndromes (GRACE)” 
just prior to the turn of the 21st century enabled a more robust understanding of 
disease recurrence by observing patients for six months following ACS. The registry 
initially included a sample of 24,055 patients from 14 countries, recruited between 
1999 and 2002, and highlighted that nearly 20% of patients would be readmitted 
with further heart-related illness within six months after an ACS, regardless of 
disease subtype.14 Approximately 75% of these readmissions were severe enough to 
warrant further surgical management. This finding provided a ripe landscape for the 
development of treatments that could improve morbidity following ACS. 
While low-dose aspirin was an established antiplatelet agent, evidence for improved 
outcomes following the addition of clopidogrel, the first in a new class of antiplatelet 
medications mediated by P2Y12 receptor inhibition, saw dual-antiplatelet therapy 
(DAPT) become a mainstay of management for three to six months post-ACS.15,16 The 
development of drug-eluting stents (DES) followed, and this technological advance 
saw reduced six-month restenosis by comparison to that from bare metal stenting 
(BMS) in a population of 176 symptomatic patients (mean six-month stenosis of 14% 
for DES versus 39% for BMS, p<0.001).17 However, repeated concerns over late-stent 
restenosis after cessation of DAPT; temporarily halted the uptake of the DES 
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treatment modality.18-21 The optimal length of DAPT was revisited and a 
recommendation for twelve months’ therapy was proposed for all patients following 
ACS.22 Ironically, this recommendation was based largely on the evidence from post-
PCI studies undertaken during the pre-DES era (PCI-CURE15 and CREDO16). The 
recommendation for 12 months of DAPT for all patients following ACS would soon 
be adopted by expert consensus guidelines.5 
While these therapeutic innovations saw improvements in morbidity, the impact 
from medication non-adherence, and specifically the non-persistence component of 
this behaviour, became more apparent as it was shown to significantly increase 
mortality following ACS.6 Compounding the issue, the use of acute interventions 
that required ongoing medication management in order to be successful, such as 
DES placement, were becoming commonplace.23 In spite of a growing dependence 
on medication therapy, interventions targeted at improving adherence and 
persistence had yet to show great promise.24  
Australian research into the problem of guideline non-adherence found that there 
was a significant opportunity to improve the discharge management of ACS, by 
focussing on the prescribing component of this task.25 The Discharge Management of 
Acute Coronary Syndrome (DMACS) study was a pre and post intervention, quality 
improvement initiative recruiting over 3000 patients from 45 hospitals across 
Australia.26 The delivery of an academic detailing intervention to 3034 hospital staff 
saw a 12% pre to post intervention improvement in guideline-concordant 
prescribing, which was defined as the combination of all four classes of guideline-
recommended medications (57% pre to 69% post, p<0.001). However, successful 
improvements in prescribing at hospital discharge appeared short-lived as a result of 
early non-persistence, with 17% of patients having stopped at least one guideline-
recommended medication at three-month follow-up.26 Patient or prescriber reasons 
for discontinuation were not reported. Figure 1.1 shows that although there was a 
large decline in guideline-concordance by three months, the proportion of guideline-
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concordant patients in the post-intervention group was still significantly higher than 
at baseline. 
Figure 1.1 Guideline-concordant prescribing at discharge and persistence at three-month 
follow-up in the DMACS study26 
 
The decline in medication adherence post-discharge was further explored by Chew 
et al who used an Australian subset of GRACE data to highlight the potential 
benefits from a shift in focus toward interventions aimed at improving guideline-
concordant medication adherence.27 This research demonstrated that non-adherence 
to guideline-recommended medications was split almost 50:50 for patient-related 
versus prescribing-related barriers and, if non-adherence could be improved to 100% 
across the population, it could see 104 lives saved per 10,000 events by 12 months 
post-discharge. The authors compared this benefit to that from the addition of a 
theoretical innovation capable of reducing 12 month cardiovascular events by 30% 
on top of that already achievable with optimal care. Based on this hypothetical 
forecast, just four more lives per 10,000 events would be saved, clearly highlighting 
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the need for further research and development into interventions that could improve 
current prescribing practices and medication adherence.27 
1.2.2 The burden of disease from ACS in Australia 
These findings are particularly important within the Australian context as the 
Australian Institute of Health and Welfare (AIHW) estimated that 17% of the 
population was suffering from cardiovascular disease (CVD) in 2008.28 Although this 
was not the most prevalent disease in Australia for that year, CVD resulted in the 
highest number of deaths by disease category, being responsible for 34% of all 
recorded deaths. Furthermore, CVD accounted for more healthcare expenditure than 
any other disease category in Australia, with the majority resulting from coronary 
heart disease (CHD) and stroke. The Australian population presents a suitable target 
with significant potential to reap benefits from interventions that can successfully 
improve medication-adherence and related outcomes following ACS. 
1.3 Medication management of ACS and adherence to the regimen 
Contemporary prescribing guidelines recommend the use of five medications 
following acute coronary syndrome (ACS).1,2,29 These include aspirin, a P2Y12 
antagonist (eg. clopidogrel), an angiotensin converting enzyme inhibitor (ACEI) (eg. 
ramipril) or an angiotensin II receptor-blocker (ARB) (eg. irbesartan), a beta blocker 
(eg. metoprolol), and a statin (eg. atorvastatin).1 Assessing each class individually, 
there is strong evidence for improvement in a range of clinical outcomes, such as 
mortality and further cardiovascular events from high-potency statins following 
ACS.30-33 There is evidence for reduced major cardiovascular events with extended 
duration DAPT in patients undergoing PCI.15,16 There is evidence for a reduced rate 
of all-cause mortality from the use of ACE-inhibitors among moderate-risk patients 
with atherosclerosis.34 And there is conflicting evidence for a benefit from beta-
blockers in patients with ACS or AMI.35-42 However, the greatest mortality benefits 
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are shown by effective use of combinations of at least three, and preferably four, 
guideline-recommended medications in long-term observational studies following 
ACS or AMI.6,12,43,44 Furthermore, combination therapy is associated with better 
patient-reported perceived health status.45 These studies demonstrate the impact of 
combination therapy in current medical practice, outside of the strictly monitored 
randomised controlled trial setting and support the guideline recommendation for 
all patients with ACS to be considered for the prescription of all four classes of 
medication at discharge.1,5 Therefore, when a person is admitted to hospital with 
ACS, they will almost certainly be discharged on a range of medicines and for those 
with their first episode of ACS, this may require them to rapidly adjust to a routine 
of regularly taking multiple medications. Very few other medical conditions increase 
medication burden as abruptly as ACS and this can create a number of challenges. 
1.3.1 The World Health Organisation’s (WHO) model of adherence 
The WHO has categorised the barriers to adherence that are commonly encountered 
by patients suffering chronic disease.8 These include condition, treatment, 
socioeconomic, health-system, and patient-related barriers. The model is designed to 
be holistic yet simple to remember, with the intention that barriers will be 
considered in conjunction with one another at an individual patient level.8 This is in 
contrast to traditional adherence assessments, whereby patient-related barriers are 
unfairly recognised as those that are most amenable to change and are addressed as 
a priority.46 Despite Morisky et al eluding to flaws in this approach nearly 30 years 
ago,47 the systematic integration of a more holistic method to improving adherence 
in modern medical practice and research has not been widely adopted, and far too 
often, the sole burden of adherence is left hanging over the patient.46 
1.3.2 Applying the WHO model to ACS 
Medication regimen complexity (MRC) is a term used to describe the cumulative 
patient effort required to take medication correctly.48 The notion of ‘change in MRC’ 
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provides a useful foundation for understanding barriers to adherence following 
ACS. MRC increases each time a patient is required to make a decision about taking 
medication. For example, two tablets taken once daily requires only one decision 
and is a less complex regimen than taking one tablet twice a day. Increasing MRC is 
associated with poorer rates of adherence49 and the initiation of five new medications 
for patients after ACS typically leads to a significant increase in MRC, undoubtedly 
contributing to the difficulty in maintaining long-term adherence.50 Understandably, 
patients with ACS as their first major health condition may find the task of taking 
several new medications quite difficult. 
When considering the WHO model, the burden attributable to medication-taking 
should be identified as a treatment-related barrier. However, adherence barriers 
overlap, and exploring the between-barrier connections can illustrate the 
complexities that exist within a regular medication-taking behaviour, for example:  
 Most health systems require patients to contribute to the cost of their 
medications. When multiple medications are started simultaneously, this can 
create a significant socioeconomic barrier.51,52  
 There is a need for reliable information transfer processes between hospital 
and community settings to ensure newly initiated medications are continued. 
Failure of these processes could be considered a health-system barrier.53,54  
 Ten to thirty per cent of patients are known to suffer depression following 
ACS. This is often underdiagnosed and may add to the condition-related 
barriers to adherence.55  
 Multiple guideline-recommended behaviour changes typically confront a 
patient following ACS, such as dietary modification, developing exercise 
routines, and stress management.1 A large proportion of patients will start to 
question their ability to make the required changes to improve their own 
outcomes (psychologically defined as low “self-efficacy”) and this should be 
considered a patient-related barrier to adherence.8,56 
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Figure 1.2 depicts the WHO adherence barriers with brief examples of how each 
barrier may relate to patients following ACS. While this figure helps to illustrate the 
broad range of root causes of adherence barriers, there is no weighting placed on the 
importance of different categories and it is important to recognise the essential role 
of the prescriber in maintaining medication adherence and persistence. There is now 
a wealth of information describing rates of discharge prescribing of guideline-
recommended medications following ACS, however, data on non-prescription 
during the sub-acute recovery phase is poorly understood. Under prescribing, 
whether intentional or unintentional, may account for a large proportion of the 
problem and this needs to be acknowledged as a potential factor when considering 
studies of guideline non-adherence following ACS.27 
Figure 1.2: Five interacting dimensions of adherence proposed by the World Health 
Organisation, with relevance to acute coronary syndrome management8 
 
36 
 
1.3.3 Complexities in measuring medication adherence 
If a desirable health outcome is dependent upon regular medication consumption, a 
reliable method for measuring such a task is essential. If performed with 100% 
accuracy, directly observed therapy (DOT) can provide a true measure of adherence. 
However, this method is unsuitable for assessing adherence from practice-based 
interventions, as the presence of a third-party recording medication consumption 
adds a known variable that would inherently be expected to improve adherence.57 
As a compromise, measurement of adherence typically involves the use of surrogate 
assessment tools, leading to a variety of assumptions about how the task being 
measured relates to the actual behaviour of adherence.8,58,59 For example, medication 
event monitoring systems (MEMS) involves the placement of sensors capable of 
detecting every time a dose of medication is removed from a container, and using 
this method to measure adherence assumes that consumption immediately follows 
the act of removing the medication from the container.60 The WHO accepts that the 
likelihood of this assumption failing is low and that MEMS give a very close 
estimation of adherence; however, their expense largely precludes widespread use.8 
Further to this, Kolandaivelu et al have outlined the barriers that can be created by 
adopting complex adherence monitoring technologies designed to pinpoint minor 
deficits in adherence, when a genuine understanding of the impact from these small 
changes is not well established.61 Their review alludes to the potential to de-
personalise the medication adherence journey by adopting such a technology-
focussed approach, and Choudhry and Winkelmayer echo these principles, 
emphasising the value of the patient-provider relationship during the development 
of an individualised approach to improve adherence.24 
As a more achievable option than MEMS for most researchers operating in a 
resource-limited environment, the combination of self-report and medication 
possession ratio (MPR) has been recognised by the WHO as “state of the art”.8 MPR 
is a calculated adherence estimate, derived by dividing the number of days of 
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medication supplied (as can be obtained from pharmacy dispensing records) by the 
number of days in an observed period. This measure relies on a more fallible 
assumption than for MEMS – assuming that collecting monthly medication supplies 
reflects a patient having taken the medication accurately on all of the days in 
between each supply.62 Similarly, if medication collection ceases, it is often unknown 
whether or not the patient or prescriber has been responsible for this decision. In 
contrast, self-report involves directly questioning the patient about their behaviour 
in relation to taking medication. For example, the Morisky Adherence Questionnaire 
(MAQ) uses four questions to qualify intentional and unintentional non-adherence.47 
Although such measures can be limited by the provision of socially desirable, rather 
than honest answers, the MAQ has shown good predictive validity in patients at risk 
of cardiovascular disease.47,63 Figure 1.3 highlights some of the risks and benefits 
associated with various surrogate assessments of adherence.64 Notably, this figure 
highlights good reliability with the pharmacy refill method, but a similar limitation 
of sparse sampling for both methods exists and this must be considered when such 
methods are used to link adherence or persistence with clinical outcomes.  
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Figure 1.3: Qualitative risks and benefits of various surrogate adherence measurement 
methods, as adapted from Vrijens & Urquhart, 2005 Journal of Antimicrobial Chemotherapy, 
reprinted with permission.64 
 
1.3.4 Non-persistence versus non-adherence 
Both the MPR and the MAQ provide surrogate estimates of adherence, however, 
they are limited in their ability to specifically detect non-persistence; a unique 
behaviour and an important component of long-term medication therapy. To ensure 
persistence is not overlooked, additional methods for its detection are required.65 
Persistence to individual medications can be self-reported as in the DMACS study,26 
but more objectively, persistence can be assessed as a component of the MPR by 
specifying an interval of non-collection that qualifies the medication as 
discontinued.65 Importantly, this method must exclude non-persistence from 
contributing toward mean MPR values reported for the remainder of the cohort, 
thus minimising the risk of miss-labelling two unique medication-taking behaviours:  
a) Taking a medication for a period of time before stopping altogether (non-
persistence), versus  
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b) Continuing the medication, but taking it haphazardly (low adherence).66  
Both behaviours could result in similar MPR values if only an MPR is calculated, yet 
each behaviour is unique by definition and should be classified accordingly in order 
to fully understand the nature of the problem observed.9  
The clinical relevance of specifically assessing medication persistence was shown in 
a prospective study by Ho et al who observed 1,521 patients admitted to 19 hospitals 
in the United States of America and found 12.1% patients discharged on all three 
medications assessed (aspirin, beta blocker and statin) had discontinued all 
medications by one month post-discharge.6 The twelve-month mortality rate was 9% 
higher in this group compared to those who continued one or more medications. 
Similarly, Kuepper-Nybelen et al observed 3,008 patients post-AMI for a median 
follow-up of 4.2 years, using a definition of adherence as taking at least three 
guideline-recommended medications for 50% of the time observed.44 The proportion 
of days covered (PDC), which is similar to the MPR, was used to quantify adherence 
and the study showed a 28% reduction in mortality among the adherers. The authors 
state that the very low, 50% cut-off, reflected intermediate adherence.44 However, 
those falling into this group more likely represented a mixture of patients with 
unique, non-adherent behaviours;9 some will have continued their medication 
throughout the observed period, but with low adherence, whereas others will have 
taken their medication continuously for a period of time, before stopping altogether 
(non-persistence). Additionally, the authors reported an 8% decrease in mortality for 
every 10% increase in PDC. However, without knowing if the root of problem lay 
with non-persistence versus low adherence, it would be difficult to use this 
information to target interventions toward improving a specific behaviour. 
Nonetheless, this study expands on the findings of Ho et al, reinforcing the 
relationship between medication adherence and mortality following MI, while 
simultaneously illustrating the importance of defining persistence as a unique 
outcome and a sub-component of adherence. In this study electronic data collection 
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was key to enabling the granularity of the data, however, Figure 1.4 illustrates a 
different comparison of these terms, by compiling data from 16,907 patients enrolled 
in 95 different studies. This shows the large and absolute impact that non-persistence 
has on the measurement of overall adherence over time, by comparison to a 
relatively smaller, yet consistently present decrease in adherence, resulting from 
incorrectly taken or missed doses.67 
Figure 1.4: Kaplan-Meier curves of adherence and persistence to medication recorded with 
MEMS devices from 16,907 patients enrolled in 95 studies, adapted from Blacshke et al, 
2012, Annual Reviews in Pharmacology and Toxicology,67 reprinted with permission. 
 
1.4 Options for improving medication adherence and persistence 
following ACS 
As a result of the development of consensus-based guideline recommendations for 
acute interventions and secondary preventive therapy following ACS,1,2,4,29,68 there 
has been a strong focus on in-hospital care and discharge prescribing across a variety 
of healthcare settings.69-74 However, simple interventions, such as discharge 
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counselling and cardiologist follow-up that may prolong the benefits of in-hospital 
prescribing interventions, have only been explored through observational studies 
whereby a cause-effect relationship cannot be determined.75-79 Despite this relative 
lack of unbiased evidence, these services are common practice in many settings and 
the American College of Cardiology/American Heart Association (ACC/AHA) 
collaborative guidelines recommend that patients return to a cardiology clinic 
follow-up between 14 days and six weeks post-discharge, depending on risk 
assessment.2 In contrast, the Australian guidelines for the management of ACS are 
less prescriptive with regards to the timing or nature of ongoing follow-up, other 
than recommending referral to cardiac rehabilitation (CR).1 As a result, Australian 
national practice audits have not focussed on these areas and little is known about 
the quality of discharge counselling or the timing of cardiologist follow-up in 
Australia.25,80-82 While advanced clinical pharmacy services within the hospital setting 
have shown minimal benefit,83 a semi-structured intervention involving multiple 
opportunities for pharmacist input has shown the potential to improve medication 
adherence following ACS.84 However, unlike discharge counselling or cardiologist 
follow-up, these novel interventions are not a routine component of post-discharge 
care within the existing healthcare system, and wider implementation has been 
limited by a lack of financial viability.85 In contrast, CR is a well-established 
component of routine post-discharge care and has the potential to improve 
medication adherence following ACS.86  
An overview of 75 systematic reviews undertaken by The Cochrane Collaboration 
assessed a variety of interventions aiming to improve medication adherence and 
other medication-related outcomes.87 The most complex of the interventions 
included in this overview focussed on improving patients’ medication self-
management, such as that involved with warfarin-based anticoagulation. While 
these interventions consistently showed positive outcomes, they could not be 
completed by all patients involved and their complexity may limit their applicability 
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to a variety of healthcare settings. Ensuring the structure of a new intervention can 
fit within an existing healthcare system and be accessible to those in the greatest 
need are essential factors in determining the long-term success of interventions to 
improve chronic disease management.88,89 Systematic reviews of interventions 
targeted at reducing medication complexity and interventions involving pharmacist-
led medication reviews were also included in this overview and were categorised as 
likely to be beneficial, however, further evidence was required before a definitive 
recommendation for wider use could be determined.87 A pharmacist-led medication 
review service that can be targeted toward specific patient groups at risk of 
medication misadventure, such as those with a recent ACS, would be an appropriate 
focus for future research.90 Although an intervention roughly fitting this description 
has been shown to be effective at improving medication adherence following ACS,84 
further research is required to demonstrate if such a study can be effectively 
implemented into a healthcare system such that the wider majority of patients can 
benefit.85,89 
1.4.1 Cardiac rehabilitation (CR) 
There is a range of benefits from successfully completing a CR program, from 
improvements in cardiovascular risk factors through to reductions in hospital 
readmission rates, and all patients should be encouraged to attend CR following 
ACS.86,91,92 However, rates of attendance are often low.93 Given the potential benefits, 
there has been significant research into the barriers to engagement with CR and 
approaches that could increase participation.94,95 Aiming to overcome the problems 
of sub-optimal access and low completion rates, programs that could be considered 
alternatives to CR have also been extensively trialled.92,96-98 However, the success of 
these programs has been variable and while research into the prospect of 
information and communication technology-enhanced solutions is promising,99 there 
is yet to be a sound alternative to traditional CR that has translated into widespread 
practice.100 Uncertainty over the long-term sustainability of such traditional services 
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creates further need to investigate how this well-accepted preventive intervention 
can be modified and improved to suit the needs of contemporary patients and 
healthcare systems.101  
In reference to medication adherence and persistence, this aspect of CR and related 
programs often varies, but typically only those that involve significant patient 
contact time have led to improvements in medication adherence.86,102,103 While CR 
completion has been shown to correlate with prolonging medication persistence,104 a 
causal effect has not been established and a ‘healthy-adherer’ effect105,106 cannot be 
ruled out as a confounder of such correlations. The healthy-adherer effect refers to a 
phenomena whereby adherent patients are observed to show better health outcomes 
as a result of adherence to a generally healthier lifestyle, rather than any specific 
treatment or intervention being tested.10101,102 Given the extent of medication non-
adherence following ACS, the inclusion of adherence screening and intervention 
components within future iterations of CR should be seen as essential.107 In turn, 
interventions aiming to improve post-discharge care of patients following ACS 
should not solely focus on medication management; they should also reinforce the 
importance of CR completion and, where possible, identify strategies to facilitate CR 
completion. 
1.4.2 Home Medicines Reviews and their suitability following ACS 
The Home Medicines Review (HMR) program is an existing community-based 
service that has the potential to be tailored to meet the needs of patients recently 
discharged from hospital following ACS. An HMR involves general practitioner 
(GP) referral of patients to an HMR-accredited pharmacist (AP), often through a 
community pharmacist (CP) liaison.108 The AP will visit the patient in their home, 
discuss their medication taking habits, and provide education or adherence 
interventions where required. Following the home visit, the AP writes a report for 
the GP noting their observations and any clinical adjustments that could be made to 
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the patient’s medication regimen. Based on this report, the GP is expected to 
complete an agreed management plan, selecting the AP’s recommendations that 
they agree to implement and/or follow up, ideally during the patient’s next 
appointment. The potential benefits of improving pharmaceutical care through post-
discharge HMRs have not been fully realised in the past and a qualitative review 
identified a lack of pre-discharge referral mechanisms as a barrier to future 
expansion of the service into this domain.109 As a result of recommendations from 
this review, a process allowing GPs to refer directly to APs was developed. The 
direct-referral process aims to increase the uptake of the service by allowing GPs and 
patients to influence the selection of the AP undertaking the review, and relieves the 
community pharmacy from the requirement of sourcing an AP. Figure 1.5 shows the 
revised process of GP to AP direct-referral under the updated HMR guidelines.110  
Figure 1.5: Facilitation of a HMR following the GP to AP direct-referral process 
GP – general practitioner, DRPs – drug-related problems 
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The HMR service is currently available in Australia, free of charge to Australian 
citizens under funding arrangements through the public health system, Medicare 
Australia. The GP, AP and CP involved with an HMR service are paid by way of 
reimbursement from Medicare Australia. Until 2009, the service had seen a 
reasonable level of early acceptance with over 220,000 reviews conducted since its 
inception in 2001.111,112 However, from 2011 to 2013, service utilisation increased by 
83.7% with over 115,000 HMRs claimed during the 2012 to 2013 financial year, most 
likely reflecting the change in referral mechanisms allowing direct referral from GPs 
to APs.113 The value of this increased utilisation was unclear, and due to budgetary 
limitations, the service was capped to 20 HMRs per month, per AP. If such increased 
utilisation can be shown to benefit specific patient groups and reduce overall 
healthcare costs, this would form a strong argument toward uncapped services 
when provided to those likely to gain the most benefit. The HMR service has been 
shown to be feasible as a post-discharge service for patients following ACS in the 
Australian healthcare setting.114 However, the effect of this service on clinical 
outcomes following ACS is unknown and this warrants further investigation.  
1.5 Justification for this trial 
Programs allowing pharmacists to provide formal medication review services exist 
across many countries. Although there are some regional differences in the structure 
of these programs, they are generally designed to improve the quality use of 
medicines and minimise the potential for medication-related harm. Previous studies 
assessing patient outcomes following post-discharge medication review services 
have found conflicting results. The HOMER trial questioned the value of the service 
as the intervention group had an increased hospitalisation rate at six months post-
discharge.115 Similarly, Barker et al trialled a home-based, post-discharge medication 
review service in patients with congestive heart failure (CHF) and found that 
patients in the intervention group had significantly longer CHF hospital stays, 
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incidence rate ratio = 2.34 (p < 0.001).116 There were no statistical differences in the 
other two primary outcomes of death and hospital readmission rates. Conversely, 
Stewart et al were able to demonstrate both a short and long-term benefit in reducing 
hospital readmissions and mortality following a post-discharge service targeted at a 
CHF population that was suspected to be at a high risk for readmission.117,118  
While the goal of reducing health-care costs through fewer and shorter 
hospitalisations appears appropriate, this outcome may not be a suitable measure for 
a service focussing specifically on medication management. A review by Benbassat 
et al questioned the validity of hospital readmissions as a marker for quality care and 
highlighted that the length of hospital stays, readmission rates, and death appear to 
be mostly predicted by unmodifiable causes, such as age, disease severity and 
comorbidity.119 The authors concluded by highlighting the importance of improving 
other clinical outcome measures, such as adherence to guideline-recommended 
therapy and improving patients’ self-management abilities.  
Although the interventions trialled in their studies included a significant focus on 
improving medication adherence, neither Holland et al nor Barker et al measured 
changes in this outcome. As such, both authors were left to speculate over the causes 
of their paradoxical findings and what mechanisms may have led to the higher 
hospital readmission rates. Conversely, Stafford et al conducted a prospective, non-
randomised, controlled cohort study of a pharmacist-led service aimed at improving 
warfarin therapy post-discharge and, while there were no significant changes in 
readmission or death rates over the 90-day follow-up period, the intervention was 
associated with a reduced rate of adverse bleeding events from warfarin therapy, 
5.3% versus 14.7% (p = 0.03) and increased persistence with therapy, 95.4% versus 
83.6% (p = 0.004).120 The pharmacists involved in this trial were HMR-accredited, but 
also received additional education, specific to the needs of patients taking 
warfarin.121 Although this study was more intensive than the standard HMR service 
as it involved multiple HMR-style home visits within the first couple of weeks post-
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discharge, the ability to focus the HMR service on specific patient groups remains a 
likely avenue for improvement of the HMR service and this warrants further 
attention through future research.90,109 Ho et al previously demonstrated the ability of 
a pharmacist-led service to improve adherence following ACS, however, their trial 
was almost exclusively in male war veterans limiting the relevance to the wider 
population, and any effects on medication persistence were not reported.84 
Furthermore, their study did not have an existing funding stream, creating a 
research to practice translational barrier, whereas adaptations of the existing HMR 
service could be implemented immediately, such that the wider community can reap 
the benefits.100 The period following hospital discharge appears an appropriate time 
to target ACS patients due to their risk for harm that can result from premature 
medication discontinuation.6,53 A targeted service delivered by APs who were 
upskilled to address ACS-specific issues and to encourage positive patient behaviour 
change could lead to improved medication-related outcomes if delivered in a timely 
manner following ACS.  
1.6 Aims and objectives 
The aim was to investigate the effect of an adaptation of the currently available HMR 
service on adherence and persistence to a guideline-concordant medication regimen 
following ACS. The service was directed towards the needs of ACS patients by 
educating the APs involved about ACS-specific patient issues and by providing 
consistent information in a structured HMR referral letter, thus improving the 
continuum of care. As such, the trialled service was termed a directed Home 
Medicines Review (dHMR). Figure 1.6 highlights the intention to target both patient 
and prescribing adherence barriers as both are described as equally prevalent by 
Chew et al.27  
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Figure 1.6: The directed Home Medicines Review as a central driver of medication adherence, 
engagement with lifestyle changes, and guideline-concordant prescribing 
GP – general practitioner, meds – medicines  
 
In addition to assessing medication adherence and persistence, it was important to 
understand the effect of the intervention on clinical outcomes, such as hospital 
readmissions and mortality; patient-focussed outcomes, such as medication beliefs; 
and process outcomes, such as intervention fidelity, to ensure any changes in 
medication adherence or persistence could be further explained as a result of the 
intervention or due to other causes.  
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Chapter Two: Development and evaluation of an education package for 
accredited pharmacists delivering directed Home Medicines Reviews 
following acute coronary syndromes 
2.1 Development 
2.1.1 Design principles 
The existing HMR service closely follows the Lemmens et al framework for 
developing and evaluating chronic disease management interventions,88  which is 
discussed in greater depth in Chapter Three:. This structure highlights the 
importance of interventions targeting both the patient and their prescriber as a dyad. 
The HMR targets the patient through the home interview process and the GP 
through the follow-up report. Somewhat similarly, the education package was 
developed and structured to be applicable in a real-life situation, either while 
educating a patient in their home or writing a recommendation for a GP to consider. 
Given that the program for HMR accreditation is non-specific, with only a chance 
that pharmacists will be tested on their ACS-related knowledge, and that 
pharmacists can seek and complete accreditation for HMRs at any stage in their 
career, it was considered important to provide an overview of the inpatient 
management of ACS and an update on current guideline-recommended secondary 
prevention strategies following ACS. The well-established Kirkpatrick’s four-level 
model for training and evaluation (described below) was adopted to further guide 
the development and evaluation of the education package.122 By including a 
thorough evaluation of the education package within the framework of the overall 
trial, it was believed that the significance of the education package as a means of 
achieving the trial’s primary outcome would be better understood. Kirkpatrick’s 
model involves a four-pillar approach to designing and evaluating education 
packages or other training materials. Specifically, these pillars included assessment 
of pharmacists’ reactions to the material, their knowledge gained by participating, 
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changes in their behaviour while undertaking dHMRs, and the outcomes resulting 
from service delivery.  
2.1.2 Content 
The education package was centred around five online lectures:  
1. Introduction to the program and the associated trial;  
2. Inpatient ACS management and a case example;  
3. Lifestyle changes, cardiac rehabilitation and chest pain action plans;  
4. Medication management; and  
5. Adherence to therapy following ACS.  
While these topic headings were chosen to ensure broad coverage of ACS 
management, significantly more focus was given to the “medication management” 
and “adherence to therapy” sections of the education package, as discussed below. 
The material was developed using multiple resources and peer-reviewed literature, 
including the National Heart Foundation of Australia’s “Guidelines for the 
management of acute coronary syndromes”,1,5 the adherence toolkit “Improving 
adherence in cardiovascular care”,123 and the World Health Organisation’s 
“Adherence to long-term therapies”.8 The education package was delivered in a pre-
recorded narrated PowerPoint® presentation format in order for the material to feel 
like a live lecture, but to also allow for convenience in terms of accessibility. The 
presentations were offered via an online learning module using the Moodle® system. 
In order to access the material, pharmacists were required to create an online 
username, request enrolment into the course, and download each presentation 
individually. The education package took a total of between three and four hours to 
complete. 
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The education package emphasised evidence-based recommendations following 
ACS according to the current Australian guidelines.1 Following the framework of 
medication reviews, there was an emphasis not only on medications that patients 
should be taking after ACS, but also appropriate resolutions for some of the likely 
DRPs that may be identified in this clinical context. Theoretically, providing 
scenario-specific education in this way would result in a change of behaviour that 
could be measured by APs’ competency in the development of relevant 
recommendations for DRPs found during the dHMR process. Although not entirely 
obvious to the pharmacists involved, assessment of behavioural changes is a major 
component of Kirkpatrick’s model and one that is often overlooked due to the 
difficulty associated with fairly measuring or quantifying behaviour change.122 This 
aspect was assessed within the process outcomes of this project, under section 4.4.2. 
The online lecture could also be used as a quick reference to return to for ideas when 
the pharmacist was writing the GP report. Table 2.1 provides examples of the topics 
and recommendations included in the medication management section.
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Table 2.1 Examples of ACS-relevant topics covered and suggested management options provided in the education package. 
PPI: proton pump inhibitors; PVD: peripheral vascular disease 
Topic Description Suggested management References 
Clopidogrel and PPI 
interactions. 
Early observational studies 
suggest some PPIs may 
decrease the activity of 
clopidogrel. 
The COGENT study provides prospective 
evidence to suggest that if an interaction did occur 
that it is of minimal significance. Other studies 
suggest pantoprazole may be the safest option. 
Bhatt et al 124, 
Juurlink et al 
125, Cuisset et 
al 126  
The use of beta-blockers in 
patients with comorbid 
diabetes, reactive airways 
disease, and/or PVD. 
Historically, beta blockers 
would be avoided unless 
absolutely essential in 
these patient groups. 
Provided the comorbid condition is under control, 
such patients should tolerate beta-blocker therapy 
long-term. In this situation, it is important to use 
beta-1 selective agents and a low starting dose. 
Everly et al 38 
The management of 
muscle aches associated 
with statin therapy. 
Incidence of myalgia 
associated with statins in 
practice is around 10%, 
which is higher than 
initially reported in clinical 
trials. 
Pharmacists can play a significant role in helping 
to differentiate between other possible causes of 
myalgia as well as recommending further options. 
Various strategies exist; however, further research 
is required to highlight which methods are most 
tolerable and offer the greatest long-term benefit. 
Eckel 127 
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The material also explored the multiple ways of identifying and managing 
adherence-related problems. This included discussion of direct questioning 
techniques, such as “Do you ever forget to take your medicines?”, which could 
highlight unintentional non-adherence, and “Do you ever change the way you take 
your medicines to suit the way you feel?”, highlighting intentional non-adherence.47 
Further to this, the material explored the notion that the confronting wording of 
such questions can be of limited value in an HMR setting where the aim is to 
maintain a patient’s trust and rapport. The “Stages of Change” model was discussed 
in terms of smoking cessation, as well as a more general application of the model to 
aid in identifying the appropriate guidance to provide with regard to all types of 
lifestyle modification following ACS.128,129 Figure 2.1 is a pictorial representation of 
this model, adapted from Prochaska and Velicer, and it is also known as the 
transtheoretical model of health behaviour change.130 
Figure 2.1: Stages of Change model reflecting the psychological stages a patient progresses 
through when considering behavioural changes, adapted from Prochaska and Velicer, 
American Journal of Health Promotion, 1997, reprinted with permission.130 
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However, the most unique part of this section was the use of the World Health 
Organisation’s “five dimensions of adherence”.8 This area was covered by providing 
examples of how each dimension of adherence could be investigated through the 
HMR process. Table 2.2 gives an overview of this section. By terming each 
dimension an “adherence barrier” the material encouraged pharmacists to discuss 
adherence in a less confronting and non-judgemental manner, by comparison to the 
direct questioning approach. This aligns with the notion of health professionals 
building and maintaining a strong rapport with a patient in order to have them gain 
trust in one’s opinions and recommendations.8 
Table 2.2: Addressing adherence with HMRs 
Adherence Barrier 8 When/how it may be noticed during the dHMR 
process 
Condition related – for 
example, suffering from 
multiple conditions or 
from conditions that may 
contribute to a lack of 
motivation towards 
adherence. 
 Pre-emptively – through assessment of the referral 
letter “conditions” and “notes” section. 
 Through recognition of the patient’s attitudes 
toward the review process and throughout the 
interview, particularly in the case of depression or 
anxiety-related condition barriers. 
Treatment related – for 
example, treatment 
duration, regimen 
complexity, and treatment 
side effects. 
 Assess the potential need to probe for this barrier, 
prior to the interview. 
 Direct questioning with regards to side effects or 
new symptoms during the interview. 
Healthcare system barriers 
– ranging from difficulty 
 Assessing the patient’s awareness of available 
programmes, such as cardiac rehabilitation, during 
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with access to 
medications, through to 
the quality of information 
transferred from hospital 
to the GP. 
the interview. 
 Identifying discrepancies between the patient’s 
medication list and that provided by the GP referral. 
 Also a potential opportunity to help in rectifying 
accidental medication omissions following 
discharge. 
Socioeconomic – this may 
include the significance of 
the financial burden of 
seeking healthcare, health 
literacy issues, and the 
lack of a good social 
support network. 
 Difficult to truly assess without direct questioning – 
potentially surrounding the cost of medicines or 
other possible access issues, such as the cost of GP 
appointments or travel to cardiology clinic 
appointments. 
 These are likely to be difficult for the pharmacist to 
change but they may be able to advise and reassure 
the patient surrounding the importance of their 
medicines in terms of improving their long-term 
health.  
Patient related – such as 
the patient’s perception of 
their disease, treatment, 
and side effects. May also 
include an assessment of 
any physical barriers to 
adherence. 
 Assessing the patient’s attitude during the 
interview. 
 Looking particularly for signs of denial/rejection of 
diagnosis, heightened concern over medication side 
effects, and low self-efficacy beliefs. 
 May also find hints towards difficulty with 
dexterity, reading medication directions, or 
swallowing tablets based on the referral or during 
the interview. 
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2.1.3 Participation and assessment principles 
Once a pharmacist had viewed each lecture in the education package, they could tick 
a completion box and move onto the next. Once all completion boxes had been 
ticked by the user, the assessment material was released. The boxes could be ticked 
without the pharmacist having viewed the presentation if they wished to 
prematurely move ahead. It was not possible to determine exactly how often this 
happened, but lecture download patterns and quiz attempt times suggested that 
only one participant attempted the quiz without sufficient time allowed for viewing 
of the lecture material.  
The assessment component consisted of 16 multiple-choice questions relating to 
three hypothetical, case-based, ACS scenarios. A mark of 75% was required to pass. 
The assessment could be attempted over an unlimited time period with an unlimited 
number of attempts allowed, but there was a ten-minute lockout period between the 
first and second attempts, and a 24-hour lockout period between any attempts 
thereafter. In between each attempt, pharmacists were allowed a two-minute review 
of their answers and individual feedback was provided for each correct and 
incorrect answer. The feedback was carefully worded to ensure that it did not give 
away the correct answer, but highlighted why the option may have been incorrect 
for a patient at two months post-discharge after ACS. As the questions related to 
types of recommendations that could be made during the dHMR process, this 
format of assessment and feedback was a further opportunity for education 
surrounding the types of recommendations that could be anticipated from the post-
ACS dHMR intervention.  
In addition to the online lectures and to further assist with guiding the structure of 
ACS-specific dHMRs, a “dHMR checklist” (see Appendix A) and sample dHMRs 
from real patients were added to the education website. To assist with accessibility 
to the package, an administrator was available to guide pharmacists through any of 
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the stages of enrolment and to answer any questions relating to the material by 
telephone. The material was also available on compact disc by request. 
2.1.4 Critical content review 
The material was reviewed internally by three pharmacists: two expert cardiology 
clinical pharmacists and one professor of pharmacy who was also an accredited 
pharmacist. This was followed by an external review from an expert general 
medicine clinical pharmacist, clinical pharmacy lecturer and clinical staff educator. 
This resulted in multiple modifications and improvements to the material. The 
education package was then submitted for review and accreditation by the 
Pharmaceutical Society of Australia (PSA), Australia’s leading body for accreditation 
of continuing education material for pharmacists. This led to further, minor changes, 
as well as the specification of learning objectives. The education package was 
awarded formal accreditation and opened online for APs to access. The package was 
advertised to Tasmanian APs through emails from the Australian Association of 
Consultant Pharmacy (AACP), as most APs were likely to have been registered with 
this organisation. 
2.1.5 Evaluation questionnaire 
A questionnaire was developed to assess the pharmacists’ satisfaction and whether 
or not the material met the learning objectives developed through the accreditation 
process. Kirkpatrick’s model highlights the evaluation of participants’ “reactions” as 
one of the four pillars of assessing training and development programs.122 The 
questionnaire was face validated by the PSA and the three internal reviewers. The 
questionnaire was set as optional in order to reduce the barriers required to 
complete the package and increase the supply of trained APs ready to undertake 
dHMRs as a part of the subsequent trial. Questionnaire responses were recorded 
anonymously, with the online education software allowing for only one evaluation 
attempt per participant. 
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2.2 Assessment and evaluation results 
2.2.1 Assessment results 
From 91 Tasmanian accredited pharmacists, 36 registered an interest in the 
education package and followed through to completing the online enrolment 
process. Of those who enrolled, 27 completed the education package to the point of 
attempting the assessment quiz. Twenty-two APs (81%) passed the quiz on their first 
attempt, three passed on their second attempt, one AP passed on a third attempt, 
and one AP did not take any further attempts after their first unsuccessful attempt. 
The results of all attempts are shown in Figure 2.2. Seventeen of the 27 APs 
attempting the quiz (63%) also completed the evaluation questionnaire. Twenty-one 
of the 27 APs (78%) who successfully completed the education package went on to 
participate in dHMRs after ACS as a part of the trial for which the package was 
developed. 
Figure 2.2: Education package assessment quiz results 
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2.2.2 Quantitative questionnaire results 
Table 2.3 highlights the questions within the evaluation questionnaire that were 
assessed by a 3-level Likert scale response. It is worth noting that the feedback was 
consistently positive for all questions; with the exception of “How enjoyable was the 
format used?” where “partially enjoyable” was the highest response. Further to the 
Likert-scale questions, there were three questions with single phrase answers and 
more than one option could be selected by each participant. When participants were 
asked: “What would you like to have seen more of in the presentations?” 41% chose 
the option “nothing more required”. Similarly, for the question: “What would you 
like to have seen less of…?” 86% chose the option “nothing less”. There was a broad 
response to the question determining the driving factors behind participant 
motivation to complete the education package, but “personal desire to expand 
knowledge base” and “personal desire to improve HMR service” received the 
highest percentage of preferences at 25% and 23%, respectively.  
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Table 2.3: Quantitative component of education package evaluation 
1. Met learning 
objectives? 
0% 18% 82% 
Not met Partially 
met 
Entirely 
met 
2. Met personal learning 
needs? 
0% 18% 82% 
Not met Partially 
met 
Entirely 
met 
3. Relevant to your own 
practice? 
0% 18% 82% 
Not 
relevant 
Partially 
relevant 
Entirely 
relevant 
4. How enjoyable was 
the format used? 
0% 65% 35% 
Not 
enjoyable 
Partially 
enjoyable 
Very 
enjoyable 
5. Confidence in applying 
the material in 
practice? 
0% 18% 82% 
Not at all 
confident 
Partially 
confident 
Completely 
confident 
9. Overall quality?  0% 0% 100% 
Poor 
quality 
Average 
quality 
Very high 
quality 
2.2.3 Qualitative questionnaire results 
Each of the nine questions had a secondary space to allow participants to enter free 
text. Most of these responses were very positive, such as:  
“Thank you for a very well presented education package. I found the information 
provided to be at just the right level for my current understanding and am very pleased 
with the knowledge that I’ve now gained” and  
“I feel I am better equipped now to have more meaningful and beneficial discussions 
with my patients/customers who have ACS. I look forward to helping improve patient 
outcomes in the future.”  
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Some provided positive comments on the accessibility of the education package, 
such as:  
“Appreciate the narration as attempting to read all of the information can be tedious 
and it can be easy to be distracted”  
but conversely, others had technical difficulties in accessing some of the narration as 
evidenced by the responses:  
“What narration?” and “Something wrong with my computer I think! Didn’t get the 
narration (but read it out loud from the bottom, so it was kinda the same ;-)”.  
This correlates with the high response of “Partially enjoyable” to question 4 as 
mentioned above. 
2.3 Discussion 
The education package was developed following a review of evidence-based 
guidelines, consideration of behaviour change strategies and review by a panel of 
experts in pharmacy and medication review. Most APs who registered an interest 
could complete the resulting package and most of the feedback was positive. The 
strong assessment results and positive feedback suggest that the material covered 
was delivered at an appropriate level of difficulty and detail, allowing a good degree 
of learning and understanding; thus putting the participants in a good position to 
partake in real-life ACS-specific dHMRs. While this may partly reflect a well-
developed product, it may be also due to the topic’s relevance within a pharmacist’s 
day-to-day practice. Whereas more complex topics, such as pharmacogenomics, 
have been shown to be difficult to teach using similarly brief education packages.131  
A potentially negative aspect recognised through the analysis of the package was 
with accessibility. Online guides were provided to outline how to complete the 
material, as were a wide variety of viewing formats, and an author was accessible by 
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phone to assist with any technical difficulties. However, the online format still 
proved troublesome for some, and both qualitative and quantitative analyses 
highlighted this issue. In spite of this finding, technical difficulties were generally 
rare and encountered by only a small minority. It is likely that the attention given 
toward maintaining accessibility was actually a relative success of the education 
package and maintaining a high level of accessibility should be considered an 
important factor for any future service review or expansion. 
The education and assessment package was evaluated against levels one and two of 
Kirkpatrick’s model for training and evaluation.122 Stafford et al followed a similar 
approach in utilising the HMR service to improve the post-discharge care of patients 
taking warfarin.120 The APs involved in the study were required to complete a 
thorough education package based on the principles of warfarin management and 
this included novel management approaches, such as point of care International 
Normalised Ratio (INR) monitoring.121 The APs involved with the warfarin 
management intervention were able to score highly on an assessment quiz and 
agreed strongly with an evaluation question measuring the perceived adequacy of 
the training offered. Although the approach described here is somewhat similar, the 
use of frameworks to guide the development, assessment and evaluation of this 
education package build on the research of Stafford et al, providing guiding 
principles to enable expansion of the package across a broader community of health 
professionals. 
Evidence-based guidelines and training evaluation frameworks have governed the 
design of an education package for increasing the capacity of APs to improve 
medication management following ACS. The results following an assessment quiz 
and evaluation questionnaire suggest this may be suitable preparation toward 
directing the HMR service to the needs of patients following ACS.  
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Chapter Three: Methodology 
3.1  Trial recruitment, randomisation, and the intervention 
3.1.1 Overview 
A randomised controlled trial (RCT) was conducted to compare a directed Home 
Medicines Review (dHMR) delivered at two months post-discharge to usual care 
following a hospital admission for acute coronary syndrome (ACS). Changes in the 
Home Medicines Review (HMR) referral process and an ACS-specific education 
package completed by study pharmacists made this program different to the 
standard HMR service. The primary outcome was the proportion of patients who 
were adherent and persistent to a guideline-concordant regimen of all four classes of 
recommended ACS medications, at six months post-discharge. Patients were 
enrolled in hospital during an admission for ACS. Figure 3.1 provides an overview 
of the trial protocol.  
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Figure 3.1: Trial Protocol Overview.  
ACS = Acute Coronary Syndrome, dHMR = directed Home Medicines Review, GP = General 
Practitioner, AP = Accredited Pharmacist. 
The design of the intervention and monitoring system was based on a conceptual 
framework for the standardised evaluation of chronic disease management 
interventions, as developed by Lemmens et al.88 Figure 3.2 is a summary of this 
framework that has been adjusted from the original model to better reflect the points 
of the framework that were considered relevant to the HMR service (shown in 
further detail in Figure 3.3). This framework highlights the importance of 
considering patient-related factors, professional-related factors and health-system 
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factors in both the design and evaluation of interventions targeted toward 
improving the management of chronic diseases. These considerations were 
particularly important throughout trial development.  
Figure 3.2: Summary of Lemmens et al framework88 
 
Figure 3.3 provides an example of how the individual components of the trial 
aligned with the framework. The framework provided a fundamental set of 
recommendations to consider. For example, that a successful intervention should 
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have all three of a patient focus, professional focus, and be compatible with the 
existing organisational structure. The efforts to address these recommendations have 
been highlighted with brief comments in blue text. For example, the professional 
focus included: the education package for the APs; and the dHMR reports written by 
APs to provide advice to the GPs; as well as an expectation of the existing HMR 
service-framework that an agreed management plan is developed following a 
review.110 
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Figure 3.3: How the dHMR addressed the specific components of the conceptual framework.88 
Blue text highlights the aspects of the trial design that were specifically addressing 
recommendations from the framework. ACS = Acute Coronary Syndrome, dHMR = directed 
Home Medicines Review, GP = General Practitioner, QOL = Quality of Life.  
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dHMR referral letter content;
      pre-existing funding for dHMR service
 Intervention barriers – GP approval and 
forwarding of dHMR referral letters
Combined effect of organisational enablers 
and barriers on overall intervention process
 Is inter-professional collaboration able 
to occur – through follow-up report 
and agreed management plan
 What is the quality of this 
collaboration – by written report only 
OR by telephone discussion OR by 
meeting discussion
 What happens when this doesn’t 
occur – i.e. the control group
Patient selection processes –
Admission for ACS
Clinical
eg. adherence, 
readmissions
Functional
eg. QOL
Health Care Expenditure – 
dHMR costs vs functional 
and clinical outcome savings
Consumer Satisfaction – 
previously established
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3.1.2 Setting 
Patient enrolment and dHMR referral occurred at the two major tertiary referral 
hospitals in Tasmania, Australia. The Royal Hobart Hospital (RHH) is a 490-bed 
public hospital with an 8-bed coronary care unit (CCU), percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG) facilities, and accepts 
patients from across the state for CABG referrals.132 The Launceston General 
Hospital (LGH) is a 300-bed public hospital with a 4-bed coronary care unit and PCI 
facilities.133 Both hospitals run cardiac rehabilitation (CR) programs that are offered 
to all ACS patients. Patients admitted to these centres generally receive verbal and 
written education regarding lifestyle changes following ACS from nurses, and 
medication counselling from nurses or pharmacists, prior to discharge. 
3.1.3 Inclusion/Exclusion Criteria 
All adults aged 18 years and over with a primary diagnosis of ACS presenting at the 
RHH and LGH were considered for enrolment into the trial. The wide age range was 
chosen to investigate differences in the discharge management of patients, and to 
examine the suitability of the dHMR intervention across different age groups. 
Disparities in treatment of ACS among patients of different ages has been previously 
recognised as an area for further interventional focus by Alexander et al in the 
CRUSADE trial134 and other studies have acknowledged the potential for 
improvement in the prescribing of and adherence to evidence-based medications 
among older survivors of ACS.135 Furthermore, suitability of the HMR service among 
the elderly has been recognised as an area requiring further investigation through a 
qualitative service review.109 
Patients were excluded from trial enrolment if they: were not returning to their 
home following hospital discharge (as this is a requirement of the existing HMR 
service); were non-Medicare eligible (for example, not a permanent Australian 
Resident as this is another requirement of the HMR service); had any degree of 
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cognitive impairment (formally diagnosed or not) such that the process of informed 
consent was obscured; or had been diagnosed with a malignancy that was expected 
to be terminal within 12 months. 
3.1.4 Randomisation 
We used a computer-generated random sequence to provide the randomisation 
coding. Patients were randomised to the control or intervention groups following 
computerised recognition that they met the inclusion criteria and provided informed 
consent. Entry of this information into the central trial database enabled the 
enrolling researcher to unlock the randomisation status for that participant.  
3.1.5 Controls  
Following randomisation to the control group, patients were offered the usual care 
processes involved with post-discharge management of ACS in Australia. Through 
the public health system, patients were able to attend a CR program at their local 
hospital as well as a cardiologist follow-up appointment, usually occurring at one 
month following discharge. The CR programs from the two different hospitals 
varied slightly in their level of physical activity, but the material covered in their 
information sessions was similar. CR referral and attendance is known to vary, 
therefore completion of CR was recorded, such that this could be controlled for in 
assessing the primary outcome. 
3.1.6 Intervention  
Patients in the intervention group received a dHMR at approximately two months 
following discharge as well as usual care. The time of two months post-discharge 
was selected as previous studies of patients with ACS have demonstrated that this is 
a time when they are most vulnerable to discontinue one or more medications.6,26,136  
70 
 
Based on pre-existing funding arrangements and recommended reasons for referral, 
the HMR service was available in Australia for all patients with ACS following 
hospital discharge.108 The uptake of this service, however, may have been limited by 
the absence of HMR referral systems in this transitional period. Furthermore, the 
currently available service could be tailored to address the expected needs of 
patients recently diagnosed with an ACS. It was hypothesised that the existing 
service could be optimised in several ways, making the proposed dHMR better 
directed toward the needs of the ACS population.  
3.1.7 Changes to optimise the existing HMR service 
Typically, HMRs are ordered by a referral letter generated by the patient’s GP. 
Referral letters may vary significantly in their level of detail, potentially leaving the 
AP with little direction prior to the patient interview. This concern was highlighted 
as a potential downfall of the service in a qualitative review.109 To address this issue, 
the enrolling researchers used a specifically designed database that automatically 
populated the HMR referral with relevant information obtained through baseline 
data collection. The referral letter was forwarded to the GP for approval and 
addition of any further information, such as medications that had changed since 
discharge. GPs were also contacted by phone to further engage them in the dHMR 
process. GP approval is a requirement for HMR payment under the existing public 
service arrangements and having the GP engaged with the intervention early was 
expected to increase their willingness to actively participate in the process, for 
example, in response to receiving dHMR reports and in the formulation of 
medication management plans. This novel approach also relieved the GP from 
having to complete most of the referral data entry, allowing for simple addition of 
only useful information. The GP may have also found the information on the referral 
letter useful, as previous research has demonstrated that standard discharge letters 
following ACS admissions do not always contain a sufficient level of information 
and sometimes take too long to reach the GP, reducing their clinical utility.26  
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In addition to the disease-specific referral letter, the service was further directed by 
offering APs across Tasmania an online education and assessment package, as 
outlined in detail in Chapter Two:. In order for an AP to complete an interventional 
dHMR according to the trial protocol, they were required to have a current 
accreditation status and have successfully completed the education and assessment 
package. Upon completion of the education and assessment package, APs gained 
recognition of continuing professional development and an AUD50 reimbursement 
for their time. Briefly, the education package involved five online lectures focussing 
on ACS management principles and methods for identifying and resolving 
adherence barriers. Assessment was through an online quiz. The online learning 
system included an ACS-specific checklist to aid dHMR-report writing and a 
selection of exemplary dHMR report findings taken from the first few completed 
reports. The primary project officer also made themselves available for phone 
consultation with the APs throughout the trial period. 
3.2 Trial outcomes 
All outcomes were measured at the endpoint of six months post-discharge. Each 
outcome included a comparison between the control and the intervention. The 
Lemmens et al framework guided outcome selection, ensuring measurement of 
important clinical outcomes as well as the individual steps of the intervention that 
required monitoring (process outcomes).88 Monitoring these individual steps, such as 
pharmacist detection of drug-related problems (DRPs) and GP acceptance of 
pharmacist recommendations, was important to measure the level of alignment 
between the theoretical plan and the practical application of the intervention, herein 
termed ‘intervention fidelity’. It was also believed that using a detailed monitoring 
and outcome reporting process may elucidate areas of practice worthy of focus in 
future research. 
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3.2.1 Primary outcome 
The primary outcome was the proportion of patients who were adherent to a 
guideline-concordant ACS medication regimen at six months. To be considered 
adherent, the patient had to be discharged on and persistent with all four classes of 
guideline-recommended medications and record a medication possession ratio 
(MPR) greater than or equal to 0.8. The approach to only calculate MPRs for 
medications to which patients were persistent,137 and the use of a dichotomous cut-
off for the MPR,138-141 are both previously accepted methods, however, the use of 
these measures as a composite within this study is a novel approach to defining 
adherence. While the degree of non-adherence to the regimen relied mostly on 
patient behaviours, non-persistence may have occurred as a result of either the 
patient not collecting a prescription or their GP not prescribing the medication. Due 
to resource and data collection constraints, it was only feasible to assess prescribing 
at discharge, therefore the direct causes of non-persistence could not be identified. 
The following sections explain the reasoning behind the approach to split adherence 
and persistence and section 3.2.1.3 illustrates how each component was calculated. 
3.2.1.1 Detection of non-persistence 
Patients were identified as non-persistent to any guideline-recommended 
medication if they were discharged with a guideline-concordant regimen, but did 
not to collect a supply of one or more medications within the first 60 days post-
discharge, or if there was a gap in dispensing equal to twice the number of days 
supplied on the previous dispensing at any time during follow-up. Non-persistence 
was further delineated into ‘early non-persistence’ and ‘anytime non-persistence’. 
Patients demonstrating ‘early non-persistence’ were those who were discharged as 
guideline-concordant but either had no collections of one or more guideline-
recommended medications, or obtained a supply of a guideline-recommended 
medication within 60 days post-discharge, but collected no further supplies in the 
following 120 days. Those demonstrating ‘anytime non-persistence’ were those who 
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collected supplies of medications both before and after the 60-day post-discharge 
cut-off, but had at least one gap in dispensing equal to twice the number of days 
supplied on the previous dispensing. The combination of ‘anytime non-persistence’ 
and ‘early non-persistence’ covers all types of non-persistent medication collection 
patterns and is termed ‘total non-persistence’ at six months post-discharge. ‘Anytime 
non-persistence’ is also presented separately among the sample who were persistent 
beyond two months (those not detected by ‘early non-persistence’). For P2Y12 
antagonists, ACEI/ARBs, and statins, the period used to determine non-persistence 
was effectively a gap of two months in supply based on typical Australian 
prescribing patterns. This was considered a clinically suitable gap in medication 
supply to denote non-persistence.142,143  
The class of medication, prescribed daily dose, and the quantity supplied were all 
recorded allowing for patients to remain persistent even if they switched between 
medications within the same class. This information was also used to determine how 
long each supply should last and a calculation of any supply gaps. The heterogeneity 
in prescribing of beta-blockers, whereby some patients may have been discharged 
with a 200-day supply and others with only a 30-day supply (most commonly 
dispensed as a 100-tablet unit of supply, but with varying doses prescribed), 
rendered this definition of persistence less sensitive for this class of medication. 
However, the algorithm could still detect early non-persistence as a result of only a 
single supply of a beta-blocker on discharge among the majority – those with a 100-
day supply or less – and this was accepted as sufficient reason to not exclude this 
medication class from the assessment of the primary outcome. The ability to detect 
early non-persistence across all guideline-recommended medications was 
considered particularly important to assess the impact of the intervention on the 
quality of care following ACS. Early discontinuation of guideline-recommended 
medications has been linked to 12-month mortality and the timing of the 
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intervention was chosen to allow for specific problems during this time to be 
addressed promptly, resulting in a need to detect such events.6  
Due to the supply arrangements for aspirin in Australia, this medication was 
typically dispensed by the discharging hospital, but subsequent supplies were 
commonly purchased without a prescription record. As such, aspirin was excluded 
from the primary outcome and antiplatelet adherence was measured only through 
the monitoring of P2Y12 antagonist supply. Although the recommended duration of 
P2Y12 antagonists had been anecdotally observed to vary across Tasmanian 
cardiologists, the trial was designed based on acceptance of the most recent 
guidelines available at the time, citing a recommendation of 12 months DAPT for all 
patients following ACS.5 Nonetheless, consideration of factors that may affect 
recommendations surrounding DAPT duration, such as the deployment of drug-
eluting stents (DES) versus other management options was identified as an 
important point to consider during the analysis of the primary outcome.144,145 
If non-persistence was detected for a particular medication, it did not contribute 
toward the average MPR calculated for any medications to which the patient was 
persistent. Separation of persistence from surrogate measures of adherence, such as 
the MPR, is important to improve the association between the measure and the 
behaviour it is intended to describe.9,66  
3.2.1.2 Detection of adherence by a modified medication possession 
ratio algorithm 
The MPR for all persistent guideline-recommended medications was calculated and 
averaged for each patient. A value greater than or equal to 0.8 was considered 
adherent, which is a commonly accepted cut-off for this measure, including when it 
is used to determine adherence to cardiovascular medicines.65,138,139 Although this 
value has often been referred to as arbitrary, a recent observational study has 
provided some clinical validation of this cut-off with reduced rates of major adverse 
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cardiovascular events (MACE) among patients suffering recent MI who had 
MPR>0.8 by comparison to those with MPR<0.8.146  The calculated MPRs of 
medications with which the patient had been persistent were averaged and the 
medians of these results for the control and intervention groups were also reported 
as a sub-analysis. This accounts for the fact that while dichotomous assessment of 
MPR is common, the best cut-off to use is unclear and further clarity toward 
understanding the magnitude of the changes in adherence may be obtained by also 
comparing group medians.9  
For this study, a specific adaptation of the MPR was used, which we have termed the 
‘modified MPR’ (MMPR). This adaptation was chosen based on the observation that 
traditional MPR calculations often give an overestimation of adherence over short 
observation periods, particularly where medication supplies may overlap. Similar 
efforts to address these problems and improve the MPR have been considered by 
other authors and this represents the basis of the algorithm presented.147 The MMPR 
was determined by subtracting the ‘days without medication’ from the ‘days in 
observed period’ and dividing the resulting numerator by the ‘days in observed 
period’ minus 1. For example, at six-month follow-up, the ‘observed period’ ended 
at 180 days post-discharge; however, the denominator to the MMPR equation was 
179, accounting for the common occurrence of within hospital medication dosing on 
the day of discharge. As such, a continuous supply of 179 days or more resulted in 
an MMPR value of 1, or perfect adherence. Figure 3.4 shows the equation used to 
obtain the MMPR for each individual guideline-recommended medication. 
Figure 3.4: Equation used to obtain the modified medication possession ratio (MMPR) as 
calculated for this study 
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The MMPR was capped at a maximum value of 1 as oversupply of cardiovascular 
medication is expected to be a result of stockpiling rather than genuine 
overuse.65,138,141 To further minimise the potential effect of stockpiling behaviours 
artificially increasing the MMPR, the quantity of any supplies collected prior to 
depletion of the current supply was added to the expected medication depletion 
date. For example, if a supply was collected one day prior to the expected depletion 
date of the previous supply, the new supply’s expected depletion date had this 
additional day added to it. If multiple supplies occurred near the end of the 180-day 
observation period, only the medication that was supplied and required up until 180 
days post-discharge was counted.  
3.2.1.3 Illustration of how the MMPR algorithm detected non-
adherence and non-persistence 
Figure 3.5 provides an example of how the algorithm dealt with overlapping 
supplies and supplies near the end of the observed period. In this figure, the second 
to fifth supplies were all collected early and summed together, giving a period 
covered according to the total supply. This was followed by a five-day gap in supply 
and the adjusted supply pattern shows how the supply collected at 155 days post-
discharge was only partly counted in the MMPR calculation, being truncated at 25 
days’ supply. Effectively, this resulted in a five-day gap and an MMPR of 0.98. 
Fixed-interval (FMPR) and variable-interval MPR (VMPR) calculations are provided 
as a point of reference. While these algorithms have been used by previous 
researchers, they were considered not suitably specific for the current study.148  
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Figure 3.5: Conversion of actual to adjusted supply for a continuously early supply pattern, 
followed by a small gap and a truncated final supply. The modified MPR algorithm and 
comparison to previously described MPR algorithms are overlayed.148 
FMPR – fixed interval medication possession ratio; VMPR – variable interval medications 
possession ratio; MMPR – modified medication possession ratio as described within the 
current study. Each supply refers to a 30-day supply of medication. 
 
Figure 3.6 again highlights how the algorithm dealt with supplies collected near the 
end of the observed period, particularly resulting in a lower MMPR by comparison 
to other adaptations. However, this figure also highlights how ‘anytime non-
persistence’ was detected and that this resulted in a ‘null’ value for the MMPR, such 
that non-persistence was reported as a separate finding, rather than artificially 
lowering the MMPR. The pattern of medication supply presented here is of 
particular interest for the current study as such a pattern could theoretically occur as 
a result of a patient restarting a medication following a post-discharge dHMR. 
However, it was decided that a full month without medication available in this 
period shortly following ACS conferred a high risk of significantly worse health 
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outcomes. As such, for the intervention to be considered to have resulted in a 
genuine benefit, the restarting of guideline-recommended medications would need 
to occur rapidly following detection of non-persistence by the study pharmacist and 
the relatively tight gap used to detect non-persistence remains justified.  
Figure 3.6: Conversion of actual to adjusted supply. A supply on discharge is followed by a 
period of ‘anytime non-persistence’, before restarting with continually early supplies. The 
modified MPR algorithm and previously described MPR algorithms are overlayed. 
FMPR – fixed interval medication possession ratio; VMPR – variable interval medications 
possession ratio; MMPR – modified medication possession ratio as described within the 
current study. Each supply refers to a 30-day supply of medication. 
 
 
In Figure 3.7 there are only two continuous supplies collected, with the first being on 
the day of discharge. As both supplies have been collected in the period prior to two 
months post-discharge and there are no supplies in the period following, the 
algorithm detected this as ‘early non-persistence’. The MMPR is again reported as 
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null and would not count toward the cumulative/average MMPR for this patient. In 
the primary outcome analysis, any finding of non-persistence would render the 
patient as non-persistent to a guideline-concordant regimen. However, for 
secondary analyses, such as analysis of median MMPRs between groups, it was 
important to be able to average the MMPRs calculated for those medications with 
which the patient had been persistent. 
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Figure 3.7: Conversion of actual to adjusted supply. A supply is collected on discharge and a continuation supply is collected early. No further 
supply denotes early non-persistence. The modified MPR algorithm and previously described MPR algorithms are overlayed. 
FMPR – fixed interval medication possession ratio148; VMPR – variable interval medications possession ratio148; MMPR – modified medication 
possession ratio as described within the current study. Each supply refers to a 30-day supply of medication. 
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During the baseline interview, the two main pharmacies that a patient attended were 
recorded, aiming to make the dispensing records as complete as possible. As the 
MPR is typically applied retrospectively to medication records of managed health 
organisations with only low rates of medication collection at non-recorded sites,147 it 
was recognised that collection of a complete medication history using the Australian 
system of medication supply may be difficult. However, dispensing records in 
Australia are rich in data, often allowing for identification of repeated dispensing 
from an original prescription. These histories were checked and if there were 
apparent gaps in a dispensing history, the patient was contacted to ask if they had 
collected medication elsewhere. Those with remaining supply gaps were assessed by 
the primary project officer. If the dispensing data showed that supplies from the 
same prescription had been collected before and after a gap of supply that could not 
be confirmed by a dispensing record (for example when the patient claimed they 
had collected elsewhere but couldn’t remember the location or name of the 
pharmacy), the record was further discussed with a second pharmacist researcher 
not involved with patient recruitment, and the patient was only included if it was 
deemed most-likely that a repeat supply had been collected elsewhere. Any gaps 
remaining unexplained or instances whereby the patient could not be contacted 
resulted in the history being deemed incomplete. These patients were considered 
lost to follow-up and removed from all outcome assessment, with the incidence of 
this occurrence reported in the results, see section 4.1.  
3.2.1.4 Self-report of medication adherence and persistence 
To allow for a significant loss of patients due to incomplete dispensing records, self-
reported medication adherence was used as an alternative measure. This was also 
reported and used to triangulate adherence in combination with the MMPR as a 
further sub-analysis. The four-item Morisky adherence questionnaire was used to 
measure self-reported adherence.47 This is a well-validated instrument, having been 
used previously with good predictive validity in patients at risk of cardiovascular 
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disease.47,63 Patients self-reported their persistence with guideline-recommended 
medications by recording their current regimens at the six-week and six-month 
survey follow-up. 
3.2.1.5 Assessing contraindications and discharge prescribing of 
guideline-recommended medications 
In the case where a patient had a clearly documented contraindication to one of the 
four guideline-recommended medication classes, their medication regimen was still 
considered “complete” provided they were taking all other guideline-recommended 
medications. For example, a patient with asthma not taking a beta-blocker but still 
taking clopidogrel, an ACE inhibitor, and a statin, was considered in the same group 
as someone prescribed all four medications. As it has been shown that the initiation 
of guideline-recommended medications following ACS is largely driven by hospital-
based doctors,149 only those discharged with a guideline-concordant medication 
regimen were assessed for the primary outcome. It was considered appropriate for 
all patients to be considered in the primary outcome assessment as the Australian 
guidelines published at the time of trial design considered all patients with ACS as 
eligible for all four medications and this was consistent with previous efforts to 
improve guideline-concordant prescribing at discharge.5,26 However, components of 
the primary outcome, such as non- persistence, were explored further among only 
those discharged as guideline-concordant to account for potentially low rates of 
discharge prescribing.82 As a follow-up to this, non-persistence was also assessed as 
a cumulative result whereby patients discharged on four, three, two, or fewer 
guideline-recommended medications had the persistence algorithm applied and the 
results summed, allowing for an assessment of this outcome across a greater number 
of enrolled patients. 
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3.2.2 Secondary outcomes 
Secondary outcomes included hospital readmission rates, length of hospital stays, 
changes in quality of life (QoL), cardiac rehabilitation (CR) completion rates, 
smoking cessation rates, and mortality. Hospital readmissions and mortality were 
further categorised as ACS-related or due to other causes. QoL was measured at six 
weeks post-discharge as a pre-dHMR baseline measure and again at six months. The 
Euroqol “EQ-5D 3L”150 was used to measure general QoL and the Seattle Angina 
Questionnaire (SAQ)151 was used to measure cardiac-specific QoL. Both instruments 
have been validated when administered individually151-154 and in combination155 to 
assess QoL in patients with coronary heart disease.  
The first section of the Eq-5D-3L comprises five questions using a 3-point Likert-
scale for the domains of “mobility”, “personal care”, “usual activities”, “pain”, and 
“anxiety and depression”. For each domain, the patient can report either no 
problems (coded as 1), some limitations (coded as 2), or severe limitations/extreme 
problems (coded as 3). The individual domains are combined to give a score ranging 
from “11111” representing perfect health, to “33333” representing the worst health 
state imaginable. To provide a quality versus quantity of life analysis, response 
patterns have been validated using population samples from specific countries, 
whereby people are asked to rate how long they would prefer to live in full health 
followed by immediate death as opposed to a longer period of time in the health 
state presented. This is known as a time-trade-off (TTO) analysis and the algorithm 
returns a utility score from -0.217 to 1, whereby 1 represents perfect health and 
scores less than 0 represent situations considered as worse than death. The algorithm 
used within this study was developed by Viney et al based on an Australian 
validation of the Eq-5D.156 In addition to the five domains, the Eq-5D-3L concludes 
with a visual analogue scale (VAS) rating for how the patient rates their current 
quality of life on a scale of 0 to 100. 
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The SAQ is a series of 19 Likert-scale questions with the length of the Likert-scale 
varying between sections. The 19 questions are broken down into five domains, with 
nine questions assessing physical limitations, one question assessing angina stability, 
two questions assessing angina frequency, four questions assessing treatment 
satisfaction, and three questions assessing QoL. The answers to the questionnaire are 
processed according to an algorithm designed by Spertus et al and this results in a 
score for each of the five domains.151 Spertus et al also demonstrated that the SAQ 
can be sensitive to subtle changes in CHD, making it suitable for the purpose of 
comparing between the control and intervention groups within the present study. 
In addition to a self-report of smoking status at baseline and the study endpoints, 
each smoker’s dependence on cigarette smoking was further categorised using the 
Fagerstrom Test for Nicotine Dependence (FTND).157 
3.2.3 Process outcomes 
In addition to reporting the important clinical outcomes that may be affected by the 
intervention, it was also recognised that there are many individual components of 
such interventions that can be measured and may highlight barriers or enablers to 
the overall success of the intervention.88 From the professional aspect of the dHMR, 
it was considered important to measure GP acceptance of the intervention through 
approval of dHMR referrals, pharmacists’ recognition of DRPs, the clinical relevance 
of the DRPs identified, and GP acceptance of pharmacists’ recommendations. Figure 
3.8 and Figure 3.9 represent the measurement of the effect of these professional and 
organisational barriers on trial implementation. Of the components highlighted in 
blue, all were measured and reported, with the exception of the quality of the verbal 
and face-to-face components of the intervention. The survey data was intended to 
provide a surrogate explanation of the quality of the information conveyed at the 
dHMR interviews, however, capturing and analysing the audio-visual components 
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of the interactions that APs had with patients and their GPs would have required 
significantly greater resources than that available. 
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Figure 3.8:Evaluation of the professional focussed components of the intervention.88 
The blue text in this figure highlights where the professional focussed components of the 
intervention fit into the Lemmens et al framework. dHMR – directed Home Medicines 
Review; MedReDi – Medication Reviews re-Directed – the title given to the trial 
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Figure 3.9: Evaluation of the health-system’s impact on the implementation of the 
intervention.88 
The blue text in this figure highlights how the local health-system structure may affect the 
implementation of the intervention described within this trial protocol. Again, the relevant 
points raised by the Lemmens et al framework have been considered. 
dHMR – directed Home Medicines Review; MedReDi – Medication Reviews re-Directed  
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From the patient’s perspective it was considered important to investigate, firstly, 
how the dHMR process may have influenced psychological variables that have been 
previously recognised as relevant to adherence behaviour, as well as how strongly 
these variables correlated to the outcome of adherence and persistence within this 
particular trial setting. A full analysis of baseline confounding on the primary 
outcome from the concepts assessed in each questionnaire was, however, considered 
beyond the scope of this project due to time and resource limitations. The concepts 
we chose to consider and the validated instruments that were used to evaluate each 
construct are detailed in Figure 3.10. 
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Figure 3.10: Evaluation of the patient-focussed component of the intervention.47,56,88,158-162 
This figure highlights the comprehensive evaluation that was designed for the patient-
focussed component of the intervention. IPQ – Illness Perception Questionnaire, PHRQ – 
Perceived Health Risk Questionnaire, BMQ – Beliefs about Medicines Questionnaire, TABS – 
Tool for Adherence Behaviour Screening, MPR – Medication Possession Ratio. MedReDi – 
Medication Reviews re-Directed 
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The concepts of knowledge,163-165 illness perception,158,166 beliefs about 
medications,167,168 and self-efficacy56,169 have all been studied separately in CHD 
populations. In developing the conceptual framework for the evaluation of chronic 
disease interventions, however, Lemmens et al recognised the important 
interrelations between these concepts and how this can affect the ultimate outcome 
of patient behaviour change.88 Risk perception159 and adherence-specific 
behaviours160 are two lesser studied concepts that may also affect or predict 
adherence and, as such, were added to our model of assessment. The following is a 
brief summary of the questionnaires selected for this purpose:  
 For adherence-specific behaviours the Tool for Adherence Behaviour 
Screening (TABS) was selected160  
 To assess medication knowledge “recall of individual medication purpose” 
was selected, as adapted from Hope et al161  
 For self-efficacy seven items from the Cardiac Self-Efficacy Scale were 
selected56 
 For beliefs about medications, eight items from the Beliefs About Medicines 
Questionnaire (BMQ)162 were selected and two items were developed to assess 
the impact of cost “The cost of my medications makes it difficult for me to 
take them regularly” and “Medications are not good value for money” which 
were assessed on the same 5-point Likert scale as the BMQ questions  
 For illness perception the eight quantitative items of the Brief Illness 
Perception Questionnaire (Brief IPQ) were selected158  
 For risk perception the Perceived Heart Risk Questionnaire (PHRQ) was 
selected.159  
All of these questionnaires have been validated in populations of patients with CHD. 
The complete questionnaire set chosen for this study can be viewed in   
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Appendix B – Questionnaire battery. 
3.2.4 Sample size 
The aim was to detect a change in the primary outcome of 15% between the control 
and intervention groups. This predicted change was based on the results of the 
recently conducted Discharge Management of Acute Coronary Syndromes 
(DMACS) study, whereby a 12% post-intervention improvement was observed on 
the proportion of patients taking the same four guideline-recommended medications 
at discharge.26 To detect a change of 15%, assuming a control group result of 45%, a 
power to detect a difference of 80% with alpha = 0.05, a minimum sample size of 186 
patients per group was required. To account for an approximate dropout rate of 
20%, the enrolment target was 465 patients. Based on Australian guidelines, those 
discharged with a diagnosis of ACS should be discharged on a guideline-concordant 
regimen and an omission of guideline-recommended medications on discharge was 
considered guideline non-concordance, unless a contra-indication or other reason for 
non-prescription was highlighted.1 It was therefore expected that all patients would 
be included in the analysis of the primary outcome and that patients with clearly 
documented contraindications to one or more specific medication classes would be 
included as adherent to that particular medication. Sub-analyses of components of 
the primary outcome, such as non-persistence among only those discharged with a 
guideline-concordant regimen were also included to improve the assessment of the 
intervention if low rates of discharge prescribing were found.  
3.2.5 Data collection 
Baseline data collection occurred in hospital at the time of enrolment and at six 
weeks post-discharge – when the participants were sent their first questionnaire set. 
The in-hospital baseline data collection included the recording of traditional 
coronary risk factors, such as prior diagnosis of hypertension, diabetes, smoking 
status, social factors (employment and home setting), and prior history of CHD. 
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Comorbidities were recorded and counted toward a comorbidity status as classified 
by the updated Charlson Comorbidity Index (CCI).170 The scale was age-adjusted 
and dichotomised in alignment with similar methodologies.171,172 The final baseline 
data collection point of six weeks post-discharge reflected the intention to gauge 
each patient’s status on each of the questionnaires in the time directly before the 
dHMR and not while in hospital, as factors, such as adherence behaviour, may be 
very high in hospital but may significantly decline over time following 
discharge.6,26,86,173,174 Patients in the intervention group were asked to ensure that they 
completed their questionnaire before their AP visit. Phone-call reminders were 
scheduled at 10 days post questionnaire mail-out to improve response rates and 
minimise the risk of questionnaires being filled after the AP visit. 
APs’ successful completion of the education and assessment package was required 
prior to starting any trial dHMR. This was recorded through an online system, 
specifically designed to guide each pharmacist through to completion of the 
package, while also monitoring their usage levels of the education website via 
separate login codes. Although completion of the package was encouraged by an 
AUD50 honorarium, programme completion could not be enforced beyond this level 
and those patients receiving a dHMR by a pharmacist who had not successfully 
finished the education and assessment package prior to the dHMR interview were 
excluded from the on-treatment analysis, as discussed in section 3.2.6. 
Following the dHMR interview, data collection started with the pharmacist’s dHMR 
report and the agreed patient-GP management plan. Collection of these documents 
allowed for assessment of pharmacists’ recognition of DRPs, the recommendations 
made to improve these problems, and the GPs’ acceptance of these 
recommendations, as described in Figure 3.8 and Figure 3.9. DRPs and 
recommendations for their resolution were categorised using the “DOCUMENT” 
system, see Appendix C – DOCUMENT DRP classification system.175 This allowed 
for identification of common DRP themes throughout the trial. Telephone follow-up 
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was scheduled two months after the interview if the reports and management plans 
had not been received. Recent amendments to the Medicare-funded HMR 
reimbursement process reinforced the requirement that an agreed management plan 
be formulated following all HMRs, which was expected to help facilitate this data 
collection point. Timely access to national records on HMR claiming were not 
available, such that receipt of a standard or directed HMR by a control patient could 
be determined. However, discussion with more active APs suggested that such risk 
was likely low as they did not commonly encounter this patient group in their 
routine practice. Furthermore, the group of APs involved in the trial was relatively 
small and most APs were in reasonably frequent contact with the project officers. 
While no events were reported by APs or the patients involved, it is possible that 
control patients may have received an HMR or dHMR and this may have gone 
unreported. 
Follow-up at six months post-discharge included requests to community pharmacies 
for patient dispensing records, hospital register checks for readmissions, lengths of 
stay, and cardiac rehabilitation referral and completion rates, and a questionnaire 
mail-out with another ten day phone call reminder. A deaths registry check for 
mortality was planned, however, this was not performed as all patients’ vital 
statuses were identified through either medical records or survey contact. 
3.2.6 Statistical analysis 
All baseline variables were compared between the control and intervention groups 
using independent samples t-tests for continuous, normally distributed variables, 
the Mann-Whitney U-test for non-normally distributed continuous variables, and 
Pearson’s chi-squared analysis for categorical variables. Fisher’s exact test was used 
for chi-square analysis with expected counts lower than the accepted cut-off for 2x2 
contingency tables, the Likelihood Ratio was used for contingency tables larger than 
2x2 with expected counts lower than the accepted cut-off, and Kappa’s test for 
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agreement was used to compare self-reported adherence against the MMPR. Where 
tests were repeated at baseline and follow-up, as with the questionnaires, 
independent t-tests or U-tests were undertaken at both time points, as well as paired 
t-tests or the Wilcoxon Signed Ranks Test depending on parametric or non-
parametric distribution, to compare for within group changes over time. All 
outcomes were reported as descriptive comparisons between the control and 
intervention groups, with significance reported at alpha = 0.05. For baseline 
assessment of comorbidities using the updated CCI, an age-adjustment was applied 
as with the original CCI,176 and this was stratified into two categories, 0-2 versus 3 or 
more. Similar stratifications have been applied previously and the dichotomous 
stratification best suited the current study.171,177 As there were several potential 
barriers that may have prevented a patient who was randomised to the intervention 
group from receiving a dHMR according to the protocol, both an intention-to-treat 
analysis and an on-treatment sensitivity analysis were applied. To remain on-
treatment, a patient had to have their home-visit before four months post-discharge 
and the AP performing the visit had to hold a current accreditation status and have 
completed the education package prior to the visit. 
As described in section 4.2.2, while investigating the persistence component of the 
primary outcome, a statistical trend was noted between “study group allocation” 
and guideline-concordant persistence to six months by univariate analysis. Binary 
logistic regression (LR) was undertaken to explore potential confounding from 
baseline variables on the effect of “study group allocation” on persistence. Only 
patients who were guideline-concordant at discharge were included due to sample-
size limitations for the other groups. For the LR, all variables measured prior to the 
home-visit were considered baseline variables, including those measured during 
hospital admission, all items of the six-week questionnaires, and CR completion 
rates. Questionnaire sub-totals were used in preference to individual items to 
minimise the risk of identifying individual items as confounders by chance rather 
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than a true effect. Individual variables were only included if the sub-total resulted in 
a large number of missing patients due to non-completion of the full questionnaire 
or if the questionnaire did not have a sub-total. The change in estimate (CE) 
approach was used to identify variables that had a potential confounding effect.178,179 
This involved generating multiple LR models by including “study group allocation” 
in each model and cycling through all baseline variables, one at a time, with 
potential confounders identified as those that caused a change in the point estimate 
of the study group allocation variable by greater than or equal to 10% (CE≥10%). 
Pearson’s Chi-Square or Spearman’s Rank Correlation tests were used to identify 
collinearity. Among collinear variables, the variable causing a greater CE was 
retained. From this set of variables, a final LR model was created by adding and 
removing variables from the model, one at a time (stepwise), and retaining variables 
that continued to cause a CE≥10%, without an excessively large increase in the 
standard error (SE), generally limited by removing variables that resulted in changes 
of SE≥10%.  
By building the LR model with both forward and backward steps, individual 
variables with the greatest unique confounding effect were identified. Variables 
showing confounding effects in a similar direction showed a reduced CE when 
included in a model with a more pronounced confounder, therefore the less 
prominent confounder was identified and removed. Due to the small sample size, 
there was a risk of including too many variables and developing a model with 
excessively large SE.180 The method described here controlled for confounding while 
containing SE and maintaining the statistical validity of the model. An excessive SE 
would also limit the application of the result in a clinical context.  
A wide variety of methods have been previously described for controlling for 
confounding in observational research,179,181-183 however, a gold-standard approach to 
control for confounding in RCTs has not been established. Despite this, there is an 
increasingly recognised need to control for confounding in RCTs.184 Although 
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commonly used to demonstrate an absence of confounding, standard significance 
testing of baseline groups does not rule out confounding bias if there is a non-
significant difference between randomised groups for a covariate that shows a 
strong impact on the outcome measured.184 Based on the currently available 
literature the method described here is appropriate to apply in the RCT setting to 
specifically identify potential confounders rather than predictors of the outcome.181 It 
is important to note that the method described here does not involve any 
significance testing in the initial stages of confounder selection. Although the use of 
significance testing to develop LR models is widespread, this approach more 
accurately identifies potential predictors of an outcome rather than confounding 
covariates. A variable that predicts a certain outcome may not always confound an 
interaction between another variable and the outcome, whereas the CE method 
directly assesses this effect.181 
All statistical analyses were performed using IBM SPSS version 21.0. (Armonk, NY: 
IBM Corp). 
3.2.7 Ethical approval 
This trial received ethical approval through the Tasmanian Health and Medical 
Human Research and Ethics Committee. Approval number: H11821. All 
participating patients provided informed consent. 
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Chapter Four: Results 
4.1 Trial recruitment, baseline demographics and discharge prescribing 
Full details of patient recruitment are provided in Figure 4.1. In summary, 359 
patients with suspected ACS were screened for enrolment into the study; 26 patients 
were excluded, 14 were discharged prior to obtaining consent, 54 did not have a final 
diagnosis of ACS, and 81 declined consent. Of the remaining 184, twelve withdrew 
consent shortly following discharge, three died soon after discharge, one patient 
died during the follow-up period, and five were lost to follow-up. Despite extensive 
efforts to obtain dispensing records from as many pharmacies possible, twelve 
patients (five controls, seven intervention patients) were excluded based on an 
incomplete dispensing record (effectively lost to follow-up). Thus, 151 patients were 
included in the intention-to-treat (ITT) analysis (76 controls, 75 intervention 
patients). An on-treatment (OT) sensitivity analysis excluded a further 16 patients 
from the intervention cohort due to non-compliance with the study protocol. Further 
discussion and assessment of the barriers to on-treatment completion of the 
intervention are reported under section 4.4 Process outcomes. The number of 
patients with sufficient information for assessment of the primary outcome was 
substantially less than the predicted sample size requirements, therefore the 
following results must be interpreted with caution as further discussed in section 
5.7.1.  
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Figure 4.1: Trial recruitment, April 2012 to April 2013 
ACS – acute coronary syndrome; post-d/c – post discharge; dHMR – directed Home 
Medicines Review 
  
Baseline demographics are outlined in Table 4.1. There were no significant 
differences in baseline demographics between the control and intervention groups. 
The cohort was predominantly white males, with a mean age of 61.8 years old. The 
primary mode of management was coronary artery stenting, with stents deployed in 
approximately 75% of patients. 
359 patients 
admitted with 
suspected ACS
26 met one or more 
exclusion criteria
13 – cognitive decline
3 – non-Medicare
4 – discharge destination 
other than home
8 – terminal malignancy
81 declined consent
14 discharged prior 
to follow up
54 final diagnosis 
not ACS
55 gave reasons
26 declined 
without 
specifying a 
reason
Common reasons for not consenting: 
trial process seemed “too difficult”; 
“don’t need any extra help”; 
“too many other appointments”; 
travelling interstate during trial 
period
184 provided 
informed consent
33 with insufficient data 
for primary analysis 
(withdrew consent, 
incomplete data, died)
N = 151 for 
intention-to-treat 
analysis 
(76 controls, 75 
interventions)
16 intervention 
patients failed to 
receive a dHMR 
per-protocol
12 withdrew consent during follow up procedures
5 were lost to follow up
12 with incomplete dispensing records excluded
3 died shortly post-d/c (1 control, 2 interventions)
1 control patient died during follow up
N = 135 for on-treatment 
sensitivity analysis 
(76 controls, 59 interventions)
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Table 4.1: Baseline demographics and discharge diagnosis 
ITT – intention-to-treat; OT – on-treatment; SD – standard deviation; LDL-C – low density 
lipoprotein-cholesterol; CCSUA – Charlson comorbidity score, updated and age-adjusted; 
(N)STEMI – (non)-ST-segment-elevation myocardial infarction; Unspec ACS – unspecified 
acute coronary syndrome; *for drug-eluting stenting, control n=60, ITT n=55, OT n=42. 
Demographic  
(N=151) 
Control  
N/76 (%) 
ITT 
N/75 (%) 
P OT 
N/59 (%) 
P 
Male gender 54 (71.1) 58 (77.3) 0.378 47 (79.7) 0.253 
Mean age (SD) 
61.1 
(10.4) 
62.6 (9.8) 0.376 
62.3 
(9.6) 
0.494 
Body mass index 
(SD) 
29.9 
(6.1) 
29.9 (6.5) 0.964 
29.9 
(5.4) 
0.962 
LDL-C (mmol/L) 
Median (IQR) 
2.7  
(2.2-3.5) 
3.0  
(2.5-3.6) 
0.307 
2.9  
(2.5-3.6) 
0.393 
Maximum troponin 
(mcg/L) 
Median (IQR) 
10.5  
(0.1-
52.1) 
8.0  
(0.6-43.9) 
0.929 
8.0  
(0.5-
45.8) 
0.875 
Caucasian 73 (96.1) 73 (97.3) 0.660 57 (96.6) 0.865 
Privately insured 27 (35.5) 29 (38.7) 0.690 20 (33.9) 0.844 
Employed 38 (50.0) 26 (34.7) 0.057 22 (37.3) 0.140 
Lived alone 15 (19.7) 14 (18.7) 0.867 12 (20.3) 0.931 
History of 
hypertension 
50 (65.8) 39 (52.0) 0.085 31 (52.5) 0.119 
Diabetes 19 (25.0) 16 (21.3) 0.593 12 (20.3) 0.523 
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Demographic  
(N=151) 
Control  
N/76 (%) 
ITT 
N/75 (%) 
P OT 
N/59 (%) 
P 
Non-smoker 54 (71.1) 51 (68.0) 0.684 37 (62.7) 0.305 
History of coronary 
heart disease 
15 (19.7) 19 (25.3) 0.410 16 (27.1) 0.312 
No prior medical 
history 
9 (11.8) 10 (13.3) 0.782 8 (13.6) 0.765 
CCSUA  
(0-2) 54 (71.1) 44 (58.7) 
0.111 
37 (62.7) 
0.305 
 (3+) 22 (28.9) 31 (41.3) 22 (37.3) 
Location (South) 49 (64.5) 51 (68.0) 0.647 42 (71.2) 0.409 
Discharge 
Diagnosis 
STEMI 34 (44.7) 35 (46.7) 
0.081 
27 (45.8) 
0.137 
NSTEMI 16 (21.1) 26 (34.7) 21 (35.6) 
Unstable 
angina 
15 (19.7) 6 (8.0) 6 (10.2) 
Unspec 
ACS 
11 (14.5) 8 (10.7) 5 (8.5) 
Coronary artery 
stenting 
60 (78.9) 55 (73.3) 0.418 42 (71.2) 0.298 
Drug-eluting stent* 38 (63.3) 35 (63.6) 0.973 28 (66.7) 0.729 
 
Discharge prescribing of guideline-recommended medications is outlined in Table 
4.2. There were more patients discharged on beta-blockers in the intervention group 
(p=0.046). There were no significant differences in the rate of prescribing for the 
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combination of all four guideline-recommended medications (guideline-
concordance) at discharge. Guideline-concordant prescribing at discharge occurred 
in 59.6% of the total cohort. 
Table 4.2: Guideline-recommend prescribing at hospital discharge 
ITT – intention-to-treat; OT – on-treatment; G-RM – guideline-recommended medications; 
GC – guideline-concordant; D/C – Discharge; ACEI/ARB – angiotensin converting enzyme 
inhibitor/angiotensin II receptor blocker. 
Discharge 
medications 
Control  
N/76 (%) 
ITT 
N/75 (%) 
P 
OT 
N/59 (%) 
P 
G-RM 
classes 
P2Y12 
antagonist 
69 (90.8) 70 (93.3) 0.563 55 (93.2) 0.755 
Statin 75 (98.7) 73 (97.3) 0.620 57 (96.6) 0.581 
Beta-
blocker 
56 (73.7) 65 (86.7) 0.046 52 (88.1) 0.037 
ACEI/ARB 60 (78.9) 59 (78.7) 0.966 45 (76.3) 0.711 
G-RM 
combos 
2 10 (13.2) 4 (5.3) 
0.246 
3 (5.1) 
0.257 3 22 (28.9) 25 (33.3) 21 (35.6) 
4 44 (57.9) 46 (61.3) 35 (59.3) 
GC at 
D/C 
<4 meds 32 (42.1) 29 (38.7) 
0.667 
24 (40.7) 
0.867 
4 meds 44 (57.9) 46 (61.3) 35 (59.3) 
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4.2 Primary outcomes 
4.2.1 Adherence and persistence by modified medication possession ratio 
The primary outcome was a composite of adherence and persistence to a guideline-
concordant regimen at six months post-discharge. Using the number of patients who 
were discharged as guideline-concordant as shown in Table 4.2, there were no 
significant differences between the control and intervention groups with 26 (59.1%) 
control patients and 22 (47.8%) intervention patients (p=0.284) maintaining 
persistence and adherence at six months. On-treatment sensitivity analysis and 
reassessment of the MMPR as a continuous variable did not reveal any further 
significant findings. To ensure non-persistence was not mislabelled as non-
adherence, an MMPR was only generated for patients who were persistent with their 
discharge medications as outlined in section 3.2.1.1. Therefore, further exploration of 
non-persistence as an individual component of the primary outcome was conducted. 
4.2.2 Early and anytime non-persistence to six months 
Among those who were discharged on a guideline-concordant regimen, non-
persistence was reported as ‘early non-persistence’ alone (same as ‘persistence to 
two months’) and in combination with ‘anytime non-persistence’ (same as 
‘persistence to six months’). Further assessment of ‘anytime non-persistence’ as an 
individual variable (same as ‘persistence from two to six months’) is also presented 
in the subsequent section. Figure 4.2 shows no significant difference in the 
proportion of patients with early non-persistence, but there was a trend toward a 
higher proportion of patients with the combination of early and anytime non-
persistence (represented by ‘total non-persistence’) in the intervention group at six 
months (p=0.065) suggesting that the dHMR may have had a negative impact on 
persistence. As a trend was identified, the result was re-examined through binary 
LR, to control for potential confounding from baseline variables; this is presented in 
section 4.2.6. 
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Figure 4.2: Proportion of patients persistent to a guideline-concordant regimen as prescribed 
at hospital discharge 
ITT – intention-to-treat; OT – on-treatment  
 
Based on the results as presented in Figure 4.2, the dHMR did not affect early non-
persistence, but there was a trend toward a difference in the combined non-
persistence measure at six months. Combining ‘early non-persistence’ and ‘anytime 
non-persistence’ reflected ‘total non-persistence’ at 6 months. However, this 
approach may have diluted the assessment of the anytime non-persistence 
component of this outcome. To better understand the type of prescription collection 
patterns affected by the intervention, Figure 4.3 shows anytime non-persistence 
among those not detected by the early non-persistence algorithm, that is, those who 
were persistent to two months but not six months. The proportion of persistent 
patients was significantly higher in the control group at 86.8%, versus 66.7% in the 
intervention group (p=0.036), again suggesting there may have been a negative effect 
on persistence as a result of the intervention. 
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Figure 4.3: Proportion of patients persistent to a guideline-concordant regimen at six 
months, excluding early non-persistence (persistence from 2 to 6 months) 
ITT – intention-to-treat; OT – on-treatment 
 
The effect of medication discontinuation was further explored by analysing 
persistence, regardless of the number of guideline-recommended medications 
prescribed at discharge. In this analysis, all patients who were prescribed a 
guideline-recommended medication were included as persistent if they continued 
with the same combination of guideline-recommended medications at two and six 
months post-discharge. The purpose of this analysis was to further identify if the 
intervention had a negative impact on persistence to guideline-recommended 
medications overall, or if this was generally limited to those discharged as guideline-
concordant, as shown in Figure 4.2. Table 4.3 shows a trend toward a lower 
proportion of persistent patients at six months in the intervention group (p=0.060 for 
the on-treatment analysis).  
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Table 4.3: Proportion of patients persistent to guideline-recommended medications, 
regardless of the combination of medications prescribed on discharge 
Results presented are for those who were persistent. ITT – intention-to-treat; OT – on-
treatment 
Time 
Control 
 N/76 (%) 
ITT  
N/75 (%) 
P 
OT  
N/59 (%) 
P 
2 months 64 (84.2) 62 (82.7) 0.799 49 (83.1) 0.856 
6 months 52 (68.4) 42 (56.0) 0.115 31 (52.5) 0.060 
 
In Table 4.4, patients with early non-persistence were excluded, as with Figure 4.3, to 
allow for investigation of the specific effect of the intervention on anytime non-
persistence. The proportion of anytime non-persistence was again higher in the 
intervention group for the on-treatment analysis (p=0.032). This suggests that non-
persistence was higher in the intervention group, regardless of the number of 
guideline-recommended medications prescribed at the point of hospital discharge.  
Table 4.4: Proportion of patients persistent to guideline-recommended medications, 
regardless of the combination prescribed on discharge, excluding early non-persistence 
Results presented are for those who were persistent. ITT – intention-to-treat; OT – on-
treatment 
Time 
Control 
 N/64 (%) 
ITT  
N/62 (%) 
P 
OT  
N/49 (%) 
P 
2 - 6 
months 
52 (81.3) 42 (67.7) 0.082 31 (63.3) 0.032 
 
Non-persistence to each class of guideline-recommended medication was analysed 
to determine if there was a particular class leading to a lower rate of persistence in 
the intervention group, as presented in Figure 4.4. The number of patients in each 
analysis reflects the number of patients discharged with a prescription for the 
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particular medication class. There were no significant differences between the 
groups for beta-blockers and ACEI/ARBs; however, there were more control patients 
persistent to P2Y12 antagonists beyond two months, 98.6% versus 89.1% in the on-
treatment analysis (p=0.044). As with Figure 4.3, anytime non-persistence was 
separated to include only those who were persistent beyond two months and the 
proportion of patients persistent to statins was higher in the control group, 92.6% 
versus 79.6% in the on-treatment analysis (p=0.034).
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Figure 4.4: Proportion of patients persistent to individual guideline-recommended medications. 
“2 months” refers to early non-persistence, “6 months” includes early and anytime non-persistence, and “2 to 6 months” reflects only those 
with anytime non-persistence. ITT – intention-to-treat; OT – on-treatment; ACEI/ARB – angiotensin converting enzyme inhibitors/angiotensin 
II receptor blockers. *Fisher’s exact test 
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Proportion of patients persistent to individual guideline-recommended medications (continued). 
“2 months” refers to early non-persistence, “6 months” includes early and anytime non-persistence, and “2 to 6 months” reflects only those 
with anytime non-persistence. ITT – intention-to-treat; OT – on-treatment; ACEI/ARB – angiotensin converting enzyme inhibitors/angiotensin 
II receptor blockers. 
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4.2.3 Mean modified medication possession ratio 
As discussed in section 3.2.1 of the methods, no MMPR value was generated for 
medications to which patients were non-persistent, to avoid medication 
discontinuation skewing the mean MMPR results. Therefore, each patient who 
continued at least one guideline-recommended medication, without a two-month 
supply-gap, had an MMPR calculated and averaged across all persistent 
medications. This reflected their level of adherence to medication with which they 
were persistent. As with persistence, MMPR was assessed as part of the primary 
outcome, but also as a discrete variable, presented in Table 4.5. The number in each 
group was slightly lower than the overall cohort, reflecting that some patients had 
discontinued all medications and these were not included in this analysis. There 
were no significant differences in the MMPR across all groups whether assessed as a 
continuous variable or by the convention of MMPR0.8 to define adherence. 
Table 4.5: MMPR at six months post-discharge among those who were persistent with at 
least one guideline-recommended medication 
MMPR – modified medication possession ratio; ITT – intention-to-treat; OT – on-treatment; 
IQR – interquartile range 
MMPR 
Control 
 N/73 (%) 
ITT  
N/72 (%) 
P 
OT  
N/56 (%) 
P 
0.8 65 (89.0) 61 (84.7) 0.441 46 (82.1) 0.262 
Median  
(IQR) 
0.95  
(0.86-0.98) 
0.96  
(0.86-0.98) 
0.618 
0.95  
(0.84-0.98) 
0.932 
4.2.4 Adherence and persistence by self-report 
Patients’ self-reported adherence was assessed using the Morisky Adherence 
Questionnaire (MAQ). Self-reported persistence was assessed via a patient or 
pharmacy-generated record of their current medication list. This served two 
purposes; firstly, as a back-up in case of a high number of incomplete medication 
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histories, and secondly for triangulation of adherence and persistence with the 
MMPR. The combined response rate for the four-item MAQ at both six-week and 
six-month time points was 66.7%. Despite the relatively simple format of the MAQ 
and placement as the first questionnaire directly following the medication list, 
eleven patients answered only some of the questions from the MAQ and these 
results were not counted. MAQ scores of 0 denoted adherence and any score greater 
than 0 reflected sub-optimal adherence. Six-week and six-month scores are 
presented in Table 4.6 showing no significant differences in the proportion of 
patients self-reporting as adherent between the groups, pre or post intervention. 
Further exploration of individual items of the MAQ did not reveal any significant 
differences between the groups at either time point (data not shown). 
Table 4.6: Number of patients self-reporting as adherent by Morisky adherence questionnaire 
ITT – intention-to-treat; OT – on-treatment 
Time 
Control 
 N/49 (%) 
ITT  
N/51 (%) 
P 
OT  
N/38 (%) 
P 
6 weeks 34 (69.4) 33 (64.7) 0.619 25 (65.8) 0.722 
6 months 34 (69.4) 33 (64.7) 0.619 26 (68.4) 0.923 
 
As with the MMPR, self-reported adherence and persistence were combined to 
consider the composite outcome of those discharged as guideline-concordant and 
reporting to be adherent and persistent with this regimen to six months. There was 
no significant difference in this finding with 13 (40.6%) control patients and 12 
(34.3%) intervention patients self-reporting as adherent and persistent to six months 
(p=0.592). 
Among those who were discharged as guideline concordant, there were no 
significant differences between the groups in the rates of self-reported persistence 
from six weeks to six months, as in Figure 4.5 (p=0.872). 
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Figure 4.5: Self-reported persistence with a guideline-concordant regimen over time 
ITT – intention-to-treat; OT – on-treatment.  
 
Table 4.7 outlines total self-reported persistence over time regardless of the number 
of guideline-recommended medications being taken at discharge. There were no 
significant differences in the proportion of patients self-reporting as persistent 
between the groups at each time point. 
Table 4.7: Total self-reported persistence over time 
ITT – intention-to-treat; OT – on-treatment. 
Time 
Control 
 N/57 (%) 
ITT  
N/54 (%) 
P 
OT  
N/41 (%) 
P 
6 weeks 44 (77.2) 43 (79.6) 0.755 31 (75.6) 0.855 
6 months 34 (59.6) 27 (50.0) 0.307 20 (48.8) 0.110 
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4.2.5 Triangulation of adherence and persistence by MMPR and self-report 
Among those discharged as guideline-concordant, there were no significant 
differences in the rates of persistence or the composite of adherence and persistence 
when both the MMPR algorithm and self-report measures were combined, as 
presented in Table 4.8. “Persistence alone” is a composite of those who were 
persistent to six months by both self-report and the MMPR algorithm. “Adherent 
and Persistent” includes a positive result for both persistent measures as well as 
having a consistent score of zero on the MAQ or an improvement on MAQ, and an 
MMPR greater than or equal to 0.8. When comparing the level of agreement between 
the two measures for each finding, the kappa statistic for persistence measures 
demonstrated moderate agreement at 47.4% (p<0.001, standard error 11.1%). For 
adherence and persistence by both measures the agreement was lower at 23.4% 
(p=0.05, standard error 11.6%). 
Table 4.8: Cumulative adherence and persistence to a guideline-concordant regimen at six 
months by both medication possession ratio and self-report 
ITT – intention-to-treat; OT – on-treatment. 
Outcome 
Control 
 N/32 (%) 
ITT  
N/35 (%) 
P 
OT  
N/26 (%) 
P 
Persistence 
alone 
16 (50.0) 14 (40.0) 0.411 10 (38.5) 0.380 
Adherent 
and 
Persistent  
8 (25.0) 8 (22.9) 0.837 8 (26.9) 0.868 
4.2.6 Multivariate model to predict persistence at six months 
As shown in section 4.2.2, there was a statistical trend toward a higher proportion of 
patients who were persistent among those discharged as guideline-concordant in the 
control group (p=0.065). This warranted further investigation for potential 
confounding from baseline variables and an LR model was developed as discussed 
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in section 3.2.6. The final model is presented in Table 4.9 showing completion of CR, 
the angina frequency domain of the SAQ, and question three of the BMQ (doctors 
prescribe too many medications) as confounders for the relationship between study 
group allocation and persistence to a guideline-concordant regimen at six months. 
Specifically, these items support the univariate finding that allocation to the control 
group led to a higher rate of persistence (OR 3.7, CI 1.1-12.3, p=0.035) and suggest 
that the intervention may have had a negative effect on persistence. The Hosmer and 
Lemeshow Test for Goodness of Fit suggested a low risk of model overfit (p=0.712) 
and this was further evidenced by relatively narrow confidence intervals. 
Table 4.9: Multivariate analysis of six-month persistence to a guideline-concordant regimen 
CI – confidence interval. 
Variable Odds ratio (95% CI) P 
Allocation to control group  3.7 (1.1-12.3) 0.035 
Completed cardiac rehabilitation 2.2 (0.7-6.8) 0.193 
Seattle Angina Questionnaire, 
angina frequency domain 
1.0 (1.0-1.1) 0.047 
“Doctors prescribe too many 
medications” 
0.7 (0.4-1.3) 0.235 
4.3 Secondary outcomes 
4.3.1 Mortality rates, hospital readmission rates, and lengths of stay  
Two intervention patients died in the period shortly following discharge, prior to the 
dHMR visit. One occurred at 6 weeks post-discharge, with the cause recorded as a 
major haemorrhagic stroke attributed to warfarin therapy. The other occurred two 
weeks post-discharge and was of an unknown cause in a private hospital. One 
control patient died three days post-discharge with an unconfirmed but suspected 
cardiac cause of death. Another control patient died from CHF during the follow-up 
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period, approximately 14 weeks post-discharge. There were no significant 
differences in the mortality rate between the groups at six months (p=0.681). 
There were no statistically significant differences in the proportion of patients with 
hospital readmissions between the control and intervention groups (25.0% vs 33.3%, 
p=0.260). One patient in the control group had 11 hospital readmissions during the 
follow-up period but was noted to have frequent admissions prior to the study. As 
such, this patient was considered an outlier and removed from further analysis of 
readmission data. After adjustment, there were a total of 30 unplanned and seven 
cardiovascular-related unplanned readmissions in the control group. There were 36 
unplanned and eleven cardiovascular-related unplanned readmissions in the 
intervention. Among those with an unplanned readmission, the median number of 
readmissions was one in each group (interquartile range 1.0-2.3 for control and 1.0-
2.0 for the intervention patients). There were no significant differences (p=0.413 for 
unplanned readmissions, p=0.706 for cardiovascular-related unplanned 
readmissions).  
One patient in the control group had a total of 35 days in hospital during follow-up. 
This patient was considered an outlier and excluded from the length of stay analysis. 
Following adjustment, 17 control patients with unplanned readmissions spent a total 
of 70 days in hospital with the median length of stay equal to 1.0 days (interquartile 
range 1.0-7.5). Twenty-five intervention patients with unplanned readmissions spent 
a total of 85 days in hospital with a median length of stay of 2.0 days (interquartile 
range 1.0-5.5). These differences were not significant (p=0.826). Of those with 
unplanned readmissions, there were no significant differences between the groups in 
the rates of admissions that lasted longer than a day (47.1% control and 52.0% 
intervention patients, p=0.753). 
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4.3.2 Cardiac rehabilitation attendance and completion rates 
Nineteen patients (10 control patients, 9 intervention patients) who were 
geographically isolated from standard CR services and known to have not 
completed CR at either of the recruiting hospitals were included in the non-
attendance group. The remaining patients had clear records to indicate that they 
either did not attend any CR sessions, they attended some sessions but did not 
complete CR, or that they attended a full CR program (typically six sessions). These 
results are presented in Figure 4.6; there were no significant differences in rates of 
attendance or completion across the study groups (p=0.509). 
Figure 4.6: Degree of engagement with cardiac rehabilitation services 
ITT – intention-to-treat; OT – on-treatment 
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nicotine dependence section of the six-week questionnaire, the smoking rate was 
27.0% and this had fallen to 13.9% by six weeks post-discharge, reflecting a self-
reported smoking cessation rate of approximately 50% following ACS. Among the 
quitters, 1 control patient self-reported that they had restarted smoking by six 
months and 2 control patients and 1 intervention patient did not respond to the 
smoking section of the six-month questionnaire, reducing the proportion of self-
reported persistent quitters to 36.4%. There were no significant differences between 
the control and intervention (p=0.170). One further intervention patient who was still 
smoking at six weeks self-reported to have quit by six months and another who did 
not respond to the six-week questionnaire reported to have quit by six months. 
The FTND was used to classify nicotine-dependence among the cigarette smokers 
within the trial. The test utilises six questions to give a dependency score ranging 
from very low to very high. Only twelve patients (eight control patients, four 
intervention patients) completed this test at both six weeks and six months. All four 
intervention patients scored very low or low at both time points. Among the control 
patients at six weeks, one scored each of very low, moderate, and high dependency, 
with the remaining five scoring low dependency. This increased at six months with 
four scoring low dependency and two for each of moderate and high dependency. 
There were no significant differences between the control and intervention group 
(p=0.105) comparing low versus moderate/high dependency. The small sample size 
of smokers significantly limited the likelihood of showing any statistical difference. 
4.3.4 Quality of life 
Patients were surveyed on their QoL at six weeks post-discharge as a pre-
intervention measure and again at six months post-discharge to assess the impact of 
the intervention. The first instrument used to assess QoL was the EuroQol’s Eq-5D-
3L. The proportion of patients reporting severe/extreme problems to any of the five 
domains was low and, as such, the Likert scale was dichotomised to those with no 
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problems versus those reporting problems. The proportion of patients with 
problems versus without problems for each domain is presented in Figure 4.7. There 
were no significant differences between the control and intervention for any of the 
domains at either time point.
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Figure 4.7: Eq-5D responses by domain at six weeks and six months. See overleaf: anxiety and depression. 
ITT – intention-to-treat; OT – on-treatment 
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Utility scores were calculated based on a value set for the Eq-5D 
derived from a validation study of an Australian population.156 
There were no significant differences between control and 
intervention at both time points as shown in 
Table 4.10. Similarly, there were no significant differences within 
each group over time (p=0.656 for the control group and p=0.934 
for the intervention group). 
 
Table 4.10: Median six-week and six-month utility scores for the Eq-5D 
IQR – interquartile range; ITT – intention-to-treat; OT – on-treatment 
Time Control N/57 (IQR) ITT N/54 (IQR) P OT N/41 (IQR) P 
Six weeks 0.774 (0.677-1.000) 0.786 (0.673-1.000) 0.711 0.745 (0.641-1.000) 0.477 
Six months 0.798 (0.614-1.000) 0.798 (0.609-1.000) 0.672 0.798 (0.609-1.000) 0.562 
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Figure 4.8 represents the median, interquartile range, and minimum/maximum 
scores for the VAS of the Eq-5D. There were no significant differences between the 
groups at either time point (p=0.590 at six weeks and p=0.680 at six months). Within 
group changes over time were also not significant (p=0.583 for the control group and 
p=0.289 for the intervention group). 
Figure 4.8: Box-plot of Eq-5D VAS. Minimum and maximum values represented by error 
bars, interquartile range is represented by the central box and the median is represented by 
the central intersect. 
ITT – intention-to-treat; OT – on-treatment; VAS – visual analogue scale 
 
Individual responses to the five domains of the SAQ were processed according to 
the algorithm by Spertus et al and are reported by domain in Table 4.11.151 There 
were no significant differences at six weeks, however, there was a trend toward a 
higher reported angina stability score at six months in the intervention group 
(p=0.054). This score corresponded to a single question from the SAQ whereby 
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using the Wilcoxon Signed Ranks Test showed that the differences in angina stability 
resulted from a decrease in score over time within the control group, z= -2.102 based 
on positive ranks with p=0.036, whereas the intervention group remained steady, z= 
-0.947 based on positive ranks (p=0.344). Both the control and intervention groups 
also reported increased cardiac-specific QoL at six months as in Table 4.11, however, 
the increase was slightly higher and with a greater level of significance in the control 
group, z= -2.882 based on negative ranks (p=0.004) versus z= -2.160 based on 
negative ranks for the intervention group (p=0.031). 
Table 4.11: Calculated median scores for the five domains of the Seattle angina questionnaire 
IQR – interquartile range; ITT – intention-to-treat; OT – on-treatment; PLS – physical 
limitation score; AS – angina stability; AF – angina frequency; TS – treatment satisfaction; 
QoL – quality of life. 
Time 
Dom
-ain 
Control N/57 
(IQR) 
ITT N/54 
(IQR) 
P 
OT N/41 
(IQR) 
P 
Six 
weeks 
PLS 
69.4 (50.0-
88.9) 
75.0 
(50.7-
94.4) 
0.208 
76.4 (52.8-
91.7) 
0.246 
AS 
50.0 (50.0-
75.0) 
50.0 
(50.0-
100.0) 
0.181 
50.0 (50.0-
100.0) 
0.130 
AF 
100.0 (80.0-
100.0) 
100.0 
(75.0-
100.0) 
0.807 
95.0 (70.0-
100.0) 
0.552 
TS 
100.0 (87.5-
100.0) 
93.75 
(81.3-
100.0 
0.183 
93.8 (81.3-
100.0) 
0.176 
QoL 
58.3 (41.7-
83.3) 
58.3 
(41.7-
83.3) 
0.802 
58.3 (41.7-
83.3) 
0.754 
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Six 
month
s 
PLS 
72.2 (54.2-
93.1) 
77.8 
(51.4-
97.2) 
0.922 
77.8 (50.0-
93.8) 
0.934 
AS 
50.0 (50.0-
50.0) 
50.0 
(50.0-
75.0) 
0.054 
50.0 (50.0-
62.5) 
0.135 
AF 
100.0 (80.0-
100.0) 
100.0 
(80.0-
100.0) 
0.179 
90.0 (70.0-
100.0) 
0.127 
TS 
100.0 (81.3-
100.0) 
93.8 
(80.0-
100.0) 
0.611 
93.8 (81.3-
100.0) 
0.710 
QoL 
75.0 (58.3-
91.7) 
66.7 
(50.0-
83.3) 
0.365 
66.7 (50.0-
83.3) 
0.642 
 
4.4 Process outcomes 
4.4.1 Intervention fidelity 
From 76 scheduled dHMRs, 17 (22.4%) failed to occur according to protocol. Eight 
patients scheduled for dHMR did not ever receive one, five dHMRs were not 
completed until after four months post-discharge, three dHMRs were undertaken by 
APs who failed to complete the education package, and one dHMR was undertaken 
after four months post-discharge and by an AP who failed to complete the education 
package. These incidents were further classified into three categories: patient-related, 
GP-related, and AP-related, to identify the primary cause of the barrier to a per-
protocol intervention. Three patients decided they did not want the service but were 
still willing to participate in trial follow-up, and in seven cases each, there were GP 
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and AP-related barriers. Such a high rate of AP-related barriers was particularly 
surprising, however, the true number of patient-related barriers is diluted in this 
assessment as there were initially 81 patients who did not consent to participation in 
the trial and 12 withdrew their consent shortly following hospital discharge. 
Although there are many reasons for declining consent, and this was often 
unspecified, not wishing to receive the intervention and/or not feeling they needed 
any help made up a large proportion of the concern voiced by non-consenters. 
Among the 59 patients who received the intervention per-protocol, the “on-
treatment” group, the median time from discharge to intervention was 65 days 
(interquartile range 61 to 75 days). The earliest visit was 37 days post-discharge and 
the latest visit still within the study protocol time limits was 114 days post-discharge. 
Therefore, even the on-treatment group had a large variation in timing of follow-up 
and any further tightening of on-treatment criteria would have made statistical 
analysis of this group invalid. Although GP follow-up is considered a component of 
the HMR cycle by the Pharmaceutical Society of Australia (PSA)110 just 26 (44.1%) of 
the APs in the on-treatment group submitted GP follow-up. All APs involved with 
the trial were prompted to submit their documentation showing that the GP had 
completed the dHMR follow-up by the project pharmacists, however, the response 
by many APs was that they never received GP follow-up. In contrast, those who 
attempted to enforce GP follow-up as a part of their routine dHMR process did so 
reasonably well, with all but one AP receiving GP follow-up in 50% or more of cases. 
Receipt of GP follow-up was not considered a requirement of the trial protocol as a 
result of this mixed interpretation of the HMR guidelines and the small sample size 
resulting from such restriction. Of those who did receive GP follow-up, seven (25%) 
were without comment and essentially ‘thank you’ notices for the service being 
completed. Twelve (42.9%) received 100% acceptance of recommendations, while in 
the remaining nine, between 20 and 80% of recommendations were accepted.  
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This summary of intervention fidelity highlights quite a significant degree of 
heterogeneity in the way the intervention was conducted, based on a relatively 
simple set of compliance measures.  
4.4.2 Drug-related problem (DRP) analysis 
AP recommendations were categorised by the DOCUMENT system, classifying 
DRPs into recognised categories of clinical importance, see Appendix C – 
DOCUMENT DRP classification system Figure 4.9 shows the percentage that each 
category was raised out of all DRPs recorded. ‘Undertreated conditions’ was the 
most common DRP raised, accounting for nearly 30% of all DRPs. Drug selection, 
compliance, education, and toxicity/ADRs each accounted for 10-15% of DRPs. 
Over/under-dose, monitoring, and unclassifiable DRPs accounted for the remainder.
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Figure 4.9: DRPs as classified by the DOCUMENT classification system. Columns correspond to the percentage each category appeared out of 
all DRPs raised. 
DRPs – drug related problems; ADRs – adverse drug reactions 
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Figure 4.10 highlights how often each DRP category was recognised as a percentage 
of all DRPs among those who were persistent versus non-persistent according to the 
anytime non-persistence outcome, as in Figure 4.3. The aim of this analysis was to 
identify if there were any themes that may explain the lower rates of persistence 
found in these patients as a result of the intervention. Apparent differences include a 
higher proportion of compliance-focussed DRPs raised in the non-persistent 
population, which suggests APs were actually detecting and attempting to address 
problems with adherence in those who were later found to have such issues by a 
more objective measure (the MMPR). Persistent patients also appeared to receive 
more education-based DRPs, however, with such correlations, it remains unclear 
whether this approach was a driver of persistence or a result of fewer genuine 
problems identified among these patients; which may have in turn, allowed more 
time to deliver education. 
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Figure 4.10: DRPs according to the DOCUMENT classification system, as identified in patients who were either persistent or not during the 
two to six month follow-up. Columns correspond to the percentage each category appeared out of all DRPs raised. 
DRPs – drug related problems; ADRs – adverse drug reactions 
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Recommendations for resolution of DRPs are presented categorically as a percentage 
of all recommendations made in Figure 4.11. Several categories were not raised at all 
and were omitted from the figure, including “prescription not dispensed”, “drug 
brand change”, “refer to hospital”, and “refer for medication review”. The provision 
of information category was presented as a cumulative of the sub-categories in this 
section, which mostly reflected education/counselling sessions and the provision of a 
written summary of medications. The high proportion of recommendations 
requiring referral to prescriber reflects the need for prescriber input into any 
recommendations that would require an adjustment to a prescription; as well as 
recommendations that suggested more than one option as a possible solution to the 
DRP raised, with the AP requesting the GP to choose the most appropriate option. 
The next most common recommendation was for DRPs whereby no 
recommendation was necessary, typically reflecting comments or observations made 
that did not require further action, but warranted classification as a DRP. This may 
have included monitoring or assessment undertaken at the dHMR, rather than a 
recommendation for ongoing monitoring. The relatively low percentage of 
education/written information recommendations, in spite of a reasonably high 
number of DRPs in the education category is most likely explained by most of these 
DRPs not resulting in further specific recommendations being made.
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Figure 4.11: DRP recommendations as classified by the DOCUMENT classification system. Columns correspond to the percentage each 
category appeared out of all recommendations made. 
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Recommendations for resolution of DRPs as a percentage of all recommendations 
made was further divided into those who were persistent or not according to the 
anytime non-persistence outcome and this is presented in Figure 4.12. Non-
persistent patients had a higher proportion of recommendations to increase the dose 
of a particular medication (p=0.006). This was investigated qualitatively to determine 
if recommendations to increase doses may have then led to these medications being 
stopped, potentially as a result of increased dose-related side effects, for example. 
However, in almost all of these cases, the drug with the recommendation to increase 
the dose was not one to which the patient was non-persistent. Persistent patients had 
a visually higher proportion of DRPs not requiring a recommendation and this may 
align with a greater amount of education being delivered at these dHMR interviews 
as shown in Figure 4.10. This would support the suggestion from Figure 4.11 that the 
“no recommendation necessary” category is partly made up by DRPs that are more 
so a formal documentation of the APs’ actions in delivering education and not 
requiring further recommendations to be made.
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Figure 4.12: DRP recommendations according to the DOCUMENT classification system, as identified in patients who were either persistent or 
not during the two to six month follow-up. Columns correspond to the percentage each category appeared out of all recommendations made. 
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To more clearly assess whether or not the intervention was focussed toward the 
expected ACS-related or adherence-related problems, each DRP was further 
classified into these two categories or not at all. Table 4.12 shows that 79.9% of all 
DRPs were relevant to ACS and this was similar across persistent and non-persistent 
patients. Just 20.5% of DRPs were relevant to adherence and this was higher for 
those who were non-persistent to at least one guideline-recommended medication 
(p=0.056). 
Table 4.12: DRPs categorised by relevance to ACS or adherence 
ACS – acute coronary syndrome 
 ACS-related n (%) Adherence-related n (%) 
Persistent (n/127) 100 (78.7) 19 (15.0) 
Non-persistent (n/112) 91 (81.3) 30 (26.8) 
Total (n/239) 191 (79.9) 49 (20.5) 
 
4.5 Patient-focussed process outcomes (survey results) 
A written, mail-out survey/questionnaire battery was utilised to measure the impact 
of the intervention on the patient at both six weeks and six months post-discharge, 
see  
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Appendix B – Questionnaire battery. The results from each section of this survey 
were analysed to explore if any changes in the primary outcome could be further 
explained by changes in associated adherence behaviours as identified through the 
conceptual framework. The combined response rate for both six-week and six-month 
questionnaires was 66.7%. 
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4.5.1 Tool for Adherence Behaviour Screening (TABS) 
At the time of trial design, the TABS had not been extensively studied as a unique 
surrogate outcome measure for defining whether or not patients were adherent. 
Instead, the TABS was used separately to further define adherence behaviours 
within the cohort. For this reason, the results from this questionnaire are presented 
in this section as opposed to the primary results. The TABS comprises eight, five-
point Likert scale questions and is split into an adherence and non-adherence 
subscale with four questions in each section. Each section is summed to give a total 
adherence and non-adherence score as well as a differential total score, whereby the 
non-adherence total is subtracted from the adherence total. Median scores are 
presented in Table 4.13 showing a wider IQR for the adherence subscale in the 
intervention group at six months with a trend suggestive of lower adherence 
(p=0.072). There were no other significant differences at either time point. Similarly, 
there were no significant differences within the groups over time. 
The individual items of each subscale at six months post-discharge were explored to 
determine if there was one particular item that was different between the groups 
which may suggest a particular behaviour that was affected by the intervention. 
There were no significant differences detected in any items from the adherence 
subscale. However, the results were skewed toward the end of the Likert scale for 
each question, therefore the TABS was further explored by arbitrarily dichotomising 
the results around the point of difference on individual questions. Among the non-
adherence subscale, the only question with a significant difference was “I put up 
with my medical problems before taking any actions” with 71.2% of intervention 
patients recording an answer of “never” compared with just 52.6% of controls 
(p=0.047). This suggests that the intervention patients may have been more likely to 
take action when noticing a change in their medical status and again this may have 
affected their medication collection patterns. This finding remained significant for 
the on-treatment sub-analysis (p=0.048) which may suggest that there was a genuine 
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effect of the intervention on encouraging patients to take action when noticing 
medical problems. The questions remaining unanswered are whether or not these 
actions involved a consultation with the patient’s GP, and if this did occur, how the 
patients felt about their medication management after seeking further advice. 
Table 4.13: TABS subscales at six weeks and six months post-discharge 
TABS – Tool for Adherence Behaviour Screening; IQR – interquartile range; ITT – intention-
to-treat; OT – on-treatment. 
Time 
TABS 
subscales 
Control 
N/57 
(IQR) 
ITT 
N/54 
(IQR) 
P 
OT 
N/41 
(IQR) 
P 
6 
weeks 
Adherence 20 
(19.0-
20.0) 
20 (18-
20) 0.278 
20 (18.0-
20.0) 0.417 
Non-
adherence 
7 (5.0-
10.0) 
7 (5-
10.3) 
0.665 
7 (5.0-
9.0) 
0.782 
Differential 12 (8.0-
15.0) 
11 (7.8-
14.0) 
0.178 
11 (8.5-
14.0) 
0.576 
6 
months 
Adherence 20 
(19.0-
20.0) 
20 
(18.0-
20.0) 
0.072 
20 (18.0-
20.0) 0.149 
Non-
adherence 
7 (4.0-
9.0) 
7 (5.0-
8.0) 
0.810 
6 (5.0-
8.0) 
0.964 
Differential 12 (9.0-
16.0) 
12 (8.0-
14.0) 
0.488 12 (8.3-
14.0) 
0.560 
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4.5.2 Medication knowledge 
Knowledge about medications for CHD was assessed by patients correctly reporting 
the indication for their medications. The indication was requested alongside the self-
report of medications, therefore the answers could be classified into a percentage of 
correct answers. Patients who submitted a survey but did not complete the self-
report of medication lists were scored as zero for knowledge. The proportion of 
patients scoring less than 100% at both time points was low, therefore the outcome 
was analysed as a dichotomous variable as shown in Table 4.14. There were no 
significant changes in scores from six weeks to six months, and no significant 
differences in scores between the groups at either time point. 
Table 4.14: Proportion of patients with 100% knowledge scores based on recall of medication 
indication 
ITT – intention-to-treat; OT – on-treatment 
Time 
Control  
N/57 (%) 
ITT  
N/54 (%) 
P 
OT  
N/41 (%) 
P 
Six 
weeks 
41 (79.9) 38 (70.4) 0.856 29 (70.7) 0.897 
Six 
months 
37 (64.9) 41 (75.9) 0.204 32 (78.0) 0.160 
 
4.5.3 Self-efficacy 
The cardiac self-efficacy questionnaire developed by Sullivan et al is a 13-item, five-
point Likert scale questionnaire.56 The questionnaire is split into two domains with 
eight questions relating to the patient’s self-efficacy in controlling symptoms and 
five questions relating to maintaining function. Each question is coded as 1-5 and an 
average for each domain is generated. For the purpose of this study, an abbreviated 
set of questions was used, removing a degree of duplication and outdated questions. 
Four questions relating to controlling symptoms and three to maintaining function 
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remained. Self-efficacy scores were moderate to high across the cohort and there 
were no significant differences in the median results for each domain at both time 
points between the groups, as in Table 4.15. Within group comparisons using the 
Wilcoxon Signed Rank Test showed no significant differences over time. Similarly, 
there were no significant differences when individual questionnaire items were 
analysed (data not shown). 
Table 4.15: Self-efficacy subscales of controlling symptoms and maintaining function 
IQR – interquartile range; ITT – intention-to-treat; OT – on-treatment; CS – controlling 
symptoms; MF – maintaining function. 
Time 
Self-
efficacy 
domain 
Control 
N/57  
(IQR) 
ITT 
N/54  
(IQR) 
P 
OT 
N/41  
(IQR) 
P 
6 
weeks 
CS 4.0  
(3.4-4.5) 
3.8  
(3.3-4.3) 
0.327 
3.5  
(3.3-4.3) 
0.159 
MF 3.3  
(2.3-4.0) 
3.0  
(2.3-4.0) 
0.998 
3.0  
(2.2-4.0) 
0.734 
6 
months 
CS 4.0  
(3.3-4.3) 
3.9  
(3.3-4.5) 
0.903 
4.0  
(3.3-4.5) 
0.620 
MF 3.7  
(2.3-4.3) 
3.4  
(2.3-4.3) 
0.819 3.3  
(2.3-4.2) 
0.698 
4.5.4 Beliefs about Medicines 
The Beliefs about Medicines Questionnaire (BMQ) is an 18-item questionnaire with 
five questions relating to each of the patient-specific domains of ‘medication 
necessity’ and ‘medication concern’, and four questions relating to the non-specific 
domains of ‘medication overuse’ and ‘medication harm’.162 Two questions from each 
domain were selected for this study based on their expected relevance to CHD as 
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well as two items developed to assess the perceived value of medication following 
ACS. For the ‘specific necessity’ scale, a higher score represents a higher perception 
of need for medication, whereas with the remaining scales a higher score represents 
a more sceptical view toward medication. The individual questions of each domain 
were summed and median scores are presented in Table 4.16. Patients’ beliefs about 
medicines were largely unaffected by a dHMR according to this questionnaire, with 
the exception of the ‘specific concerns’ domain which remained steady among 
control patients, z= -0.242 based on negative ranks (p=0.809), but decreased over time 
for intervention patients, z= -2.124 based on positive ranks (p=0.034) (assessed by 
Wilcoxin Signed Ranks Test, not shown in the table).  
  
139 
 
Table 4.16: Beliefs about medicines subscales and perceived medicine value 
IQR – interquartile range; ITT – intention-to-treat; OT – on-treatment 
Time Subscale 
Control 
N/57 (IQR) 
ITT N/54 
(IQR) 
P 
OT N/41 
(IQR) 
P 
Six 
weeks 
Necessity 
8 (7.0-9.0) 
8 (8.0-
9.0) 
0.458 
8 (8.0-
9.0) 
0.468 
Concern 
6 (4.0-7.8) 
6 (4.0-
6.5) 
0.764 
6 (4.0-
7.0) 
0.755 
Overuse 
5 (4.0-6.0) 
5 (4.0-
6.0) 
0.312 
5 (4.0-
6.0) 
0.583 
Harm 
4 (3.0-6.0) 
4 (3.0-
5.0) 
0.369 
4 (3.0-
5.0) 
0.562 
Value 
4 (4.0-6.0) 
4 (4.0-
6.0) 
0.873 
4 (4.0-
6.0) 
0.836 
Six 
months 
Necessity 
8 (7.0-9.0) 
8 (8.0-
9.0) 
0.484 
8 (8.0-
9.0) 
0.152 
Concern 
6 (4.0-7.0) 
5 (4.0-
6.0) 
0.071 
5 (4.0-
6.0) 
0.170 
Overuse 
5 (4.0-6.0) 
5 (4.0-
6.0) 
0.896 
5 (4.0-
6.0) 
0.474 
Harm 
4 (3.0-6.0) 
4 (3.0-
5.0) 
0.406 
4 (3.0-
5.0) 
0.420 
Value 
4 (3.0-6.0) 
4 (4.0-
6.0) 
0.266 
4 (4.0-
6.0) 
0.261 
4.5.5 Brief Illness Perception Questionnaire (Brief IPQ) 
The Brief IPQ contains eight questions that require patients to rate the perceived 
impact of their condition on various aspects of their life using a zero to ten scale, 
with ten being attributed to the most significant impact.158 The original questionnaire 
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also included a ninth question which is open-ended, but this was omitted for the 
purpose of assessing the impact of an intervention. Figure 4.13 shows the proportion 
of responses to each rating for each question at six weeks post-discharge. Questions 
are reported in the order they were asked, as in   
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Appendix B – Questionnaire battery. The six-month follow-up responses are 
presented in Figure 4.14. Responses to questions two “How long do you think your 
heart condition will continue?” and four “How much do you think your treatment 
can help your heart condition?” were consistently high at both time points. There 
were no significant differences between the groups at either time point.  
Using the Wilcoxon Signed Ranks Test to explore within group differences over 
time, there was a significant increase found among intervention patients for the 
median rating of question three “How much control do you feel you have over your 
heart condition?”, z= -2.521 based on negative ranks (p=0.012), but the control group 
remained steady, z= -0.592 based on positive ranks (p=0.554). This could be expected 
as a result of the intervention with disease self-management discussions occurring 
during the dHMR home-visits. This finding remained true for the on-treatment 
sensitivity analysis, z= -2.323 based on negative ranks (p=0.020). The on-treatment 
analysis also revealed a higher level of concern (question six) over time among 
intervention patients, z= -2.087 based on negative ranks (p=0.037). 
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Figure 4.13: Proportion of ratings to each question of the Brief Illness Perception Questionnaire at six weeks post-discharge 
ITT – intention-to-treat 
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Proportion of ratings to each question of the Brief Illness Perception Questionnaire at six weeks post-discharge (continued) 
ITT – intention-to-treat. 
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Figure 4.14: Proportion of ratings to each question of the Brief Illness Perception Questionnaire at six months post-discharge 
ITT – intention-to-treat. 
 
0
10
20
30
0 1 2 3 4 5 6 7 8 9 10
R
e
s
p
o
n
s
e
s
 (
%
)
Control
ITT
p=0.449
How much does your heart condition affect 
your life?
0
10
20
30
40
50
60
70
0 1 2 3 4 5 6 7 8 9 10
p=0.485
How long do you think your heart 
condition will continue?
0
10
20
30
0 1 2 3 4 5 6 7 8 9 10
Rating scale
p=0.484
How much control do 
you feel you have over 
your heart condition?
0
10
20
30
40
0 1 2 3 4 5 6 7 8 9 10
p=0.702
How much do you think your treatment 
can help your heart condition?
145 
 
Proportion of ratings to each question of the Brief Illness Perception Questionnaire at six months post-discharge (continued) 
ITT – intention-to-treat. 
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4.5.6 Perceived Heart Risk Questionnaire (PHRQ) 
The PHRQ was designed to assess patients’ perceptions of their risk for having a 
heart event of similar or worse nature in future. The questionnaire follows a similar 
zero to ten rating scale as with the Brief IPQ.159 The proportion of responses to each 
rating for each question at six weeks is shown in Figure 4.15 and the six-month 
follow-up results are shown in Figure 4.16. For questions one to three, the majority 
of responses were five or higher at both time points, suggesting a relatively high 
perceived risk of future heart events. For question four “How bad would it be for 
you if you were to have the same heart problem again?” the responses were more 
consistently toward the upper end of the scale at both time points, suggesting that 
most patients recognised the potentially fatal outcome of a future event. There were 
no significant differences between the groups at each time point, nor within the 
groups over time.
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Figure 4.15: Proportion of ratings to each question of the Perceived Heart Risk Questionnaire at six weeks post-discharge 
ITT – intention-to-treat 
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Figure 4.16: Proportion of ratings to each question of the Perceived Heart Risk Questionnaire at six months post-discharge 
ITT – intention-to-treat 
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Chapter Five: Discussion 
5.1 Primary outcomes 
In this randomised controlled trial of a dHMR at two months post-discharge versus usual care 
following ACS, there was no significant difference in the primary outcome of adherence and 
persistence to a guideline-concordant regimen at six-months (p=0.284). This composite outcome 
encompassed two behavioural processes; medication adherence,8 and persistence,9 and further 
examination of the persistence component of this outcome showed a trend toward a lower 
proportion of persistent patients in the intervention group at six months (p=0.065). This trend 
was supported through multivariate analysis, which showed the control group were more likely 
to be persistent after controlling for confounding (OR 3.7, CI 1.1-12.3, p=0.035). There was some 
variance in execution of the trial protocol and an on-treatment analysis was conducted, which 
primarily excluded patients who received dHMRs close to the six-month follow-up. This showed 
lower rates of persistence to P2Y12 antagonists at two months, and statins between two and six 
months. Similarly, for all patients who were discharged on at least one guideline-recommended 
medication, persistence between two and six months was significantly lower in the on-treatment 
group. Possible reasons for these somewhat unexpected outcomes were explored utilising the 
process outcomes and survey data collected, as well as through comparison to similar previous 
studies. However, the findings must also be considered in light of several study limitations, such 
as the small sample size and variable intervention fidelity.  
This study utilised a conceptual framework for the evaluation of chronic disease interventions to 
guide the development and evaluation of the intervention. A benefit of this approach was that 
changes occurring in the primary outcome could be further explored through assessment of 
interrelated variables.88 For example, the primary outcome was assessed objectively through 
pharmacy refill records, but also subjectively through a validated adherence questionnaire, the 
MAQ, and be self-report of persistence. These methods showed only moderate statistical 
agreement, with the self-reported adherence and persistence results suggesting an overall null 
effect from the intervention. While a combination of self-report and MPR has been recommended 
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by the WHO,8 it is important to recognise that there are subtle differences in the constructs 
assessed with a brief adherence questionnaire, by comparison to collection of pharmacy refill 
records. Each method reflects a unique aspect of the overall behaviour of medication adherence, 
such that the two surrogate measures may only be slightly related.9 Nonetheless, the majority of 
the other 76 questionnaire items similarly showed no significant differences from between group 
analyses. There were, however, a few subtle changes in questionnaire outcomes, particular 
through analysis of within group changes over time, and these tended to add support to the 
finding of lower persistence in the intervention group. The following sections will expand on the 
analysis of the questionnaires and other process outcomes, aiming to identify possible 
explanations for the lack of improvement in the primary outcome and the decline in persistence 
among patients in the intervention group. 
5.2 Patient-focussed process outcomes and persistence 
A battery of validated surveys was compiled to assess several adherence-behaviour concepts at 
six weeks as a baseline, with a follow-up comparison at six months. If there were changes in the 
primary outcome it was expected that changes in adherence behaviours and beliefs would help 
to explain why the intervention had either a positive or negative effect. Two-thirds of the cohort 
responded at both time-points and this was accepted as a good response rate given the time 
required to complete the lengthy questionnaire. The TABS questionnaire was summed into two 
subscales to identify behavioural preferences particularly associated with adherence versus 
preferences particularly associated with non-adherence. There were no significant differences 
observed between the groups, nor within group changes over time. The ability to detect 
differences in these scales was most-likely limited by ceiling effects as a result of most patients 
answering strongly for or against each of the Likert-scale questions. However, when the 
questions were dichotomised around the point of difference, the intervention group were more 
likely to record an answer of “never” versus all other options for the non-adherence item “I put 
up with my medical problems before taking any actions” compared with the control group 
(p=0.047). This may have reflected an effect of the intervention in encouraging patients to take 
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action if they noticed problems and this may have also affected medication dispensing records. 
However, there was no correlation between this item and persistence at six months. This item 
stimulated further interest into the types of actions patients were more willing to take, and if 
related to medications, whether or not they chose to involve their GP in the decision-making 
process around these actions. 
Beliefs about medications were assessed using the BMQ and there were no significant differences 
between the groups at either time point for the BMQ or the additional perceived medicine value 
questions. However, within group analysis for the question “I sometimes worry about the long-
term side effects of my heart medication” showed no significant change in the control group, but 
a significant decrease over time for the intervention (p=0.034). It is of interest that Horne et al 
found a strong relationship between a higher level of concern and a desire to change the 
medication regimen in their validation study of the BMQ.162 Several other studies have 
confirmed a link between higher scores for the specific concerns scale of the BMQ and poorer 
medication adherence.185-188 It is possible that those in the intervention group who held a high 
level of concern at six weeks adjusted their medications in some way, possibly through guidance 
from the intervention, and this somewhat relieved their concern such that it was lower when 
reassessed at six months. To further support this theory, a higher level of concern over side 
effects at six weeks was significantly correlated with non-persistence at six months (p=0.045, data 
not shown).  
Ideally, a component of the pharmacist home visit would be a discussion of the benefits from 
continuing medication and/or providing education on the generally low incidence of serious side 
effects among the medications typically prescribed following ACS; as well as advice on how to 
appropriately manage side effects, should they occur. While this should, in part, reinforce 
education initially provided by hospital and community pharmacists, the two-month home visit 
should also provide an opportunity to tailor the information provided based on a review of the 
individual’s tolerance of their new medications to that point. The education package focussed on 
both of these concepts of the benefits from guideline-recommended medications and 
management of side effects, and 25% of all DRPs were either for ‘education’ or ‘toxicity/ADRs’, 
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as shown in Figure 4.9. Therefore, it would seem that both of these issues were addressed during 
some dHMRs. However, it is not clear whether the concerns decreased particularly among those 
who received the intervention and remained persistent, which would suggest a lower concern 
mediated by education; versus those who became non-persistent, potentially showing a lower 
concern as a result of no longer taking the medication. A better understanding through further 
behavioural research about how concerns over medication side effects can be effectively 
managed to improve adherence and persistence would be beneficial.  
Illness perception according to the eight Likert-scale items of the Brief IPQ showed no significant 
differences between the groups at either time point. However, the intervention group reported 
an increase over time in the ‘perception of control’ over their condition (p=0.012) while the 
control group remained steady. It was also found that higher perceived control at six weeks 
correlated with higher rates of persistence (p=0.043, data not shown). It is possible that the 
intervention improved perceived control at some stage prior to the six-month follow-up. If such 
effects were conveyed sooner, they may have led to a different outcome on persistence. Further 
behavioural research looking to improve the understanding of changing a patient’s perception of 
control over time and the effect this has on persistence would be valuable in guiding the design 
of future interventions. 
Medication knowledge, self-efficacy, perceived heart risk, and QoL did not appear to 
significantly differ between groups nor were there significant changes noted over time within 
the groups. However, components of all of these questionnaires, other than medication 
knowledge, were identified as potential confounders causing a CE≥10%. Due to the small sample 
size and strict LR methodology, only a single domain of the SAQ and a single-item from the 
BMQ remained as confounders in the final LR model. Nonetheless, this shows that at least some 
of the domains and/or individual items of these questionnaires interacted with medication 
persistence as assessed by pharmacy refill records. Although the power to detect significant 
differences in the majority of the questionnaire items was limited by the sample size, the 
approach to gather this wide variety of data proved useful. The assessment of medication 
knowledge was particularly brief due to a lack of validated questionnaires available within the 
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ACS setting and this most-likely added further limitations to the assessment of this outcome. It is 
possible that knowledge-related changes, such as an increased awareness of medication side 
effects may have led to patients stopping medications within the intervention group; however, as 
such an effect was not monitored, it can only be recommended to be further considered as an 
outcome of future studies.  
By controlling for confounding from perceptions and beliefs, the univariate finding of lower 
persistence among intervention patients was supported and the statistical power of the study 
was improved.189 Furthermore, use of appropriate analysis to compare within group changes 
provided several links to support the finding of lower persistence in the intervention as a 
potentially true effect rather than a statistical error. Future research into adherence-focussed 
interventions would benefit from assessing a wide variety of adherence and persistence related 
concepts, as studied here, particularly to control for potential confounding from baseline 
differences in patients’ beliefs and perceptions. 
5.3 Drug-related problems and persistence 
The categorisation of DRPs and recommendations to resolve them were explored by comparing 
persistent against non-persistent patients to determine if there were any differences, particularly 
in adherence/persistence-related categories. Although the most frequently cited DRP 
classification was “undertreated conditions” for both persistent and non-persistent patients, 
there was a visibly higher proportion of “compliance”-related DRPs and a lower proportion of 
“education”-related DRPs among non-persistent patients, as presented in Figure 4.10. This 
suggests that for at least some non-persistent patients, there were problems identified with 
medication adherence or persistence (the ‘compliance’ DRP category) during the home visit. For 
a variety of possible reasons, such as the intervention not being consistently delivered in a timely 
fashion, the recognition of adherence problems did not lead to improved adherence or 
persistence at six months. These potential design-related barriers are explored further in sections 
5.5 and 5.6.  
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The categorisation process saw a disproportionately large number of “refer to prescriber” 
recommendations across both persistent and non-persistent patients and this limited the utility 
of this tool as a means to clarify how the intervention may have led to lower rates of persistence. 
The ‘increase dose’ category, however, showed a significant difference with 16.7% of all 
recommendations for non-persistent patients being to increase the dose of a medication, versus 
just 2.5% for persistent patients (p=0.006), as presented in Figure 4.12. These patients were 
explored further to determine if the recommendations to increase the dose of a medication may 
have led to non-persistence of that medication or a medication with similar side effects, such as 
beta blockers and ACEI/ARBs sharing a similar dose-limiting effect of lowering systolic blood 
pressure. In all of these cases, the medication(s) that were discontinued did not appear to be 
related to recommendations to increase the dose of other medications. This individual case 
review also confirmed that this category had been labelled correctly and it was found that most 
of these recommendations were for ACEI/ARBs or beta blocker dose escalation. A possible 
explanation for the higher proportion of ‘increase dose’ recommendations among non-persistent 
patients could be that persistence problems appeared too complex to attempt to resolve by 
comparison to making subtle adjustments in the dosing of medications that the patient was 
tolerating. This is supported somewhat by Table 4.12 showing ‘ACS-focussed’ DRPs were four 
times more likely to be identified than ‘adherence-focussed’ DRPs. Allocating a lower priority to 
adherence-related problems by comparison to other identified issues appears surprising. 
However, this is supported by previous research involving a community pharmacist-led risk 
factor modification intervention, whereby pharmacists consistently developed goals for multiple 
cardiovascular risk factors, with the exception of medication adherence.190 Although this finding 
only provides justification for a null effect rather than significantly lower rates of persistence in 
the intervention group, it is important to consider that medication management may have been 
optimised in other ways, not necessarily related to persistence. Similarly, a greater degree of 
understanding and confidence in managing non-adherence or non-persistence may be required. 
The clinical significance of alternative outcomes, such as dose titration, warrants further 
exploration in light of this finding. Upward dose titration of both ACEIs/ARBs and beta-blockers 
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was briefly cited as an appropriate medication management recommendation within the 
educational material and this target has been used previously in transition-of-care interventions 
among patients with ACS.191,192 Although there is evidence to suggest that treatment with beta 
blockers,36,37 and ACEI/ARBs,34 may decrease the rate of mortality following ACS, there is a lack 
of clinical evidence to support dose escalation among this population.36,37 Importantly, the major 
research supporting dose titration comes from improvements in mortality for patients with CHF 
rather than ACS.193,194 Therefore, this outcome was not used to assess the intervention within the 
current study as the long-term benefits from dose titration following ACS, although likely to be 
beneficial, have not been clearly defined. In contrast, non-adherence and non-persistence to 
guideline-recommended medications has been consistently correlated with worse clinical 
outcomes.6,44 As the effect of the intervention in the current study appeared to result in fewer 
patients persisting with guideline-recommended therapy, it would seem pertinent for future 
research to continue to focus on developing interventions that can improve medication 
persistence. The following sections explore further possible explanations for this unexpected 
finding within the current study. 
5.4 Individual dHMR report review and further case-based discussion 
The planned assessment of DRPs and recommendations using the DOCUMENT categorisation 
system did not show a particularly strong reason for lower persistence in the intervention. 
Therefore, the reports of all patients who were guideline-concordant at discharge and non-
persistent at six months (26 patients, per Figure 4.2) were re-analysed to determine if there were 
written recommendations within the dHMR reports to cease or pause guideline-recommended 
therapies. Similarly, case examples of clinically significant interventions in medication 
management were identified and will be discussed as a comparison. To reduce the risk of 
individual bias, summaries of all non-persistent patients were distributed among the research 
team and cases of interest were discussed to determine if the identified management paradigms 
could be fairly attributed as a likely result of the intervention. 
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Of the 26 patients in the intervention group who were non-persistent, there were no dHMR 
reports whereby recommendations to overtly cease guideline-recommended therapies were 
recorded and this reflected positively on the education and performance of the APs involved. 
There were four cases ‘of interest’ identified, three of which may have missed an opportunity to 
minimise non-persistence based on the content recorded in the report, and one whereby there 
were recommendations made which may have inadvertently led to a gap in medication use. 
Although four out of 26 cases appears insignificant, having four more persistent cases in the 
intervention group may have led to a non-significant difference between groups due to the 
relatively small number of patients enrolled. Therefore, these cases require further exploration to 
identify possible themes.  
Case one dealt with a suspected statin-induced side effect of muscle pain. This patient had a gap 
in supply of their statin therapy and this may be expected when managing such issues. 
Importantly, they restarted on a lower dose of a potent statin and appeared to continue this, with 
anecdotal follow-up showing persistence with this medicine in the period between six and 
twelve months post-discharge. Although this isolated case contributed to non-persistence in the 
intervention group, the patient arguably gained a long-term benefit from the intervention.146 This 
potentially shows a limitation of the two-month permissible gap in the algorithm used to detect 
non-persistence. 
Among the three other cases, there was a theme of premature cessation of DAPT. Case two was a 
patient who presented with a STEMI and received PCI with DES as a primary treatment strategy. 
They were discharged with a recommendation of DAPT for twelve months and triple therapy 
with warfarin for three months due to the risk of apical thrombus following their large initial 
infarction. At the home visit, the AP noted cessation of both warfarin and clopidogrel and this 
was recorded in the report; however, there were no comments about why these medications 
were stopped, nor reference to education conveyed to the patient or GP about the potential 
benefit gained from continuing DAPT to 12 months. Arguably, it may have been appropriate for 
the project officer to intervene further in this case to ascertain if there was some form of bleeding 
incident or other explanation for not continuing DAPT in a patient with recently deployed DES 
       
      
157 
 
due to the high risk of restenosis.18-20,22 However, this did not occur and there was no further 
explanation for this anomaly. In cases three and four, the patients had received PCI with BMS as 
a primary treatment strategy and both were found to be non-persistent to DAPT during dHMR 
follow-up. With further investigation it was noted that both of these cases had been 
recommended very short, three-month durations of DAPT by the interventional cardiologist at 
hospital discharge. Such cases were previously discussed among the trial committee during the 
recruitment phase and it was determined that they were appropriate to include in the trial, given 
the guideline recommendations to continue DAPT to twelve months in all patients with 
confirmed ACS.1,5 Although the cardiologist’s practice may have been a potential barrier to 
improving persistence by way of pharmacist-led intervention, it does not explain the lower rates 
of persistence as a result of the intervention. While a primary treatment strategy of DES 
correlated with persistence to a guideline-concordant regimen (data not shown), it was not 
identified as a confounder of the relationship between study group allocation and persistence. 
Therefore, it is likely that the impact from cardiologist recommendations for shorter DAPT 
durations in those not receiving DES was similar across the control and intervention groups. 
Nonetheless, in neither case did the AP record recommendations to continue DAPT for twelve 
months. Although all three cases represent potentially missed opportunities to recommend 
continuation of treatments in accordance with national guideline recommendations,5 it would 
seem unlikely that the pharmacist could have prevented non-persistence given the prescriber 
recommendations to discontinue medications in at least two of these cases. Therefore, individual 
case review did not help to clarify a mechanism for the lower proportion of persistent patients 
within the intervention group. 
Whether using validated methods, such as the DOCUMENT categorisation system, or by simple 
case-based assessment, the dHMR reports provided little explanation for the lower rates of 
persistence among intervention patients. However, the dHMR intervention hinged largely on 
face-to-face interactions, telephone interactions, and rapport building between the AP and their 
patients/GPs. Furthermore, Carter et al showed that an AP’s ability to listen to their patient may 
affect the patient’s willingness to participate in future HMRs.195 Assessing these interactions in 
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some way was recognised as important during the adaptation of the conceptual framework to 
this study, as shown in Figure 3.9. However, specifically assessing the quality of these 
interactions would have required at least audio recordings of the home interviews and possibly 
of any further interactions between APs and patients/GPs. This would have been expensive and 
more invasive and, as such, it was considered beyond the scope of the current study. Such 
detailed understanding may be an appropriate point of investigation for future studies of similar 
interventions. If audio recordings are deemed overly invasive or expensive, surveys of patient’s 
perceptions, as with Carter et al may at least capture a basic level of understanding in this area.195 
Not having any part of the survey directed at understanding patients’ satisfaction or perceptions 
toward the quality of the intervention was a downfall of the current study. 
While the above three cases described potentially missed opportunities among patients who 
were at risk of non-persistence and had a potential to benefit from a successful intervention, 
there were also cases identified that showed the ability of the intervention to detect interventions 
of high clinical significance. By the time of two months post-discharge, patients were likely to 
have visited their GP and community pharmacist at least once each. Therefore, it should be 
assumed that without a scheduled dHMR, these examples of medication misadventure would 
have continued and put the patient at risk of serious harm. The first case had received PCI with 
DES following a diagnosis of in-stent restenosis following an MI eight months earlier. They had 
been diagnosed with AF following their previous infarction and were discharged on triple 
therapy involving warfarin, aspirin, and prasugrel. Specifically, prasugrel had been prescribed 
as a substitute for clopidogrel due to the assessment that the patient was now at a higher risk of 
re-infarction. At the two-month home visit, the AP noted that the patient was persistent with 
triple therapy, however, he had also been advised by his ex-wife, who was one of his primary 
carers, to continue taking the clopidogrel. The patient attended different community pharmacies 
and the collection of four concomitant antithrombotic medications was not detected until the 
home visit. The AP liaised with the patient’s GP accordingly and ensured clopidogrel was not to 
be continued, as well as recommending that all of the patient’s 14 prescription items be 
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reconciled to the same collection date. This case represented significant medication 
misadventure, with the potential for harm minimised by way of dHMR intervention.  
A second case example involved a patient who had a cerebrovascular accident (CVA) two 
months prior to their index admission of a NSTEMI. They were discharged from hospital on a 
combination product of aspirin and dipyridamole, which had been initiated following the CVA, 
as well as a new prescription for clopidogrel. Such combination therapy was unintentional and is 
inappropriate, not only for the added risk of bleeding, but also because dipyridamole has wide 
variation in its pharmacodynamics effects and has been associated with an increased risk of 
ischaemic coronary events in unstable IHD.196,197 Given the time-course association of when 
dipyridamole was initiated, it is possible it was even implicated as a contributor to the recent 
NSTEMI. However, in this instance, the event was detected by the project officer while aiming to 
follow-up on the scheduling of the patient’s home visit. The patient was using a community 
pharmacy-prepared dose administration aid and they were in the process of switching the 
packing of this device to a new community pharmacy, closer to their current place of residence. 
During this time, the interventional cardiologist, hospital pharmacist, GP, and two different 
community pharmacists had either not detected this unusual combination or chose not to query 
it. Therefore, it is unlikely this event would have otherwise been detected. While the aim of this 
study was not to improve medication management through involvement of any of the project 
officer’s clinical judgement, this incident was briefly discussed among the trial committee and 
determined too serious to avoid. The patient’s GP was contacted to begin resolving the issue and 
the medications listed on the administration aid submitted with the six-week survey from the 
patient confirmed that dipyridamole had been ceased. This particular event is of interest because 
large meta-analyses have been used in attempt to demonstrate the relative safety of 
dipyridamole in the IHD population.198 In such studies, however, the variability of effect can be 
lost as a result of a small number of patients with worsening disease being diluted by a slightly 
larger number of patients showing improvements.197 Somewhat similarly, the effects observed in 
the current study are limited by the small sample size and a larger study is required before a 
more definitive assessment of the intervention can be considered. However, the poor 
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intervention fidelity, as discussed in section 5.6, would require a significant degree of attention if 
such larger studies were to be conducted. 
Another case highlighting a unique attempt to manage a complex patient who stopped all 
medications, has also been reported elsewhere.199 In this particular case, the AP had suggested to 
re-introduce guideline-recommended medication slowly over time. Such an approach, while 
patient-centred, would not have achieved a positive outcome by the MMPR, emphasising the 
need for flexibility in the assessment of such interventions. Overall, the individual case analysis 
added little further in explaining the finding of lower persistence among the intervention group, 
other than a minor trend of missed opportunities among a few cases. There were, however, cases 
of serious medication misadventure identified, which highlighted the potential for 
improvements in outcomes resulting from optimised medication management. Although this 
was only a small proportion of the overall cohort, these cases had gone unnoticed by other health 
professionals and were likely to have resulted in serious negative outcomes if they remained 
unresolved. Furthermore, the analysis of DRPs as a process outcome did not highlight the 
significance of these cases and they would not have been reported based on investigation of pre-
planned trial outcomes alone. Future research involving patients at risk of medication 
misadventure should aim to include assessments of a variety of surrogate markers of clinical 
outcomes following pharmacist intervention, for example, the prevention of potentially serious 
ADRs.  
Similar recent studies of HMRs further emphasise this point. A retrospective analysis of 
international normalised ratio (INR) control among war-veterans or war-widows who were 
treated with warfarin found no difference in the time in therapeutic range (TTR – an assessment 
of INR control over time) in the six months following receipt of an HMR by comparison to both 
the control group TTRs and to the same patients’ TTRs from the six months prior to their 
HMR.200 The secondary outcome was a composite of thrombotic and haemorrhagic events, which 
also saw no difference following HMR intervention, and the study concluded that HMRs 
appeared to have no impact on INR control. In contrast, Stafford et al utilised a similar model of 
directed pharmacist home visits offering intensive follow-up of patients recently discharged 
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from hospital, who were either starting or continuing warfarin therapy. This study also found no 
change in TTR between the intervention and control groups; however, the composite of 
thrombotic and haemorrhagic events was lower in the intervention group at the 90-day follow-
up. Furthermore, persistence with warfarin was significantly higher in the intervention group, 
and the primary outcome, which was a composite of minor and major haemorrhagic events 
occurred less frequently among intervention patients. Collectively, the wide variety of 
improvements suggested that the intervention resulted in important clinical benefits and these 
effects were probably not solely mediated by INR control.120 The comparison of these two studies 
highlights the importance of obtaining a variety of outcomes to adequately assess the impact of 
pharmacist interventions among patients at risk of medication misadventure. 
5.5 Comparisons with similar adherence-focussed interventions 
The process outcomes and individual case analysis offered some plausible explanations for the 
lower persistence observed among intervention patients as well as highlighting a need to 
consider other outcomes not related to adherence when assessing such interventions. 
Comparison against other interventional studies may help to draw out key differences that could 
lead to improvements in the design of future interventions aiming to improve adherence and 
persistence. 
5.5.1 Intervention design differences 
The main element of the intervention within the current study, was a one-off, semi-structured 
home visit at two months post-discharge. By comparison Ho et al designed a multi-faceted 
pharmacist-led intervention following ACS, which achieved a pre-specified improvement in 
adherence of 15% at twelve months.84 The intervention was relatively complex involving the 
delivery of education from a pharmacist on discharge, with repeated follow-up at one week and 
one month post-discharge. Intervention patients received a dose administration aid (DAA), 
information on how to use it, their refill dates were synchronised, and multiple reminders to 
refill their medications were sent by way of an automated voice messaging system. While the 
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semi-structured nature of the dHMR intervention meant that certain features, such as DAAs, 
could be implemented if necessary, Ho et al more consistently ensured all components of the 
intervention would be delivered to each patient and this may have more consistently covered a 
wider variety of adherence barriers. Interestingly, the estimated costs of this intervention were 
similar to that of the intervention described in the current study, perhaps reflecting a shorter 
amount of time spent with patients at each interaction, less funding provided to GPs, and the use 
of technology-based adherence aids, which can be relatively inexpensive.  
Another important factor may be the repeated follow-ups both before and soon after discharge. 
Patients’ information needs change over time post-ACS, as does their desire to be involved in 
treatment decisions, therefore interventions engaging early with this process may help to tailor 
the later opportunities for follow-up.201 Xavier et al also showed the potential for repeated follow-
ups to improve adherence following ACS and saved costs, in this instance, by utilising a less 
expensive workforce of community health workers to deliver a case-management style of 
intervention.202 The timing of both Xavier et al and Ho et al with follow-up occurring soon after 
discharge may also be relevant as cardiologist follow-up has been correlated to improved 
medication adherence, only if completed within six weeks post-discharge.78 Future research into 
adherence-focussed interventions following ACS should aim to utilise both a variety of 
technological advances and an adapting workforce, including skilled professional-support 
workers where appropriate. This should aim to ensure a wide variety of adherence barriers are 
consistently addressed, the patients are engaged early with the service, and costs of the 
intervention are contained. Such research should explore the impact of variations in service 
delivery, such as allowing APs to recommend an appropriate duration of follow-up. This could 
potentially be with the same AP but not necessarily requiring travel to the patient’s home, for 
example, a clinic-based follow-up prior to a GP appointment or when collecting a medication 
refill at their community pharmacy. The study by Ho et al allowed this type of directed follow-up 
beyond thirty days at the pharmacist’s discretion.84 Such amendments to the HMR service may 
improve its ability to be patient-centred and this should be explored, with future research 
models pushing the barriers of the current HMR model. Although there is some potential for 
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follow-up within the Australian healthcare system by way of a medication use review (MURs), 
known as a “Medscheck” within a community pharmacy, the current funding arrangements do 
not allow these to occur within the twelve months following an HMR. It is not clear if any 
evidence has guided the decision for such a long time between formal follow-up opportunities 
and the impact from this cost-containment approach may affect the opportunity of the services to 
be better integrated to serve the needs of the patient. It seems likely that a much shorter 
timeframe would be appropriate if such services were to be utilised as useful follow-up to a 
complex dHMR, although further research is required to confirm this notion. Further barriers 
associated with limitations of the current HMR service model are explored in section 5.6 
5.5.2 The impact of sample size and different approaches to assessing adherence 
and persistence 
The current study saw significantly lower rates of persistence at six months among intervention 
patients. However, the assessment of changes in the primary outcome, including both adherence 
and persistence, was somewhat limited by the small sample size. Ho et al recruited a relatively 
larger sample than the current study with 241 patients followed to twelve months, allowing for 
greater statistical power. The study by Xavier et al also had the advantage of a larger sample with 
806 patients followed to twelve months. While both studies achieved statistically significant 
improvements in adherence, the clinical significance was unclear and the study by Ho et al was 
scrutinised; being labelled as a potentially massive added cost-burden to the healthcare system if 
it was to be funded across all patients with ACS.85 Interestingly, the results of an insurance 
claims database study observing 4,015 patients post-MI saw reduced rates of major adverse 
cardiovascular events (MACE) by comparing those with MPR≥80% versus those with lower rates 
of adherence post-ACS.146 This was a relatively similar improvement in adherence to that 
achieved by Ho et al and it is likely that the larger sample size and twice the duration of follow-
up improved the statistical power to detect follow-on differences in clinical outcomes resulting 
from the different levels of adherence. The results of a sub-study of the MI-FREE trial were 
somewhat similar to this large database study, suggesting that achieving a high level of 
adherence may be more important than making larger gains in patients with poorer baseline 
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non-adherence.203 This new data suggests a particularly high level of adherence is required to 
improve clinical outcomes.146,203 This is, however, in conflict with previous research, whereby it 
was shown that those who continued just one guideline-recommended medication survived 
longer than those who stopped all medications.6 It may be that those with small gaps in 
adherence and those with large gaps in persistence all stand to gain benefit from targeted 
intervention, however, the intervention may need to be appropriately tailored to the individual 
in order to address these vast differences in adherence behaviour.  
This raises some questions requiring further exploration in future research. For example, can we 
identify those in the greatest need of intervention and thus avoid attempts to intervene with 
patients who did not require it in the first place? Algorithms to highlight patients at risk of 
medication misadventure are being developed, such as the PADR-EC score,204 however, there is 
little useful guidance on selecting patients at risk of medication non-adherence or non-
persistence within the literature. Current guidance suggests there is a wide variety of patient 
variables that may be implicated in non-adherence and it is not clear which variables are most 
important.205 The survey results from the current study suggest that development of a brief 
tailored questionnaire may be useful in identifying those likely to be at risk of non-persistence, 
however, it was not within the scope of this project to explore predictors of non-persistence.  
Another question raised is whether or not one intervention can appropriately deal with such 
contrasting behaviours from minor non-adherence to complete non-persistence. Ho et al has 
shown that those with moderate adherence can be effectively targeted to achieve higher levels of 
adherence, however, little is known about the success rates of interventions delivered to those 
who stop multiple medications. It is likely that these patients may require a significantly greater 
amount of time during follow-up by comparison to those already achieving moderate levels of 
adherence. The current study highlighted that aiming to improve adherence and persistence by 
targeting the entire population of patients with ACS through a one-off intervention is unlikely to 
be successful and may even be deleterious.  
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The combination of simple and complex interventions within a healthcare system may allow for 
a greater variety of adherence barriers to be targeted over time. For example, a hospital 
pharmacist or ‘transition of care’ liaison pharmacist could be instated as the gatekeeper of 
interventions, utilising validated systems to aid in determining who is likely to benefit,204 
enabling the process to occur in a timely manner, tailoring the intervention components to the 
needs of the individual, and monitoring for a variety of clinical improvements. Such methods 
appear practical with only minor adaptations to existing intervention frameworks, however, 
further research of such models is required to determine if they could be effective in improving 
patient outcomes. 
5.6 Intervention fidelity 
Guidance from the conceptual framework ensured a variety of patient-focussed process 
outcomes were considered in the explanation of the intervention’s effect on the primary 
outcome. Similarly, several processes were considered as essential components of the 
intervention design, such that a dHMR could be considered to have occurred per protocol or not, 
as an assessment of ‘intervention fidelity’. Based largely on timing of the dHMR visit and 
completion of the education package prior to undertaking a dHMR, fidelity appeared to be 
reasonably good with 77.6% of scheduled dHMRs occurring per-protocol. However, the 
requirement of GP follow-up was not considered a component of the trial protocol and the home 
visit timing was relaxed to anywhere between discharge and four months post-discharge. Both 
these factors were considered important components of the intervention, but were completed to 
such low levels that statistical analysis of an on-treatment group would not have been possible if 
they were mandated. The low rate of GP follow-up at 44.1% is a potentially significant limitation 
of the service and suggests poor integration within the healthcare system.88 A tighter timing 
around the point of two months post-discharge may have been appropriate as the aim was to 
ensure continuation of medication therapy and a gap in supply of less than a month was used to 
define non-persistence. The effect of timing alone was explored through ad-hoc analysis, 
excluding all dHMRs that occurred later than eleven weeks post-discharge (three weeks after the 
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expected home visit) and while the numbers were small, the trend appeared to remain consistent 
with the on-treatment findings as in Figure 4.2 (data not shown). Therefore, delayed timing of 
the home visit as a single factor in isolation could not be considered as the sole reason for lower 
persistence among intervention patients.  
When barriers to on-time completion and GP follow-up were investigated, it was interesting to 
note that this appeared to be somewhat provider specific. There were some APs who were more 
consistently punctual on both these aspects and although this did not show a change in outcome 
by sub-grouping, the sample was likely too small to power such analysis. This showed, however, 
that the current format of dHMR intervention could be delivered closely against the designed 
protocol. Unfortunately, there was no clear theme of attributes among those who more 
consistently achieved these components of the service, such that enablers to on-time completion 
could be identified. Further exploration through focus groups with APs may help to identify 
barriers and enablers to timely and complete delivery of the intervention. Research into GPs’ 
perceptions about the HMR service suggests that there may be some aspects of the existing HMR 
structure that limit its delivery in a timely and complete manner, such as the processes and 
paperwork involved and that inconsistency with the quality of reports received.206 The GPs 
interviewed suggested that a standard reporting format would be desirable.206 This may partly 
explain the lack of GP follow-up for some patients in the current study. Investigation of patients’ 
perceptions suggests that both these points of timely visits and GP follow-up are key to keeping 
the patient engaged.207 Those experiencing delays and/or failure to receive a specific GP 
appointment to discuss the review expressed a lack of faith in the health system as a result.207 The 
combined effects of delayed visits and low GP follow-up within the current study could clearly 
relate to disengagement with the health system and help to explain the potentially deleterious 
outcome on medication persistence. It may be appropriate to consider a co-designed approach, 
whereby stakeholders, such as GPs, community pharmacists, APs, and patients are interviewed 
to help develop the design of the intervention as has been previously suggested.208,209 
Within the current study the tailoring of the intervention was deliberately limited to ensure the 
standard HMR funding mechanisms could be followed. Not only did this allow the trial to be 
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undertaken with a small budget, it was thought this would also improve the translation of any 
observed outcome into practice, which has been previously identified as an area of unmet 
need.100,210 This approach, however, may have limited the success of the intervention, possibly 
even contributing to the negative outcome on persistence. Other studies have shown similarly 
negative outcomes from relatively brief post-discharge follow-up interventions.115,116,211 
Conversely, Ho et al and Xavier et al both showed improvements in adherence when the 
intervention was initiated at the point of discharge and continued during the transitional 
period.84,202 While the current study was coordinated centrally by two researchers (both 
registered pharmacists) who would consult with patients, APs, and GPs; the aim of these 
interactions was largely to facilitate the intervention to occur under the standard funding 
arrangements – effectively ensuring completion of paperwork and arranging home visits. These 
interactions with the patient could have sought to obtain further useful information while they 
were in hospital. Transfer of such information to the GP and AP may have better integrated the 
service within the existing healthcare system and allowed for tailoring toward the needs of the 
individual.201,212 The period post-discharge following ACS is typically busy with cardiac 
rehabilitation, GP, and specialist appointments and this was one reason for selecting a slightly 
delayed follow-up at two months. In theory, the home visit has an advantage over these other 
follow-up opportunities of being able to observe the patient’s medicine storage and 
administration routine. However, such detailed level of insight may not be required for all 
patients and greater involvement from the project officers could have further served to identify 
those needing more detailed follow-up based on early contact with the patient by phone, or 
through interrogation of their first month’s medication refill record. If a more engaged approach 
involving specialist referral pharmacists were to be successful, it would have required an 
additional component of funding in order to translate the service into practice. However, this 
would be much smaller and more achievable than the funding required to deliver an entirely 
new service.  
This study is not the first to demonstrate difficulties in achieving an accurately implemented 
intervention by adaptation of an existing service.210,213-215 There is, however, a lack of information 
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on ways to improve the translation of outcomes from successful clinical trials into routine clinical 
practice.216 The current study provides insight into the conduct of the existing HMR service 
within Australia, suggesting that a significant proportion of reviews are not conducted in a 
timely manner and to completion with GP follow-up. Future research should consider ways of 
delivering interventions in a consistently timely and complete manner. The current study noted 
that some providers were able to more consistently provide a timely and complete service, 
showing that the intervention can be implement as intended. However, there was not sufficient 
exploration into the barriers or enablers of this higher level of intervention fidelity. The existing 
body of research highlights that GPs require interventions to be reported succinctly and patients 
need to be engaged throughout the process.109,206,207,217,218 Broad stakeholder engagement during 
the design phases of interventions may help to enable successful implementation.208,209 If small 
add-ons to existing formats are required in order to facilitate this and to improve the integration 
of the service within the healthcare system, this may be more desirable than to risk an existing 
intervention leading to a deleterious outcome. 
5.7 Limitations 
5.7.1 Sample size 
The final sample size was approximately half that intended based on power calculations using 
the decline in persistence observed from the DMACS study as a guide.26 The small sample 
recruited was further reduced by a slightly lower than expected rate of guideline-concordant 
discharge prescribing.26,81 Despite these limitations, the trial demonstrated a statistical trend in 
the persistence component of the primary outcome and by controlling for confounding, LR 
analysis supported this univariate finding. Therefore, a potential strength of the study was the 
comprehensive measurement of baseline variables to allow for development of the LR model 
and improved statistical power.189 However, inclusion of variables into the LR model was also 
limited by a large increase in standard error if more than four variables were included, 
suggestive of model overfit. While the careful selection of variables saw that the most important 
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confounders were included, it is possible that a larger sample size may have led to tolerance of 
inclusion of more variables in the model, and this may have led to a different outcome. 
However, a sample of 50 consecutive clinical trial reports from major journals showed that this 
would be an unlikely event as controlling for confounding most commonly led to a similar 
outcome as that from univariate analysis.219 While LR somewhat improved the confidence lost 
from a lower than expected sample recruited, the small sample size limits the generalisability of 
the results. The lack of a trend toward an improvement and poor intervention fidelity suggest 
refinement of the model of intervention is required prior to conducting further studies of 
pharmacist-led interventions aiming to improve medication adherence or persistence.  
5.7.2 Collection of patient dispensing records for the MMPR 
As there was no central database or mechanism accessible that contained information on patient 
dispensing records, these data needed to be collected from individual pharmacies. This created a 
potential limitation of missing data due to patients collecting medication at one or more 
pharmacies that they could not remember by name. As described in the methods, however, there 
were multiple steps to improve the quality of these records and any remaining uncertainties 
were adjudicated by a third researcher not involved with data collection or recruitment. This 
resulted in only 12 patients (7.4%) (five control patients and seven intervention patients) who 
were excluded as a result of uncertainties in their medication records. This is comparable to the 
1-8% of missing data commonly observed through the use of automated records to generate 
MPRs,139 and although this was a relative strength of the study given the need for manual 
submission of the dispensing records, it is possible that the excluded patients may have had 
significant benefits from the intervention or were significantly worse-off in the control group, 
but either possibility went unnoticed and is a limitation to the generalisability of the results. 
Consent to access of a patient’s electronic health record containing data, such as medication refill 
histories may overcome data collection problems for the MMPR. Such records exist in Australia 
but are yet to be widely adopted by patients. 
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5.7.3 Inability to assess improvements in guideline-concordant prescribing 
Ideally the study would have investigated the effect of the intervention on improving guideline-
concordant prescribing, assessing for example, how many patients were started on new, 
guideline-recommended medications following the intervention, despite not being prescribed 
them at discharge. Failure to initiate and up-titrate therapy after hospital discharge is a known 
problem and it has been shown that GPs are reluctant to initiate new medications without 
further review from the cardiologist,71 yet specialist review rarely occurs on a regular basis.79 
Others have argued that this problem should be effectively ignored and all focus put onto 
perfecting medication management within the hospital.71 However, there is clearly a 
communication and responsibility misunderstanding that should be rectified. When patients are 
in hospital following ACS, their stays are usually short and their health status is dynamic. 
Therefore, there may be relative contraindications to initiating ACE-inhibitors or beta-blockers, 
such as low heart rate or blood pressure recordings. Once stable, however, these patients may 
stand to gain cardio-protective benefits from late/delayed initiation of these agents and further 
work is required to break down these barriers to guideline-recommended medication initiation 
post-discharge. 
5.7.4 Use of the dHMR report as the primary record of the dHMR content 
Although there were multiple components to the assessment of intervention fidelity, the dHMR 
report was the central pillar used to assess the APs’ activity and the potential impact the 
intervention. While this report should reflect the most important points covered during the 
dHMR, the detail contained within the report varied significantly between APs and this may 
have been an unfair assessment of their overall contribution during the home-visit. For example, 
previous research has highlighted that there are valuable education and counselling sessions 
delivered throughout a home-visit that are rarely mentioned in reports.109,112,218 Carter et al have 
further highlighted that an AP’s attentiveness and listening skills affect patients’ beliefs that the 
HMR would have a positive outcome and their willingness to have further such interventions in 
future.195  
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A strength of the current study was the collection of further information, such as recording the 
timing of the HMR in relation to the patient’s most-recent medical event (ACS), further 
education of the APs involved with specific information relevant to ACS and adherence 
management, and collection of GP follow-up of AP recommendations. However, further 
information could have been collected to assess the quality of such intervention. For example, 
interviews and qualitative analysis of the beliefs of patients195 and GPs206 involved with the HMR 
service may add further granularity to the assessment of the quality of the service and how it 
was received by those involved. Further to this, audio-recording to understand what further 
information is conveyed and potentially even video-recording to ascertain an understanding of 
non-verbal communication used may offer a significant opportunity to understand the strengths 
and weaknesses of particular APs' approaches to the dHMR. 
5.7.5 dHMR quality control 
As the intervention was based around an existing service, the ability to impact the quality of the 
intervention was limited by the existing governance framework for HMRs. Following 
registration as a pharmacist, AACP require completion of a one-day course, a multiple choice 
questionnaire, and four hypothetical cases (2xHMRs and 2xRMMRs (residential medication 
management reviews)) before a pharmacist becomes accredited and can undertake HMRs as a 
freelancer. After this point, the only feedback given to the AP regarding the quality of their 
reviews is that from the patient, GP, or if they actively seek peer review. While it is in the AP’s 
best professional interest to aim to conduct the best quality review possible such that the GP will 
continue to refer patients to their service, there is no guarantee of this. Previously recognised 
problems with timing and completion of the HMR service were identified within this 
study.109,206,217,218 Although some APs more consistently delivered complete and on time 
interventions, the incentive to do so may not be sufficient and this could be investigated further. 
Anecdotally, the fixed level of reimbursement for HMRs has been known to further impact the 
quality of the service delivered. APs may, somewhat rightfully, aim to ensure their service 
remains financially lucrative, or at least on par with their other pharmacy-based activities and 
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this may curtail the time available for the home visit, report write-up, or verbal communication 
with the GP. Alternative approaches to reimbursement, such as a fee-for-service model based on 
the type of DRPs addressed, or payment on an hourly rate, managed by a service director, could 
be explored to allow those in need of a more thorough intervention to receive it. This could be 
balanced by those in lesser need of intervention receiving the full process in an appropriately 
shorter timeframe. Co-locating the AP within the GP’s clinic may overcome the travel barrier to 
delivery of a shorter intervention for those identified as unlikely to require a home visit. 
5.8 Future directions 
This study provided a detailed assessment of a dHMR delivered two months post-discharge 
following ACS and there are several recommendations for future research based on the results 
and comparison to the existing literature. 
5.8.1 Development of an algorithm to reliably predict non-adherence and/or non-
persistence  
Large observational studies initially demonstrated that the population of patients with recent 
ACS may be at risk of stopping potentially life-saving medication and present a suitable target 
for adherence-focussed interventions.6,44,75 In addition to this, a clinical benefit from a very high 
level of adherence has been shown in comparison to lower levels of adherence to guideline-
recommended medications following ACS.146,203 Importantly, these studies highlight that 
although there is a need to improve adherence and persistence following ACS, there is also a 
reasonably large proportion of patients who are adhering and persisting with therapy to an 
acceptable standard. Intervening in these patients will waste resources and could be 
deleterious.85 Developing algorithms to identify those at the greatest risk of non-persistence and 
non-adherence could help to minimise this potential problem. Although further testing is 
required, the PADR-EC tool has been developed to predict elderly patients at risk of adverse 
drug reaction-related admission to hospital, such that these patients could be targeted with 
medication management intervention.204 Although there is a wealth of research investigating 
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predictors of medication non-adherence and non-persistence following ACS,144,205,220-222 a similar 
formula to that of the PADR-EC that could predict patients at risk of non-adherence or non-
persistence has yet to be shown to be effective in a prospective cohort. The ability to detect 
patients most likely to be at risk of medication non-adherence or non-persistence could see only 
those needing intervention to receive it. This could minimise the sample required to observe a 
clinically significant benefit and the waste of resource associated with delivering an intervention 
to patients who did not require it. 
5.8.2 Explore the effect of tailoring interventions to the needs of individuals while 
fitting within the existing healthcare system 
Within the problem of medication non-adherence following ACS, there may be two quite distinct 
behaviours leading to sub-optimal clinical outcomes. There are a group of patients who are non-
persistent and stop medications altogether,6 and a seemingly different group of non-adherent 
patients who appear to continue medication but take it somewhat haphazardly.203 Both these 
subgroups of the ACS population are likely to benefit from appropriately tailored intervention, 
however, it would seem unlikely that both would benefit from the same intervention unless such 
intervention could be dramatically tailored toward the needs of the individual. The literature 
shows that those whom appear to be persistent but are in need of guidance to improve their rate 
of adherence are amenable to intervention when it is initiated prior to discharge and involves 
multiple follow-ups.84,202 The current study builds on this by highlighting that a one-off 
intervention delivered at two months post-discharge or later is unlikely to improve persistence 
among those struggling with this component of long-term medication adherence. Within the 
Australian healthcare system, various methods of follow-up to improve pharmaceutical care 
exist, such as HMRs and MURs. However, the interventions could be better integrated, 
potentially through oversight from specialist pharmacist administrators or liaisons who could 
utilise evidence-based algorithms to determine which patients would benefit from particular 
types of intervention. The AP would be competent in conducting a variety of services of differing 
intensity and, if they could provide reasoning behind a recommendation for more intense 
follow-up in certain settings, the liaison pharmacist may be able to approve the funding to do so. 
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This could allow for services to be not only integrated with each other, but to be wrapped 
around the patient, which may be particularly appropriate for those presenting with multiple 
adherence barriers, potentially not taking any of their prescribed medication.199 Such an 
approach also remains appealing from a perspective of being rapidly translatable into routine 
practice as it would only require minimal adjustment to current funding arrangements.100 The 
addition of an administrator or manager to oversee the allocation of funding would be the main 
added cost. These recommendations only require minimal adjustments to the protocol of the 
current study, specifically, further involvement from the recruiting pharmacists. Such alternative 
options should be explored with further research into pharmacist-led interventions targeted at 
patients with ACS. 
5.8.3 Ensure a variety of clinically relevant outcomes are explored and assessed 
during follow-up 
The education package delivered to APs contained an equally balanced component of 
adherence-focussed and medication management-focussed material. The intention was that a 
solid understanding of medication management principles following ACS would help to 
empower APs to provide education on the benefits of individual medications and develop 
methods for managing common side effects. However, it is likely that this training, as well as the 
APs’ general knowledge base, led to resolution of a variety of DRPs not solely related to 
medication adherence. Table 4.12 supports this theory, highlighting a much larger proportion of 
ACS-focussed versus adherence-focussed DRPs were identified. The case analysis similarly 
showed that some patients experienced quite significant medication misadventure following 
ACS and some of this was resolved through the intervention. However, there could be several 
other reasons for APs focussing more on medication management rather than adherence, such as 
a lack of time to properly delve into adherence barriers, insufficient training for managing 
adherence barriers, and that the medication management issues appeared as more obvious 
problems to manage. Furthermore, other research has shown medication adherence can be 
identified by pharmacists, but is not always given a high priority.190 Future research should aim 
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to identify medication management principles that can lead to positive clinical outcomes 
following ACS and measure these as a component of the intervention outcomes.  
5.8.4 Explore the effects of giving further support to the practitioners involved, 
using a high level of training and ongoing peer review 
During the trial, APs could contact the primary project officer for advice regarding patient issues 
and while this occurred it was relatively infrequent. These conversations were documented in 
the patient’s file but not formally analysed. In addition to advice from the primary project officer, 
one of the APs involved was a highly experienced pharmacist, who also lectured in therapeutics 
and could have been considered a suitable mentor for more junior APs involved. Similarly, a 
small company of APs undertook several dHMRs and they usually utilised a system of 
mentorship for their junior APs. However, the remainder of the APs practised independently 
and although it was not assessed, it is thought they did not seek detailed peer advice regarding 
their reviews. While it is not particularly well documented within the literature, formal systems 
for professional review exist, such as ‘360-degree review’ and ‘ClinCAT’ (based on the mini-
PAT) clinical peer review systems.223-226 Some institutions use these tools widely as methods to 
assess and provide ongoing support for staff regularly involved in patient care. Such oversight 
may also be a suitable approach to overcome the need for audio-visual monitoring of the dHMR 
home visit. If APs could be further engaged with peer-review, they may consider it appropriate 
to invite a peer-reviewer to attend some of their visits with them. While the current 
arrangements for HMR funding would not support this approach, this could be considered as an 
aspect of future research into these types of intervention, allowing a specialist and experienced 
AP or clinical pharmacist to attend a couple of home visits with the AP prior to their 
involvement in a trial setting. 
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5.8.5 Intervention development and evaluation may benefit from guidance involving 
conceptual frameworks and the principles of co-design utilising stakeholder 
engagement 
The conceptual framework by Lemmens et al provided important guidance in determining a 
variety of process outcomes to measure throughout the trial.88 The questionnaire items were 
carefully selected, as shown in Figure 3.10, and only included if there was previous evidence 
showing that the constructs assessed were related to adherence or persistence. The education 
package was developed with input from multiple expert clinicians and extensively peer-
reviewed. And feedback on the trial protocol was sought from experienced APs. However, GPs 
and patients were not consulted in the design of the intervention protocol, nor were their 
perceptions of the intervention assessed during trial follow-up. Similarly, the AP’s acceptance 
and perceptions of the intervention were not sought, largely due to resource limitations. Existing 
research suggests wider engagement during both the design and evaluation stages is important 
for future research of pharmacist-led interventions.206-209 
The conceptual framework also ensured a thorough assessment of intervention fidelity. The low 
rate of GP follow-up and significantly varied timing of the intervention were two important 
outcomes that highlighted frequent variation from the trial protocol. This finding is not unique 
to this study, with translational studies often showing poor implementation due to unforeseen 
barriers.213-215 There were, however, pockets of excellence in this regard with some providers 
more consistently providing on time and complete reviews. However, barriers and enablers to 
effective execution of the trial protocol were not explored and such follow-up should be 
considered a component of future translational research. 
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Chapter Six: Conclusion 
This study aimed to tailor the existing HMR service to the needs of patients with recent ACS and 
demonstrated no benefit in terms of adherence and persistence to a guideline-concordant 
regimen at six months post-discharge. Persistence to a guideline-concordant regimen was lower 
among intervention patients at six months and this univariate finding was supported by 
controlling for confounding. Furthermore, support was given to this finding through survey 
analysis involving assessment of patients’ adherence behaviours, beliefs about medicines, and 
illness perception. A major problem identified was poor intervention fidelity with a large 
proportion of dHMRs occurring well after the intended two months post-discharge and a low 
rate of dHMRs completed to the point of GP follow-up. Nonetheless, this study alongside a 
review of relevant literature can provide guidance for future research aiming to improve 
outcomes for patients with ACS. In particular, there were several case examples of positive 
outcomes from the intervention and some providers were able to demonstrate consistently 
higher intervention fidelity. The findings from this study and the existing literature suggests that 
future research of pharmacist-led interventions may benefit from exploring factors such as, 
targeting the intervention to those at risk of non-adherence or non-persistence, broad 
stakeholder engagement throughout development and evaluation of the intervention, and 
further flexibility in the model of intervention delivered.  
This research was not without limitations including a smaller than intended sample size, risks 
associated with the completeness of the refill records used for the primary outcome, an inability 
to assess for improvements in guideline-concordant prescribing post-discharge, a lack of 
understanding over the quality of the verbal information delivered during the intervention, and 
a lack of processes for coaching or mentoring APs to improve the quality of this information. 
These limitations created a variety of challenges in explaining the impact of the finding of lower 
persistence among intervention patients. In particular, the poor intervention fidelity suggests 
that further research is required to understand whether or not the result stems from a poorly 
designed or poorly implemented intervention. It is important that such research into adherence 
and persistence following ACS continues. On the basis of the findings from the current study, a 
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dHMR service delivered at two months following ACS could be deleterious. Further research 
exploring alternative approaches to modifying this service for a better chance of improving 
outcomes is required. 
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Chapter Eight: Appendices  
8.1 Appendix A – dHMR checklist 
  
 Yes No Further details if required: 
Was the patient taking guideline meds at hospital discharge according to the dHMR 
referral? 
   
ACE Inhibitor    
Beta Blocker    
Aspirin + clopidogrel/prasugrel/ticagrelor    
Statin    
    
Currently taking guideline meds?    
ACE inhibitor/ARB    
Is ACE inhibitor/ARB being titrated toward maximum tolerable dose?    
Beta blocker    
Is beta blocker titrated to maintain resting heart rate close to 60 bpm?    
Is the beta blocker dosing regimen appropriate? (e.g. metoprolol tartrate should be 
twice daily post-ACS) 
   
Antiplatelet therapy    
What is the patient’s expected treatment time for dual antiplatelet therapy?  Are 
they aware of this? 
   
Has the patient had any bleeding issues?    
Is the patient at increased risk of bleeding? (e.g. history of bleeding, age > 65 years, 
etc)  
  Consider PPI if risk factor is present 
If aspirin + clopidogrel – would it be worth considering the combination tablet?      
Statin/cholesterol-lowering therapy    
Any new muscle aches or pains noted?    
Is LDL-C moving towards target levels if known?    
    
Medication Side Effects    
Any new side effects or medication-related concerns?    
Are you able to reassure patient or is a medication change potentially required?    
    
Medication Adherence    
Direct questioning    
Indirect questioning, eg. adherence barriers:    
Condition-related, eg. duration of condition    
Treatment-related, eg. side effects, regimen complexity    
Health-system, eg. costs, continuity of care    
Social barriers, eg. friends and families influence    
Patient-related, eg. too busy for medications   N.B. many more possible examples 
    
Cardiac Rehab    
Currently attending?    
Completed?    
Not started? Consider reinforcing benefits    
    
Smoking Cessation (where relevant)    
Dietary advice required?    
Exercise advice?    
Chest Pain Action Plan?    
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8.2 Appendix B – Questionnaire battery 
Home Medicines Review Following Heart Events 
 
Participant Questionnaire Set 
 
Questionnaire 1: Medication List and Medication Adherence 
Patient Study Number:  Completed by?   Patient / Carer 
 
Please collect together all your current medicines and list them below.  Take a moment to 
notice the layout of the table – there is a separate section for the name, strength, dosing 
time, and number of tablets that you take.  The final column is a short test of your 
medicine knowledge.  You should try to answer this yourself, without any aids.  Do your 
best, there is no penalty for any incorrect information.  There is a second page if required. 
Current 
Medication 
(brand or 
drug name) 
Strength  Time 
when 
you 
take it? 
How 
many 
you 
take? 
What is it 
for? 
Example: 
Prednisolone 
 
5mg 
 
Morning 
 
½  
 
Arthritis 
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Current 
Medication 
(brand or 
drug name) 
Strength  Time 
when 
you 
take it? 
How 
many 
you 
take? 
What is it 
for? 
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We are interested in how you take your medication.  Please place a cross (X) in ONE box 
that best applies to you.  There is no right or wrong answer, we are looking for an honest 
answer. 
 Yes   No 
1. Do you ever forget to take your medication?     
2. Are you careless at times about taking your medication?   
3. When you feel better, do you sometimes stop taking 
your medication? 
  
4. Sometimes, if you feel worse when you take your 
medication, do you stop taking it? 
  
 
People’s view of their medications (Questionnaire 2) 
Many people find a way of using their medicines that suits them.  This may differ from the 
instructions on the label or from what their doctor had said.  Here are some ways in which 
people have said they use their medicines.  For each statement, please place a cross (X) in 
ONE box that best applies to you. 
 
 
N
e
v
e
r 
R
a
re
ly
 
S
o
m
e
ti
m
e
s
 
O
ft
e
n
 
A
lw
a
y
s 
1. I get confused about my medication      
2. I have strict routines for using my regular medication      
3. I keep my medications close to where I need to use 
them      
4. I ensure I have enough medication so that I don’t run 
out      
5. I strive to follow the instructions of my doctors      
6. I make changes in the recommended management 
to suit my lifestyle      
7. I vary my recommended management based on how 
I am feeling      
8. I put up with my medical problems before taking any 
actions      
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How confident do you feel about taking your medication? (Questionnaire 3) 
We are interested in finding out how confident you are in using your medication and 
your belief in its effect.  For each statement, please place a cross (X) in ONE box that 
best applies to you. 
 
N
o
t 
a
t 
a
ll
 
c
o
n
fi
d
e
n
t 
S
o
m
e
w
h
a
t 
C
o
n
fi
d
e
n
t 
m
o
d
e
ra
te
ly
 
c
o
n
fi
d
e
n
t 
V
e
ry
 
C
o
n
fi
d
e
n
t 
C
o
m
p
le
te
ly
 
c
o
n
fi
d
e
n
t 
1. How confident are you that you can 
control your chest pain by changing your 
activity levels 
     
2. How confident are you that you can 
control your chest pain by taking your 
heart medication 
     
3. How confident are you that you know 
when you should call or visit your doctor 
about your heart disease 
     
4. How confident are you that you know 
how to take your heart medication 
correctly 
     
5. How confident are you that you can 
maintain your usual activities at home 
with your family 
     
6. How confident are you that you can 
maintain your usual activities at work      
7. How confident are you that you can get 
regular aerobic exercise (work up a sweat 
and increase your heart rate) 
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How you feel about your medications? (Questionnaire 4) 
We recognise that not everyone feels the same way about medicines and 
everyone’s view and perspectives are important.  This questionnaire will help us 
understand your thoughts about taking medicine.  Please indicate your thoughts or 
beliefs about medicines by placing a cross (X) in ONE box per statement that best 
indicates the way you feel about taking medicines.   
 
S
tr
o
n
g
ly
 
d
is
a
g
re
e
 
D
is
a
g
re
e
 
N
e
it
h
e
r 
a
g
re
e
 
n
o
r 
d
is
a
g
re
e
 
A
g
re
e
 
S
tr
o
n
g
ly
 a
g
re
e
 
1. Without my heart medication I would be 
very sick      
2. Having to take my heart medication 
worries me      
3. Doctors prescribe too many medications      
4. Most medications are addictive      
5. My heart health in the future will depend 
on my heart medication that I am taking 
currently 
     
6. I sometimes worry about the long-term 
side effects of my heart medication      
7. Natural remedies are safer than 
medications      
8. Medications do more harm than good      
9. The cost of my medications makes it 
difficult for me to take them regularly      
10. Medications are not good value for money      
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How does your heart condition affect you? (Questionnaire 5) 
In order to gain an idea of how much you believe that your heart condition affects 
you, please circle ONE number per question that best indicates how you feel about 
your heart condition.  This questionnaire extends over two pages. 
1. How much does your heart condition affect your life? 
no affect at 
all 
0 1 2 3 4 5 6 7 8 9 10 
severely 
affects my 
life 
2. How long do you think your heart condition will continue? 
a very short 
time 
0 1 2 3 4 5 6 7 8 9 10 forever 
3. How much control do you feel you have over your heart condition? 
absolutely no 
control 
0 1 2 3 4 5 6 7 8 9 10 
almost total 
control 
4. How much do you think your treatment can help your heart condition? 
not at all 0 1 2 3 4 5 6 7 8 9 10 
extremely 
helpful 
5. How much do you experience symptoms from your heart condition? 
no symptoms 0 1 2 3 4 5 6 7 8 9 10 
many severe 
symptoms 
6. How concerned are you about your heart condition? 
not at all 
concerned 
0 1 2 3 4 5 6 7 8 9 10 
extremely 
concerned 
7. How well do you feel you understand your heart condition? 
don’t 
understand 
at all 
0 1 2 3 4 5 6 7 8 9 10 
understand 
very clearly 
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8. How much does your heart condition affect you emotionally? (For example, does it make you 
angry, scared, upset, or depressed?) 
not at all 0 1 2 3 4 5 6 7 8 9 10 
extremely 
affected 
9. How serious do you think your current heart condition is? 
not at all 
serious 
0 1 2 3 4 5 6 7 8 9 10 very serious 
10. How do you rate your chance of having the same, or developing the same heart problem again in 
your lifetime? 
unlikely to 
happen again 
0 1 2 3 4 5 6 7 8 9 10 
almost 
certain to 
happen 
again 
11. Compared to other people of your same age and gender, how would you rate your chance of 
having the same heart condition again? 
unlikely to 
happen again 
0 1 2 3 4 5 6 7 8 9 10 
almost 
certain to 
happen 
again 
12. How bad would it be for you if you were to have the same heart problem again? 
not very bad 
at all 
0 1 2 3 4 5 6 7 8 9 10 very bad 
 
Smoking Status 
Do you smoke cigarettes? 
Yes No 
 
If you answered “Yes”, please complete the short questionnaire on the following 
page.  If you answered “No”, please skip the following page and proceed to the 
questionnaire marked “EQ-5D” on the front cover. 
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Questionnaire 6 (Cigarette Smokers Only) 
This questionnaire will tell us important information about your cigarette habits.  
Please place a cross (X) in ONE box per statement that best indicates your normal 
smoking habits.   
1. How soon after you wake up do you smoke your first cigarette? 
Within 5 
minutes 
6 – 30 minutes 31 – 60 minutes After 60 minutes 
2. How many cigarettes a day do you smoke? 
10 or less 11 – 20 21 – 30  31 or more 
3. Do you find it is difficult to refrain from smoking in places where it is forbidden (eg. In church, at the 
library, in cinemas, etc.)? 
Yes No 
4. Which cigarette would you hate most to give up? 
The first one in the 
morning 
All others 
5. Do you smoke more frequently during the first hours after awakening than during the rest of the day? 
Yes No 
6. Do you smoke if you are so ill that you are in bed most of the day? 
Yes No 
 
Thank you for completing this survey.  Please continue to the next survey marked 
“EQ-5D” on the front cover. 
  
© 1997 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group 
Health Questionnaire 
(English version for Australia) 
This questionnaire has 
been removed for 
copyright reasons
